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Abstract
Mobile applications (“apps”) are increasingly used in medical education and prac-
tice. However, many medical apps are of variable quality, lack supporting evidence
and fall outside the remit of regulators. In this thesis, I explore how the quality and
credibility of apps for healthcare practitioners could be improved. I argue that inter-
disciplinary collaboration throughout the app life-cycle is critical and discuss how this
can be facilitated. My argument rests on prior work in eHealth and neighbouring dis-
ciplines, and on original research in transfusion medicine.
Blood transfusion can be a life-saving medical treatment. However, it also car-
ries risks. Failures to provide irradiated and cytomegalovirus-negative blood compo-
nents according to guidelines are frequently reported in the UK. Such incidents put
patients at risk of serious complications. Haemovigilance data indicates that enhanc-
ing practitioner knowledge may reduce mistakes. Thus, I worked with medical experts
to develop and evaluate the Special Blood Components (SBC) mobile learning app. To
facilitate this work, I created two tools: the Web App Editor (WAE) and the Web App
Trial (WAT). The former is a collaborative editor for building apps in a web browser
and the latter is a system for conducting online randomised controlled app trials.
The results are reported in ve studies. Studies 1 and 2, based on interviews with
seven practitioners, revealed shortcomings in an existing transfusion app and the SBC
prototype. Study 3 demonstrated how students using the WAE were able to collaborate
on apps, including an app in stroke medicine. Study 4, an evaluation of the revised SBC
app with 54 medical students, established the ease of use as acceptable. In study 5, a
WAT pilot study with 61 practitioners, the SBC app doubled scores on a knowledge
test and was rated more favourably than existing hospital guidelines.
In conclusion, creating high quality medical apps that are supported by evidence is
a considerable undertaking and depends on a mix of knowledges and skills. It requires
that healthcare practitioners, software developers and others work together eectively.
Hence, the WAE and WAT are key research outcomes. They enabled participants to
contribute improvements and assess the usability and ecacy of the SBC app. The
results suggest that the SBC app is easy to use and can improve practitioner knowledge.
Further work remains to pilot and evaluate the SBC app in a hospital setting.
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Lay summary
Doctors, nurses and other healthcare sta increasingly use mobile devices, such
as “smartphones” and “tablets”, in their work. But many medical mobile software ap-
plications (“apps” for short) are of poor quality and largely unproven. In this thesis, I
investigate why this is and how medical apps for healthcare sta could be improved. To
do this, I identied lessons from previous research and from a project where I worked
with healthcare professionals to create a new app in blood transfusion.
Blood transfusions in the UK are very safe, but gaps in medical sta knowledge
of which patients should be given specially prepared blood
1
lead to mistakes that can
make patients very sick. To help improve sta knowledge of this topic, I created the
Special Blood Components (SBC) mobile learning app. The SBC app was built according
to comments from over one hundred doctors, nurses, medical students and others.
I also created two tools to make it easier to build and test apps with others. The
rst tool, the Web App Editor (WAE), is a collaborative editor where several authors can
work together. I used the WAE to create the SBC app and others have also used the
editor to build other apps, including one for patients with stroke. The second tool, the
Web App Trial (WAT), is a system for testing apps with users. Using the WAT, I assessed
if the SBC app improved knowledge in sta from three Scottish hospitals. I found that
knowledge levels were low and improved when the SBC app was used. Sta also rated
the SBC app higher than existing hospital guidelines.
In summary, improving medical apps for healthcare sta requires that people with
a mix of skills and knowledges work together over a long time. Therefore, the WAE
and WAT tools are important research outcomes. They made it easier to collaborate
and update the SBC app according to sta comments. The tools also helped collect
evidence suggesting that the SBC app is easy to use and can improve sta knowledge.
Additional research in hospitals is required to know with greater certainty whether
the use of the SBC app can improve patient care.
1
These special kinds of blood components are known as irradiated and cytomegalovirus-negative
blood (see the main text for an in-depth explanation).
5
This page is intentionally left blank.
Declaration
I declare that this thesis was composed by myself, that the work contained herein is
my own except where explicitly stated otherwise in the text, and that this work has not




This page is intentionally left blank.
Peer-reviewed outputs
• Monsen, K. and McClelland, D. B. L. (2014). An evaluation by nal year medical
students of an app supporting correct use of irradiated and CMV-negative blood
components. In Abstracts of the Annual Serious Hazards of Transfusion (SHOT)
Symposium, 9 July, 2014, The Lowry Theatre, Salford Quays, Manchester, UK, vol-
ume 24. Presented at the 2014 SHOT Symposium
• Monsen, K. and McClelland, D. B. L. (2013). Is this patient in the risk zone? An app
for checking the indications for irradiated and CMV negative blood. In Roberts,
D., editor, Abstracts of the XXXI Annual Scientic Meeting of the British Blood
Transfusion Society, 16-18 October, 2013, Birmingham, UK, volume 23. Supplement
2. Presented at the BBTS meeting
• Monsen, K. (2013). Transforming audiences into contributors: A development
environment for enabling user-driven innovation in HTML5 apps. In Proceedings
of the Moving Targets conference, October 15-16 2013, Dundee Contemporary Arts,
Scotland.
9
This page is intentionally left blank.
Acknowledgements
I am grateful for the excellent support and guidance provided by my supervisory
team: Prof. Jon Oberlander, Dr. Debbie Maxwell, Prof. Simon Biggs and Prof. Chris
Speed. I am also indebted to Dr. Brian McClelland and his colleagues at the Scottish
National Blood Transfusion Service (SNBTS) who have contributed extensively to the
project. Many other healthcare professionals have generously supported the research,
including (in alphabetical order):
• Dr. Shubha Allard, Consultant Haematologist and Chair of BCSH.
• Dr. Karen Bailie, Consultant Haematologist, SNBTS.
• Dr. Paula Bolton-Maggs, Medical Director of SHOT.
• Ms. Susan Cottrell, Nurse Specialist in Education, SNBTS.
• Mr. Amanpreet Dhesi, Patient Blood Management Team NHSBT.
• Dr. Lise Estcourt, Research Registrar, NHSBT.
• Mrs. Sandra Gray, Head of Nursing (Clinical Services), SNBTS.
• Mrs. Catherine Innes, Transfusion Practitioner, SNBTS.
• Dr. Alastair Nimmo, Consultant, Royal Inrmary of Edinburgh.
• Ms. Debbi Poles, Research Analyst, SHOT.
• Dr. Charles Wallis, ICU Consultant, Western General Hospital Edinburgh.
• Mr Douglas Watson, Clinical Eectiveness Coordinator, SNBTS.
• Ms. Alison Watt, Operations Manager, SHOT.
• Dr. Sharon Zahra, Consultant and Clinical Lead, Tissue and Cells, SNBTS.
Furthermore, Dr. Niall Anderson provided statistics advice. Sta and students at
the Pennypit Community Learning Centre helped me to explore research ideas in a
friendly setting. Helen Mamalaki piloted the Web App Editor while creating an app
for stroke patients under the supervision of Prof. John Lee and Dr. William Whiteley. I
am also grateful to the medical professionals and students who have provided feedback
on the SBC app.
This thesis would not have been possible without the scholarship provided through
the Design in Action knowledge exchange project. Financial support from the Edin-
burgh College of Art Postgraduate Research Expenses fund enabled me to attend and
present at conferences both nationally and internationally. Last but not least, I want
to thank my friends and family, especially Cecilia, for their support. Any omissions or
mistakes are my own.
11




1.1 Research aim and rationale . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2 Justication for a mobile learning web app . . . . . . . . . . . . . . . . 8
1.3 Objectives, methodology and outputs . . . . . . . . . . . . . . . . . . . 10
1.4 Special Blood Components (SBC) app . . . . . . . . . . . . . . . . . . . 12
1.5 Web App Trial (WAT) evaluation system . . . . . . . . . . . . . . . . . 15
1.6 Web App Editor (WAE) authoring tool . . . . . . . . . . . . . . . . . . . 18
1.7 Contributions to knowledge . . . . . . . . . . . . . . . . . . . . . . . . 20
1.8 Thesis outline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2 Related work 27
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.1.1 Healthcare information technology . . . . . . . . . . . . . . . . 31
2.1.2 Socio-technical dimensions . . . . . . . . . . . . . . . . . . . . 34
2.2 Adoption of medical apps . . . . . . . . . . . . . . . . . . . . . . . . . . 39
2.2.1 Clinical use of mobile devices and apps . . . . . . . . . . . . . . 42
2.2.2 “Appication” of medical guidelines . . . . . . . . . . . . . . . 45
2.2.3 Mobile learning in medical education . . . . . . . . . . . . . . . 47
2.3 Design of medical apps . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.3.1 User-centered design, lead users and co-design . . . . . . . . . 51
2.3.2 Case studies and design guides . . . . . . . . . . . . . . . . . . 55
2.3.3 Implementation design and organisational change . . . . . . . 59
2.4 Evaluation of medical apps . . . . . . . . . . . . . . . . . . . . . . . . . 62
2.4.1 Methodological and epistemological issues . . . . . . . . . . . . 67
2.4.2 Risks and unintended consequences . . . . . . . . . . . . . . . 71
2.4.3 Regulation and quality assurance . . . . . . . . . . . . . . . . . 73
2.5 Chapter summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3 Blood transfusion in the UK 83
3.1 Composition and function of human blood . . . . . . . . . . . . . . . . 84
3.2 Blood component manufacture . . . . . . . . . . . . . . . . . . . . . . . 85
3.3 Clinical transfusion process . . . . . . . . . . . . . . . . . . . . . . . . . 88
3.4 Safety and haemovigilance . . . . . . . . . . . . . . . . . . . . . . . . . 92
3.5 Use of special blood components . . . . . . . . . . . . . . . . . . . . . . 98
3.6 Causes of mistakes and mitigation strategies . . . . . . . . . . . . . . . 101
3.7 Chapter summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
13
14 TABLE OF CONTENTS
4 Methodology 107
4.1 Aims and assumptions . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.2 Theoretical and methodological framework . . . . . . . . . . . . . . . . 109
4.2.1 Action research . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.2.2 User-centered design and agile development . . . . . . . . . . . 113
4.3 Epistemological position . . . . . . . . . . . . . . . . . . . . . . . . . . 115
4.4 Ethical considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
4.5 Software development process . . . . . . . . . . . . . . . . . . . . . . . 119
4.5.1 Technical architecture, design decisions and stakeholders . . . 122
II EMPIRICAL STUDIES 125
5 Study 1: Review of an Existing Transfusion App 127
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
5.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
5.3.1 Clinical content and presentation . . . . . . . . . . . . . . . . . 134
5.3.2 Platelet dose calculator . . . . . . . . . . . . . . . . . . . . . . . 141
5.3.3 Usability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
5.4.1 Thresholds and recommendations . . . . . . . . . . . . . . . . . 152
5.4.2 Potential for errors . . . . . . . . . . . . . . . . . . . . . . . . . 153
5.4.3 User experience . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
5.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
6 Study 2: Concept Validation of the Proposed App 159
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
6.1.1 Initial SBC prototype . . . . . . . . . . . . . . . . . . . . . . . . 161
6.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
6.3.1 Systems for managing special requirements . . . . . . . . . . . 168
6.3.2 Causes of mistakes . . . . . . . . . . . . . . . . . . . . . . . . . 170
6.3.3 Professional knowledge boundaries . . . . . . . . . . . . . . . . 172
6.3.4 Suggestions for improving existing procedures . . . . . . . . . 174
6.3.5 Improvements to the SBC prototype . . . . . . . . . . . . . . . 175
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
6.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
TABLE OF CONTENTS 15
7 Study 3: Collaborative App Design with the WAE 181
7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
7.1.1 Origin as a constructivist learning tool . . . . . . . . . . . . . . 183
7.1.2 Technical architecture . . . . . . . . . . . . . . . . . . . . . . . 186
7.2 Part 1 - Use of the WAE in education . . . . . . . . . . . . . . . . . . . 191
7.2.1 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
7.2.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
7.2.3 Views on future app development . . . . . . . . . . . . . . . . . 199
7.3 Part 2 - Use in stroke app development . . . . . . . . . . . . . . . . . . 201
7.3.1 Methods and context . . . . . . . . . . . . . . . . . . . . . . . . 201
7.3.2 Helen’s background . . . . . . . . . . . . . . . . . . . . . . . . 202
7.3.3 Experience of using the Web App Editor (WAE) . . . . . . . . . 204
7.3.4 Improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
7.3.5 Collaboration in medical apps . . . . . . . . . . . . . . . . . . . 210
7.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
7.4.1 Future work and limitations . . . . . . . . . . . . . . . . . . . . 214
7.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
8 Study 4: Usability Evaluation of the SBC App 219
8.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220
8.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220
8.2.1 Online questionnaire . . . . . . . . . . . . . . . . . . . . . . . . 222
8.2.2 Remote monitoring . . . . . . . . . . . . . . . . . . . . . . . . . 223
8.3 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224
8.3.1 Respondent demographics . . . . . . . . . . . . . . . . . . . . . 224
8.3.2 Blood transfusion experience . . . . . . . . . . . . . . . . . . . 225
8.3.3 App interaction times . . . . . . . . . . . . . . . . . . . . . . . 226
8.3.4 App ratings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
8.3.5 The information section . . . . . . . . . . . . . . . . . . . . . . 228
8.3.6 The indications section . . . . . . . . . . . . . . . . . . . . . . . 231
8.3.7 The checklist section . . . . . . . . . . . . . . . . . . . . . . . . 232
8.3.8 The quiz section . . . . . . . . . . . . . . . . . . . . . . . . . . 234
8.3.9 Interaction design . . . . . . . . . . . . . . . . . . . . . . . . . . 235
8.3.10 Usability score . . . . . . . . . . . . . . . . . . . . . . . . . . . 237
8.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237
9 Study 5: A Randomised Controlled Pilot of the SBC App 239
9.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 240
9.1.1 Methodological considerations . . . . . . . . . . . . . . . . . . 241
9.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244
9.2.1 Selection of control treatment . . . . . . . . . . . . . . . . . . . 246
16 TABLE OF CONTENTS
9.2.2 Outcome measures and hypothesis . . . . . . . . . . . . . . . . 246
9.2.3 Population and sampling . . . . . . . . . . . . . . . . . . . . . . 247
9.2.4 Power calculation . . . . . . . . . . . . . . . . . . . . . . . . . . 249
9.2.5 Inclusion criteria . . . . . . . . . . . . . . . . . . . . . . . . . . 250
9.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251
9.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254
9.4.1 Ecacy of the SBC app . . . . . . . . . . . . . . . . . . . . . . . 255
9.4.2 Post hoc analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 256
9.4.3 Acceptability of the SBC app . . . . . . . . . . . . . . . . . . . 258
9.4.4 Limitations and lessons learned . . . . . . . . . . . . . . . . . . 261
9.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263
III SYNTHESIS 265
10 Discussion 267
10.1 Research aim and related work . . . . . . . . . . . . . . . . . . . . . . . 268
10.1.1 Prior work in eHealth and related elds . . . . . . . . . . . . . 268
10.1.2 Prior work in transfusion medicine . . . . . . . . . . . . . . . . 269
10.2 Findings from the empirical work . . . . . . . . . . . . . . . . . . . . . 270
10.2.1 Study 1: review of an existing app . . . . . . . . . . . . . . . . 271
10.2.2 Study 2: concept validation of the proposed app . . . . . . . . . 271
10.2.3 Study 3: collaborative app design with the WAE . . . . . . . . . 273
10.2.4 Study 4: usability evaluation of the SBC app . . . . . . . . . . . 273
10.2.5 Study 5: randomised controlled pilot of the SBC app . . . . . . 274
10.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
10.3.1 Challenges of evaluating medical apps . . . . . . . . . . . . . . 278
10.3.2 Role of interdisciplinary collaboration . . . . . . . . . . . . . . 279
10.3.3 Need for collaborative tools and training . . . . . . . . . . . . . 280
10.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
10.4.1 Implications for transfusion medicine . . . . . . . . . . . . . . . 286
10.4.2 Implications for medical app design . . . . . . . . . . . . . . . . 287
IV REFERENCES 289
V APPENDICES 321
A Interviews with practitioners 323
A.1 Information and consent form . . . . . . . . . . . . . . . . . . . . . . . 323
TABLE OF CONTENTS 17
A.2 Topic guide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 324
A.3 Follow-up message . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
B Web App Editor evaluation 327
B.1 Survey consent and questions . . . . . . . . . . . . . . . . . . . . . . . 327
B.2 Interview consent and topic guide . . . . . . . . . . . . . . . . . . . . . 330
C Survey of medical students 333
C.1 Participant information sheet . . . . . . . . . . . . . . . . . . . . . . . . 333
C.2 Terms of use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333
C.3 Evaluation questionnaire . . . . . . . . . . . . . . . . . . . . . . . . . . 335
D Web App Trial evaluation 343
D.1 First invitation to practitioners . . . . . . . . . . . . . . . . . . . . . . . 343
D.2 Reminder to practitioners . . . . . . . . . . . . . . . . . . . . . . . . . . 344
D.3 Second reminder to practitioners . . . . . . . . . . . . . . . . . . . . . . 345
D.4 Participant information sheet . . . . . . . . . . . . . . . . . . . . . . . . 346
D.5 Items in the knowledge test . . . . . . . . . . . . . . . . . . . . . . . . . 348
D.6 Flow through the Web App Trial . . . . . . . . . . . . . . . . . . . . . . 355
E List of gures 365
F List of tables 369
G Abbreviations and denitions 371







The study of the use, design and evaluation of mobile software applications (“apps”)
in healthcare is an emerging area of research that is increasingly salient as more health-
care practitioners decide to use smartphones and tablets in their work and training.
In this thesis, I explore this phenomenon through the collaborative development and
evaluation of an app aiming to improve a challenging area of blood transfusion.
This introductory chapter begins by summarising the research aim and rationale.
This is followed by an overview of the empirical setting, objectives and methodology.
The main outputs, contributions to knowledge and conclusions are then outlined. The
chapter concludes by signposting the remainder of the thesis.
3
4 CHAPTER 1. INTRODUCTION
1.1 Research aim and rationale
Mobile medical apps are heterogeneous software applications designed to perform or
aid a large range of healthcare tasks. Running on widely adopted mobile devices, such
as smartphones and tablets, apps provide healthcare practitioners with access to de-
cision support, medical guidelines, educational materials and other resources in a fa-
miliar and portable format. As a result, many practitioners use apps in their medical
education and practice on a regular basis (Mobasher et al., 2015; O’Reilly et al., 2014;
Carter et al., 2014; Payne et al., 2012; Franko and Tirrell, 2012).
However, the safety and eectiveness of many medical apps is uncertain as they are
of variable quality and lack supporting evidence (Boulos et al., 2014; Buijink et al., 2013;
Ozdalga et al., 2012; Haey et al., 2013b; McCartney, 2013; Derbyshire and Dancey,
2013; Eng and Lee, 2013; Bender et al., 2013; Wolf et al., 2013). Prior work suggest this is,
at least in part, the result of design processes that do not suciently engage with users
and evaluation research (Pagliari, 2007; Car et al., 2008; Masters, 2014; Visvanathan
et al., 2012; Hamilton and Brady, 2012; Haey et al., 2013b; O’neill and Brady, 2012;
Zhou et al., 2012).
Thus, the aim of the thesis is to explore how the quality and credibility
of medical apps intended for healthcare practitioners could be improved by
collaborative design and evaluation processes. I identify lessons from prior work
and from a project where I collaborated with practitioners to create and evaluate apps
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aiming to improve blood transfusion practice. Furthermore, as there is a shortage of
established tools for developing and evaluating medical apps with others, I created
a collaborative app editor and a system for conducting online randomised controlled
trials of apps. Before detailing the outcomes, and the knowledge contributions that
stem from them, it is necessary to elaborate the rationale of the research collaboration.
Access to safe blood transfusions is a global priority as it is a common and life-
saving treatment (World Health Organization, 2008, 5). However, it is also a complex
process with many possible points of failure associated with serious risks (McClelland
and Philips, 1994; Contreras and de Silva, M, 1994; McClelland, 1998; Heddle et al.,
2012). The purpose of the research collaboration was to improve the management of
two serious complications of blood transfusion, known by the abbreviations TA-GvHD
and TT-CMV (summarised in table 1.1).





TA-GvHD is a rare and almost always
fatal immunological condition where
transfused donor lymphocytes (white
blood cells) attack the recipient. TA-
GvHD is prevented by providing Gamma
or X-ray irradiated cellular blood com-
ponents to at-risk transfusion patients.
As there is no eective treatment, the
correct use of irradiated blood compo-
nents is critical to prevent TA-GvHD
(Treleaven et al., 2010).
TT-CMV is transmission of Cytomegalovirus
(CMV), a widespread herpes virus, via blood
transfusion. CMV infection is usually harm-
less, but can lead to life-long disability or death
in vulnerable patients, such as neonates. In the
UK, TT-CMV was previously prevented by pro-
viding at-risk patients with blood from donors
who screen negative to CMV. After univer-
sal leucodepletion (whereby cells harbouring
CMV are removed) this is no longer required
for most patients (SaBTO, 2012b).
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Both are prevented by providing at-risk patients with correct blood components.
These are manufactured using irradiated blood and/or blood from donors who are
Cytomegalovirus (CMV) negative (see chapter three for additional details). However,
identifying at-risk patients and ensuring that they receive these “special blood com-
ponents” is challenging. In the UK, about one hundred failures are reported annually
(gure 1.1), and more are likely undetected. These incidents, which put patients at
risk of TA-GvHD and TT-CMV, occur in complex care environments for a range of
reasons. For example, organisational and human factors causes include distractions in
the workplace, miscommunication and understang (Bolton-Maggs et al., 2016, 22).
Figure 1.1: Failures to provide irradiated and/or cytomegalovirus (CMV) negative blood
components reported to the Serious Hazards of Transfusion (SHOT) haemovigilance
scheme between 2008 and 2012. Clinical errors include failure to communicate the
need for special blood components to the lab. In lab errors, the request was made but
not acted upon (Cohen et al., 2010, 27). Source: Dr. Paula Bolton-Maggs, Debbi Poles
and Alison Watt. Used with permission from SHOT.
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Deciding whether to provide a patient with special blood components also requires
awareness and detailed knowledge of nearly two dozen clinical indications. Hence, a
recurring reason for mistakes is a lack of knowledge among healthcare practition-
ers of the correct use of special blood components. The following example, where
a patient who should have received irradiated blood was erroneously provided with
non-irradiated blood, illustrates the problem (Knowles and Cohen, 2011, 26):
“The admitting doctor noted the past history of Hodgkin’s disease but was not
aware of the requirements for irradiated blood.”
This case was reported to Serious Hazards of Transfusion (SHOT), a professionally-
led body that monitors transfusion errors and “near-misses” in the UK. SHOT have
highlighted the issue in several of their reports and have recommended that this aspect
of medical education is improved (table 1.2).
Table 1.2: A selection of ndings and recommendations related to the correct use of
special blood components published by SHOT between 2010 and 2012.
“Many cases of failure to request irradiated products [—]
demonstrate a lack of adequate knowledge in clinical sta”
Bolton-Maggs and
Cohen (2012, 33)
“All haematology units must devise specic educational pro-
grammes for all their sta members providing the rationale
and indications for specialist components and this informa-
tion should be accessible at the time of making the requests”
Knowles and Co-
hen (2011, 28)
“The existence [...] of special transfusion requirements must
be taught to junior doctors in all hospital specialities.”
Cohen et al. (2010,
55)
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1.2 Justication for a mobile learning web app
Failures to provide irradiated and CMV-negative blood to at-risk patients could thus
be reduced by improving practitioner knowledge. Despite SHOT’s recommendations,
there is a shortage of appropriate learning resources. For instance, Learn Blood Trans-
fusion (LBT) – a continuing medical education programme used throughout the UK –
does not contain detailed learning materials about this topic. Instead, the most promi-
nent resources are the national guidelines (Treleaven et al., 2010; SaBTO, 2012b), local
hospital guidelines and medical handbooks (e.g. Norfolk, 2013).
However, these documents are of limited pedagogical value as they are not intended
for educational use and assume prior knowledge. There is hence a need for educational
resources aimed at practitioners who may be new to this topic or who want to improve
their existing knowledge. This includes knowledge not just of the clinical indications,
but also of topics such as the causes and mechanisms of TA-GvHD and TT-CMV, the
role of immunodeciency, immunosuppressive drugs and other relevant medical histo-
ries, the manufacture and properties of cellular blood components, genetic risk factors
(shared HLA haplotypes) and common causes of mistakes.
Medical professionals are expected to know and make use of a growing amount
of specialised information and medical guidelines (Allen and Harkins, 2005; Dimond
et al., 2016). It is therefore critical that educational interventions meet the needs of
busy healthcare practitioners. Prior work suggests that the use of online learning
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(e-learning) can be a exible and eective strategy for improving knowledge of the
principles of safe transfusion practice (Graham, 2015; Smith et al., 2014, 2011), while
catering for diverse learning styles (Cottrell and Donaldson, 2013).
Educational materials that are designed according to the constraints of mobile de-
vices, such as the small screen size and shorter interactions, can oer eective learning
experiences (Orr, 2010, 107). Mobile devices can enable “just in time” and “bite-size”
patterns of accessing information, making them, as Traxler (2007, 7) put it, “uniquely
suited to support context-specic and immediate learning”. They can also be used on
the ward, at the point of care and in other settings, thereby extending the reach of
traditional desktop-based e-learning (Traxler, 2009, 10). Mobile devices may also help
to manage information overload by functioning as cognitive aids that improve recall
in a clinical situation (Low et al., 2011; Bullock et al., 2015).
With the advances in web technologies, such as widespread support for Media
Queries in Cascading Style Sheets, it is possible to create mobile “web apps” that are
compatible with smartphone, tablet and desktop computers (Rivoal, 2012; Orr, 2010).
If developed using a framework that incorporates these technologies (Heitkötter et al.,
2013), a single web app could disseminate learning materials to widely used smart-
phone, tablet and desktop computers, including legacy systems used in the NHS. This
would open up new ways of accessing learning materials and could further the goals
of continuing medical education in this area.
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1.3 Objectives, methodology and outputs
As shown in table 1.3, the research aim was broken into seven objectives which formed
the basis for two literature reviews (chapters two and three) and ve empirical studies
(chapters ve through nine). To achieve the objectives, I adopted an action research
methodology (laid out in chapter four) where I worked with domain experts, healthcare
practitioners and others. Figure 1.2 summarises the main steps in the process.
I began by reviewing prior studies, existing practices and interventions, and by test-
ing the proposed concept with potential users. I then proceeded to iteratively design
and evaluate the app, while simultaneously creating collaborative tools and methods
for building, sharing and evaluating work in progress with contributors. Drawing on
these activities, I reected on transferable lessons for improving the quality and cred-
ibility of medical apps for healthcare practitioners (discussed in chapter ten).
The research outputs consist of a combination of software applications and con-
tributions to knowledge. This is a somewhat problematic distinction as software can
be considered a knowledge product, is integral to research in many disciplines (Goble,
2014) and is increasingly recognised as a research contribution outside of computer
science (The Software Sustainability Institute, 2015). Before discussing the knowledge
contributions, I will therefore describe the three resulting software applications:
1. The Special Blood Components (SBC) app;
2. The Web App Trial (WAT) evaluation system; and
3. The Web App Editor (WAE) authoring tool.
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Table 1.3: Summary of the research objectives.
1. Map the key issues related to the use, design and evaluation of medical apps.
2. Analyse the manufacture and clinical use of blood components in the UK.
3. Review an existing blood transfusion app targeting UK healthcare practitioners.
4. Validate and improve the proposed mobile learning app with practitioners.
5. Create and test a collaborative authoring tool for collaborative app design.
6. Evaluate the usability of the Special Blood Components (SBC) app.
7. Assess the acceptability and impact of the SBC app with healthcare professionals.
Figure 1.2: A simplied representation of the stages of the action research project. The
rst ve phases sought to explore specic questions through a range of methods. Each
phase corresponds to an empirical study, reported in chapters ve through nine.
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1.4 Special Blood Components (SBC) app
The SBC app aims to promote the correct use of irradiated and CMV-negative blood
components by providing healthcare practitioners with access to learning materials
and clinical indications. The usability, eectiveness and acceptability of the SBC app
have been evaluated multiple times, resulting in several revisions (illustrated in gure
1.3). Designed as a responsive web app, it is compatible with smartphones, tablets and
desktop computers, including legacy web browsers (Internet Explorer 6+) used in the
National Health Service. Figures 1.4 and 1.5 illustrate the main screens of the app.
Figure 1.3: The Special Blood Components (SBC) app, showing evolution over the
course of the project (from left: November 2014, September 2013 and April 2013).
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Figure 1.4: Screenshots of SBC app taken on a wide-screen display (16:9 aspect ratio)
in landscape orientation (from top: “Terms of use”, “Welcome” and “About” pages).
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Figure 1.5: Screenshots showing examples of the learning materials, clinical indications
table and detailed recommendations oered by the SBC app.
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1.5 Web App Trial (WAT) evaluation system
To assess the impact and acceptability of the SBC app, I created the Web App Trial
(WAT) system. It is a web-based application for conducting online randomised con-
trolled trials of web apps. Using the system, I conducted an evaluation of the SBC app
with healthcare practitioners from three Scottish hospitals (reported in chapter nine).
Figures 1.6-1.7 show the WAT from the perspective of a research participant.
Authenticated users can access the collected data through a web-based interface
(gure 1.8). The results can be explored using graphs generated by the system or ex-
ported as comma delimited data (CSV) for statistical analysis. Like the SBC app, the
WAT is compatible with smartphones, tablets and desktop computers (including legacy
web browsers down to Internet Explorer 6). Key features of the WAT system are sum-
marised in table 1.4.
Table 1.4: Key features of the Web App Trial (WAT) system.
XSupport for participant information sheet and consent handling.
XParticipant screening against inclusion criteria.
XPre- and ad hoc randomisation of participants.
XSelective display of interventions according to user’s trial arm allocation.
XInline embedding of interventions alongside evaluation questions.
XQuestion order randomisation and automatic scoring.
XVisual indication of progression through the evaluation.
XTiming of user actions at key progression points.
XData capture, validation, analysis and export.
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Figure 1.6: Screenshot of the WAT system, showing the participant information page
for the SBC app evaluation (reported in chapter eight).
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Figure 1.7: The Web App Trial (WAT) system as a research participant randomised to
the app arm, and half-way through the evaluation, would see it.
Figure 1.8: Screen captures from WAT showing the real-time analytics reported by the
system (clockwise from top left corner: response rate and scores by arm; demographics;
individual and aggregate scores by arm; and completion times).
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1.6 Web App Editor (WAE) authoring tool
The third software output from the research is the Web App Editor (WAE). It is a
browser-based authoring environment that enables collaborative development of web
apps. I used the WAE to create the SBC app (gure 1.9) and it was also used in a Masters
dissertation project to create an app that elicits symptoms of patients with transient
ischaemic attack or “mini stroke” – see gure 1.10 and chapter seven for details.
I also used the editor to teach two certied introductory courses in mobile app
development (examples of some of the apps created by the students are discussed in
chapter seven). Thus, the WAE is both a research and development tool, as well as
an outcome of the research process that evolved over the course of the project. The
current version incorporates functionality from many open source software projects
and the core features are summarised in table 1.5. The editor requires a Github.com
account and is available at: https://www.webappeditor.com.
Table 1.5: Key features of the Web App Editor (WAE).
XMultiple authors can collaborate on apps in real-time.
XQuick preview of apps on mobile and desktop devices.
XVersion control through integration with GitHub.com.
XFile creation, uploading, renaming, deletion and moving.
XText, audio and video communication between collaborators.
XBuilt-in code-highlighting, syntax linting and folding.
XEntirely web-based without dependency on installed software.
XCongurable user interface based on le tabs and panels.
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Figure 1.9: Annotated screenshot of the Web App Editor (clockwise: le manager for
GitHub repository; live app preview; collaborative code editor editing an HTML le;
editor with an open Javascript le; preview of a static media resource).
Figure 1.10: An app created using the WAE to help stroke patients communicate their
symptoms. Screenshot used with permission of the app’s author Helen Mamalaki.
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1.7 Contributions to knowledge
The thesis contributes to knowledge by oering a critical and reexive (Finlay, 2002)
analysis of the research, design, engineering and socio-technical (c.f. Hughes, 1987)
challenges of developing and evaluating medical apps for and with healthcare practi-
tioners. I argue throughout the thesis that concerns related to the lacking quality and
credibility of many medical apps cannot be eectively addressed by “market forces”
(such as consumer behaviour on app stores), “vetting” by trusted third parties or top-
down regulation by governmental bodies with relatively limited resources.
Rather, these issues are symptoms of limitations in the current app commission-
ing, development and evaluation practices. Drawing on prior work, and using the
SBC app as example of how healthcare practitioners, medical students and others con-
tributed quality improvements and helped evidence its usability and ecacy, I suggest
that these issues could be overcome by development strategies that promote on-going
interdisciplinary teamwork.
Dedicated collaborative app design and evaluation tools, such as the WAE and WAT,
can facilitate such strategies, but are still in their infancy. It is also critical to develop
and reward the digital skills of healthcare practitioners so that they can become critical
consumers of apps and can actively shape the information technologies that they are
increasingly reliant on. I will now summarise how the ve empirical studies, which
contribute to knowledge in several elds (see table 1.6), support this thesis.
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One 5 X X X
Two 6 X X X
Three 7 X X
Four 8 X X X
Five 9 X X
The rst study is a review of an existing transfusion app that aims to support
clinicians who are prescribing platelets. It was carried out with seven practitioners in
haematology and anesthesiology. The study, among the rst independent reviews of
an app in transfusion medicine, revealed notable weaknesses in the usability, clinical
content and platelet dose calculator. It highlights how medical apps released with bugs
and usability problems are not only likely to be rejected by practitioners, but could also
contribute to new medical errors. To prevent these issues, it is essential to ensure the
budget, training, quality assurance and collaborative processes are in place to detect
bugs and roll out xes in a timely manner.
The second study is a qualitative assessment of the SBC prototype. Conducted
alongside the rst study and with the same participants, the study demonstrates the
value of soliciting feedback from healthcare practitioners from dierent medical spe-
cialities early in development. Their critique helped rene the scope, purpose and
framing of the project. It also helped improve the content and usability of the app. The
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ease of recruiting, coupled with the generous use of their time and interest in the topic,
conrmed that engaging healthcare practitioners at the start of the design process is
feasible. However, sustaining engagement throughout the iterative design cycle was
challenging due to a lack of existing collaborative tools – prompting the third study.
The third study concerns the Web App Editor (WAE), the collaborative web-based
authoring tool that I created to make it easier to develop the SBC app with others. In
this study, I evaluated the editor with students on introductory courses in mobile app
development that I taught, and in a Masters project aiming to create an app to elicit
symptoms of stroke patients. In these contexts, the WAE enabled users with little
prior experience to learn about, create and test mobile apps. Given the right tools
and support, even those who are new to app development can acquire the skills to
contribute to apps. This extends to healthcare practitioners who should be encouraged
to critically analyse and contribute to apps in their area of expertise.
Study four is a usability evaluation of the revised version of the SBC app. It was
conducted during a blood transfusion training day at a large Scottish University. 54
nal year medical students rated the usability of the SBC app as acceptable and their
feedback prompted a re-design and expansion of the educational content. The study
illustrates the importance of using formative feedback from multiple user groups in the
iterative design process. Also, it conrmed the high level of adoption and enthusiasm
for mobile devices and apps among medical students and junior practitioners.
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Finally, study ve assessed the impact of the most recent version of the SBC app on
practitioners’ performance on a knowledge test about the correct use of irradiated and
CMV-negative blood. This was a surrogate measure of practice improvement, which
unfortunately was infeasible to assess directly (see the start of chapter nine for a de-
tailed discussion). 61 doctors, nurses and biomedical scientists from three Scottish
hospitals participated in this online randomised controlled pilot study. The results
conrmed gaps in knowledge reported by SHOT and suggested that the SBC app is
an acceptable and ecacious learning aid that can enhance practitioners’ knowledge.
The study also highlights some of the barriers encountered to conduct a study with
patient outcomes and demonstrated the feasibility of remotely assessing medical apps
with healthcare practitioners using the WAT system.
1.8 Thesis outline
This chapter has introduced the research context, aims, rationale, objectives and
outcomes. Chapter two, the rst of two literature chapters, situates the research
in the literature on healthcare information technology and the adoption, design
and evaluation of mobile medical apps in healthcare.
Chapter three, the second literature chapter, provides an introduction to current
blood transfusion practice in the UK. It also explains the role of irradiated and
cytomegalovirus (CMV)-negative blood in preventing TA-GvHD and TT-CMV.
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Chapter four is the methodology chapter. It discusses the pragmatic and eclectic
research approach necessitated by the interventionist nature of the project. The
approach combines concepts from action research, human computer interaction,
user innovation theory, healthcare evaluation and software engineering.
Chapter ve is the rst of ve empirical studies. It draws on the qualitative
evaluation of an existing transfusion app with seven practitioners. Their review
of the app, which was designed to support the prescription of platelets, identied
several transferable lessons which are discussed in detail.
Chapter six presents a formative evaluation study of the SBC app prototype. It
explores practitioners’ prior experiences of special blood components, views on
the causes of mistakes and potential interventions, including the proposed app.
Additionally, improvements to the prototype are identied.
Chapter seven temporarily shifts focus from the context of blood transfusion
to consider how the process of medical app development could be improved.
The chapter explores how the Web App Editor, a multi-user app authoring tool,
can facilitate digital skills development and eective collaboration during app
development in educational settings.
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Chapter eight is a usability evaluation study of the second revision of the SBC
app. 54 medical students, attending a compulsory blood transfusion training day
at a large Scottish university, rated the ease of use of the SBC app on the System
Usability Scale and oered feedback to identify areas of improvements.
Chapter nine is the nal empirical study. It assesses the impact of the latest
version of the SBC using an online randomised controlled pilot study with 61
practitioners from three Scottish hospitals.
Finally, chapter ten analyses the ndings of the ve empirical studies in relation
to previous work and the original research aim. It also discusses the limitations
of the research, conclusions and implications for practice and future work.
The bibliography and appendices follows. A glossary of abbreviations and de-
nitions for frequently used terms is also provided (starting on page 371).
This page is intentionally left blank.
Chapter 2:
Related work
This chapter reviews prior work related to the adoption, design and evaluation of
medical apps for healthcare practitioners. After describing the methods and scope of
the review, I situate it in the wider research landscape by outlining the origins of the
study of healthcare information technologies and its socio-technical dimensions.
With this groundwork in place, I then discuss recent studies related to the adoption
of medical apps by healthcare practitioners. This is followed by a review of prior work
and perspectives on the design of medical apps. The penultimate section discusses
evidence underpinning the use of medical apps, methodological and epistemological
issues for medical app evaluation, potential risks and the limited success to date of in-
terventions aiming to assure the quality of medical apps. Finally, the chapter concludes
with a summary of the key issues and state of research.
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2.1 Introduction
This review maps key issues associated with the adoption, design and evaluation of
medical apps for healthcare practitioners. It is a formidable task as the volume, breadth
and rapid development of healthcare information technologies pose considerable dif-
culties to researchers. This is aptly summed up by Car et al. (2008, 19) who argue
that it is “... impossible for any individual to read, critically appraise and synthesise
the state of current knowledge, let alone remain up-to-date in this dynamic area”.
As a multidisciplinary area of research, and with contributions originating from the
social, engineering and health sciences (gure 2.1), the literature is fragmented. Studies
are published in discipline-specic journals, in outlets that cater to niche interests of
particular scholarly and medical communities, or in the grey literature where much of
the most recent technological development is reported. Cross-cutting journals were
only founded relatively recently, such as the 2012 Journal of Mobile Technology in
Medicine, and are still in the process of becoming established. The terminology also
varies considerably between disciplines (Greenhalgh et al., 2004, 38).
To overcome these issues, I adopted a pragmatic search strategy that borrowed
from scoping review methodology (Arksey and O’Malley, 2005). Hence, I searched
iteratively using broad keywords to identify relevant systematic reviews, drilling down
into individual studies and using back-referencing (snowballing) to identify further
relevant work.
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In searching the literature, I relied on three main tools: “Discovered”, a service by
the University of Edinburgh for searching electronic journals; the US National Institute
of Health PubMed database; and the Google Scholar literature search engine. A list of
search terms and phrases used is oered in table 2.1.
I have concentrated on literature from the last decade to limit the scope of the re-
view, and to ensure it is up to date with current technologies. As there is a limited
amount of recent work from within the transfusion medicine community on the use
of mobile computer technology, I also considered work on medical apps from other
medical specialties, such as cardiology, dermatology, endocrinology, oncology, micro-
biology and pharmacology.
Figure 2.1: Location of the thesis in the related literature.
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However, consolidating knowledge from such a wide range of areas is dicult due
to the heterogeneity of both the apps under consideration and the (often qualitative)
methods employed to review them. There is also a lack of current and comprehen-
sive systematic reviews. Systematic reviews of earlier generations of computer-based
interventions, such as those oered by Car et al. (2008) and Greenhalgh et al. (2004),
were useful in overcoming some of these issues.
Table 2.1: Terms and phrases used to to identify prior literature.
Theme Terms
Blood transfusion
BCSH, CMV, errors, guidelines, HLA, irradiated, hotspots,
mistakes, near misses, SHOT, SaBTO, statistics, TA-GvHD,
transfusion app, transfusion process.
Decision support
accuracy, algorithm, cognitive aids, cognitive biases, com-
puterised decision support, decision tree, frugal decision,
heuristics, medical decision making, rule-bound thinking,
triage, speed.
General
app, device, ehealth, handheld, mhealth, mobile, smart-
phone, tablet.
Medical Mobile Apps
adoption, certication, clinical use of apps, contamination,
context of use, eectiveness, evaluation, FDA, hacking, hy-
giene, legal, medical app, medical device, meta, MHRA,
mobile medical app, NHS, policy, randomised controlled
trial, safety, survey, systematic review, trust, review, reg-
ulation, unintended consequences.
Methodology
design, epistemology, ethics, evaluation, human factors,
innovation, implementation, methods, mobile app design
guidelines, theory, translational medicine, statistics, suc-
cess factors, usability, user experience, user interface.
Mobile Learning
app-based learning, blended learning, continuing profes-
sional development, evaluation, learning design, learning
outcomes, medical education, pedagogy, simulation, situ-
ated learning, social learning.
2.1. INTRODUCTION 31
As the focus of the thesis is on medical apps for healthcare practitioners, studies of
apps for patients and health-conscious consumers have only been considered in pass-
ing. Additionally, there are many approaches to design, innovation, medical practice
and education, software engineering and evaluation. The purpose is not to provide a
comprehensive review of these areas, but rather to map out some of the most relevant
issues in relation to the collaborative design of medical apps. To situate recent devel-
opments pertaining to mobile medical apps in its broader context, I will now outline
the history and scope of the eld of healthcare information technology.
2.1.1 Healthcare information technology
The modernistic vision of computers as an enabler of ecient and eective healthcare
services goes back to the 1950s era of mainframe computers (Kaplan, 1995). Academic
interest in the use of computers in healthcare can be traced back to at least 1968 with
the founding of the journal Computers and Biomedical Research (see table 2.2). Since
then the eld has expanded in both depth and breadth.
Electronic healthcare or “eHealth” is a relatively new term that only entered into
common use after the turn of the millenium (Pagliari et al., 2005). Although the term
lacks a succinct and widely agreed denition, it is often used to refer to a wide range
of Internet technologies applied within a healthcare context. Perhaps the most widely
cited denition is the one oered by Eysenbach (2001, 1):
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“e-health is an emerging eld in the intersection of medical informatics, public
health and business, referring to health services and information delivered or en-
hanced through the Internet and related technologies. In a broader sense, the
term characterizes not only a technical development, but also a state-of-mind, a
way of thinking, an attitude, and a commitment for networked, global thinking,
to improve health care locally, regionally, and worldwide by using information
and communication technology.”
Mobile medical applications could be classied as a form of eHealth that also be-
longs to the subeld of mobile healthcare (“mHealth”). As with eHealth, the boundaries
of mHealth are imprecise and there are multiple denitions and uses of the term.
For example, mHealth carries connotations to telemedicine – the remote provision
of healthcare services through information and communication technologies, such as
telephone or video conferencing – as well as the provision of health services in rural
areas and in developing countries as part of the ICT for development movement.
Table 2.2: Selected journals in medical informatics by year of rst issue.
Journal Year
Journal of Mobile Technology in Medicine 2012
International Journal of E-Health and Medical Communications 2010
International Journal of Telemedicine and Applications 2008
Electronic Journal for Health Informatics 2006
Journal of Medical Internet Research 1999
IEEE Transactions on Information Technology in Biomedicine 1997
Telemedicine Journal and e-Health 1995
Journal of Medical Systems 1977
International Journal of Medical Informatics 1970
Computers and Biomedical Research 1968
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This diverse use of the term could be attributed to the wide applicability of mobile
technologies, implicit in the denition of mHealth by Estrin and Sim (2010, 759):
“Mobile communication devices, in conjunction with Internet and social media,
present opportunities to enhance disease prevention and management by extend-
ing health interventions beyond the reach of traditional care – an approach re-
ferred to as mHealth”.
Placing emphasisis on the enabling role of mobile technology in healthcare, the
World Health Organisation denes mHealth as:
“Medical and public health practice supported by mobile devices, such as mobile
phones, patient monitoring devices, personal digital assistants (PDAs), and other
wireless devices” (WHO, 2011, 6).
Studies that fall under the rubric of mHealth cover a wide range of technologies and
medical applications (Klasnja and Pratt, 2012). For example, personal digital assistants
(PDAs) in medical education and clinical practice (Baumgart, 2005), short message ser-
vice (SMS) for promoting healthy lifestyles in smokers (Vidrine et al., 2012) and women
with young children (Fjeldsoe et al., 2012), radio-frequency identication (RFID) to re-
duce patient misidentication (Thuemmler et al., 2007), miniature computer devices
and digital sensors to monitor patients’ vital signs and breathing patterns during se-
dation (Kuroda et al., 2013; Drummond et al., 2013), and the use of smartphones to
monitor elderly patients with chronic conditions (Boulos et al., 2011).
Similarly, studies of current generations of medical apps span many application
areas, such as the estimation of blood loss during operations (Sharareh et al., 2015),
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detection of hepatitis C (Arono-Spencer et al., 2016) and hemolysis (Archibong et al.,
2016), medical calculators (Bierbrier et al., 2014) and the development of aordable
and portable medical devices, such as electrocardiograms (Chung and Guise, 2015),
glucometers (Ramljak et al., 2013) and pulse oximeters (Scully et al., 2013).
These examples illustrate the diverse ways in which mobile technologies may sup-
port specic areas of transfusion medicine and general healthcare practice. How-
ever, success is contingent not only on narrowly “technical” qualities (which are often
stressed), but also on the compatibility with the organisational context of use (Edmond-
son, 2003; Greenhalgh et al., 2004; Granlien, 2010; Doherty, 2014).
2.1.2 Socio-technical dimensions
Since the early work of the 1950s, the understanding of the socio-technical nature of
healthcare information technology interventions have evolved signicantly (see Berg,
1999). Computer technology is now deeply embedded in contemporary healthcare
(Lindsey, 2007, 336). Scholars in the socio-technical tradition view technology as so-
cially constructed and inseparable from the social setting where it is produced (hence
the contraction).
It is beyond this chapter to discuss the underpinnings of this perspective and in-
terested readers are directed to seminal works such as Hughes (1987); Winner (1980);
Pinch and Bijker (1984); Williams and Edge (1996). Suce to say that a critical overview
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of healthcare information technology cannot ignore the social, economic, cultural and
political aspects of the topic. A striking international example of the latter is the ap-
proval of the eHealth Resolution by 192 member states of the United Nations in 2005.
Car et al. (2008, 84) argue that the resolution showed “... global political commit-
ment that has translated in unprecedented investment in IT within healthcare”. Hence,
healthcare information technologies are interwoven with implicit and explicit visions
of the future, and never far from the political limelight. For example, they are often
couched in terms of creating more personalised (“patient-centered”) and cost-eective
healthcare services, which are highly politicised claims (Kreindler, 2013). To illustrate
this using a UK perspective, I will briey examine projects and policies within the
National Health Service (NHS).
Composed of devolved bodies for England, Wales, Scotland and Northern Ireland,
the NHS is an important symbol of the British welfare state. It can be dated back to
1942 in Sir William Beveridge’s report Social Insurance and Allied Services, and the 1946
National Health Service Act. The NHS has since dramatically expanded in both scope
and budget (approaching 10% of the UK’s GDP in 2010), and it continues to undergo
changes where digital technology plays a signicant role (Nueld Trust, 2012).
For the 65-year anniversary, Timmins (2013) edited a collection of interviews with
65 parliamentarians, ocials, health and social care leaders and other commentators,
such as clinicians, managers, academics, patient groups and journalists. Although the
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accounts are diverse, there are ve recurring themes: the challenges of caring for an
aging population, technology-based healthcare interventions, ecient resource utili-
sation, quality of care and patient empowerment.
For instance, people live longer than ever before and this is projected to alter the age
distribution of the UK population, as shown in gure 2.2. Such demographic changes
have implications for care services as the elderly have more complex and costly health-
care needs due to multiple age-associated chronic conditions (Lehnert et al., 2011).
Consequently, there is signicant interest in how information and communication
Figure 2.2: Age structure of the UK population in 2010 and 2035. Source: UK Oce for
National Statistics (2011).
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technologies could support the elderly and chronically ill. For example, assistive tech-
nologies, robots, remote monitoring and telecare systems aim to enable people to live
at home longer and reduce the burden on care homes (Boissy et al., 2007).
Similarly, Living It Up was a project targeting the over 50s, led by NHS Scotland
and NHS24, a patient information and self-help initiative. The project aims to “...de-
liver innovative and integrated health, care and well-being services, information and
products via familiar technology ... enabling people to keep better connected with their
communities and those they care for and receive care from” (Mair and Lennon, 2015,
3). The project ts with the Scottish government’s eHealth policy for 2011-2017 which
justies investment in IT based on the potential for improving quality and reducing
cost (NHS Scotland, 2011).
The Scottish strategy reiterates common claims regarding the benets of IT, such
as: “Making use of information and technology eectively can bring about quality im-
provements in healthcare services and eciency savings in healthcare across NHSS.
It also crucially frees up sta time for patient care and reduces waiting times.” (NHS
Scotland, 2011, 16). This one-sided picture is representative of widely held optimism
towards healthcare technology, and echoes the views of the commentators on the fu-
ture role of technology in the NHS (Timmins, 2013).
While few would dispute that IT is critical to modern healthcare, deterministic
views of technology are theoretically unsupported and can disempower marginalised
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groups, including women, who are more likely to be on the receiving end of technology
projects (Williams and Edge, 1996; Faulkner, 2001; Henwood and Hart, 2003; Lindsey,
2007). When change is attributed to the “inevitable progress of technology”, rather
than the social, political, economic and cultural forces that resist or drive such changes,
human agency and the option to intervene in change processes is made invisible.
One can disprove determinist claims by pointing at counter-examples. For instance,
Wilson (2002) provides a case study where nurses in a large NHS hospital contested the
introduction of a computerised care planning system that was designed to reduce the
risk of litigation. The nurses who were expected to use the system felt that it reduced
patient time and failed to capture the value of their work and skills. The system was
eventually scrapped due to the failure to constructively resolve these concerns.
Similarly, failure to engage with healthcare practitioners contributed to the demise
of the £12.4 billion NHS National Programme for Information Technology (NpfIT).
The programme was a government-sponsored megaproject that was delivered by the
newly created NHS Connecting for Health agency. Initiated in 2002 to improve the IT
infrastructure and to link electronic health records in England (National Audit Oce,
2006), the programme carried tremendous political prestige.
While dierent commentators consider the NpfIT a partial success or an outright
failure (Cross, 2006; Eason, 2007), it did not deliver on core objectives, ran over budget
and behind schedule, and was eventually cancelled in 2011. The Public Accounts Com-
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mittee (2011) was highly critical and provided a detailed review of the shortcomings
of the project. They highlight issues such as poor consultation with healthcare pro-
fessionals and inadequate nancial and risk management. Furthermore, Coiera (2007)
suggests that the NpfIT oers important lessons for areas such as system procurement,
patient safety, engagement with clinicians, leadership and evaluation.
These examples illustrate that the impacts of healthcare information technologies
are shrouded in political narratives, multifaceted, unpredictable, subjective and rarely
carefully investigated (a claim I return to at the end of this chapter). With this brief
overview of the broader eHealth research landscape completed, I will now discuss cur-
rent research on mobile medical apps - starting with work that examines why and how
medical apps are used by healthcare practitioners.
2.2 Adoption of medical apps
To understand the extent that healthcare practioners utilise medical apps, their motiva-
tions and potential issues that medical app use may give rise to, it is useful to consider
the technical, economic, social and cultural changes that have paved the way.
Smartphone and tablet devices have become aordable mass-market consumer
electronics that are replacing earlier mobile devices, particularly in emerging mar-
kets (Gartner, 2013). These devices can be distinguished from their predecessors by
their smaller size, more powerful processors, larger memory, wider range of embed-
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ded sensors, increased connectivity options and greater capability to run sophisticated
software applications. That said, older generations of mobile phones are predicted to
continue to dominate in many parts of the world (Nielsen, 2013).
Current mobile computing devices, such as smartphones, tablets and “wearables”
(including “smartwatches”, wristbands, glasses, jewelry and other articles), are incre-
mental innovations (Abernathy and Utterback, 1978) that extend earlier healthcare in-
formation technologies, such as computers on wheels, laptops, pagers, personal digital
assistants (PDAs) and so on. However, it is not just the shape and features of mobile
devices that is evolving, but also the services and networks that underpin them.
With the growth of the Internet and the creation of online app stores, it has become
easier to publish mobile software to a large audience. Coupled with the expansion of
faster communications infrastructure, this is enabling new ways of creating and dis-
tributing software and data in many industries, not least in healthcare (Ofcom, 2014a).
Doctors, nurses and other healthcare practitioners rely heavily on computerised infor-
mation systems to carry out their duties (Reddy and Dourish, 2002, 344). Professional
and industry interest in mobile devices and apps thus stems from the utility of access-
ing medical information via familiar and widely used portable computer technology,
and the growing market for such devices and software.
To illustrate the growth and diversity of medical apps, one may consider the great
diculty of identifying and classifying recent work in this area. For example, Mosa
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et al. (2012) provides a broad classication of medical apps according to target audi-
ence (clinicians; students and patients) and purpose (diagnosis; drug reference; medical
calculator; literature search tool and many smaller subcategories). The classication
is based on 83 medical apps described in peer reviewed journals. As the number of
health-related apps are estimated to have exceeded 165,000 as of September 2015 (IMS
Health, 2015), this is clearly a limited taxonomy based on a very small sample.
Touching on some of the social and cultural issues, the growing use of medical
apps by both patients and healthcare practitioners have generated signicant media
interest. It is an area of research that “makes a good story” as occasionally it borders
the realm of cyborgian science ction. For example, research into biomedical sensors
embedded in contact lenses to provide wireless blood glucose monitoring for diabetics
(Yao et al., 2011) was covered in the international press.
Moreover, professional interest is evident by the Royal Society of Medicine’s annual
conference on medical apps, now in its fourth year (RSM, 2016). That said, Robinson
et al. (2013) and Dimond et al. (2016, 5) highlight concerns related to the perceived lack
of professionalism associated with the clinical use of mobile devices, especially in front
of patients. However, other studies suggest that there is a growing use and acceptance
of mobile device in the healthcare settings among patients (Illiger et al., 2014), nurses
(Johansson et al., 2014) and doctors (Bullock et al., 2015).
Similar concerns and changes in attitude were observed with regards to the adop-
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tion of health-related websites following the widespread adoption of the Internet in
the late 1990s (Diaz et al., 2002; Cline and Haynes, 2001). The key concern was that the
web contained (potentially misleading) medical resources that digitally savvy patients
could use to make healthcare decisions. Indeed, Lupton (2014) argues that medical
apps could be analysed as socio-technical artefacts produced in the setting of contin-
uing digitisation of medical information brought about by the Internet.
Changes in attitudes toward medical apps could perhaps be explained by the accep-
tance of mobile devices in the personal sphere, and the rise of distributed professional
and patient networks that make use of these technologies. For example, Masters et al.
(2016, 538) argue that the distinction between using a medical app for education and
clinical practice is blurring as mobile devices are used daily to carry out a wide range
of work and domestic tasks. So how are apps used in clinical practice?
2.2.1 Clinical use of mobile devices and apps
Healthcare practitioners’ ownership and use of medical apps have been explored in
several surveys. For instance, Mobasher et al. (2015) investigated the use of smart-
phones and tablets among 287 doctors and 564 nurses in ve hospitals in a single NHS
Trust. Over 95% of the responding doctors and nurses owned a smartphone, and 50%
of doctors reported using their smartphone instead of a bleeper. Nearly 80% of doctors
also owned a medical app, and of these 90% said that they used it in their practice.
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The study also found that medical app ownership and use was lower among nurses
(35% owned medical apps, of which 67% reported using it in their work). There is a need
for more work exploring nurses’ use of mobile devices, although it is possible that some
of these dierences in self-reported use could be attributed to the gendered nature of
care and technology work (Lindsey, 2007). For example, Hardyman et al. (2013) found
that smartphone usage was more frequent in male junior doctors (p<0.01).
In a survey of 76 surgical trainees in Scotland, Carter et al. (2014) found that nearly
all owned a smartphone and over half reported using it to access medical apps in their
practice. The apps included guidelines, calculators, anatomical references and study
guides. Seven of the participants had noted errors in the outputs of medical apps,
adding to concerns over lacking quality (discussed at the end of the chapter).
In another small study, O’Reilly et al. (2014) surveyed smartphone ownership and
the clinical use of apps among 61 junior doctors at two Irish university hospitals. Again,
almost all reported owning a smartphone and using it on-call for a variety of purposes,
such as to aid in diagnosis, dose medications, nd interactions between medications
and to access medical emergency protocols.
Additionally, many of the junior doctors felt that having a smartphone improved
their eciency, time management, communication with patients, condence, level of
knowledge and safety. They also felt that it reduced stress and the need to ask for help
from senior colleagues. Although there is little strong published evidence to support
44 CHAPTER 2. RELATED WORK
this belief, the smartphone was perceived by new doctors as an important tool that
improve their ability to carry out their responsibilities with condence.
This view is, however, supported by work undertaken by Bullock et al. (2015), dis-
cussed in detail in the later section on medical education. They found that junior doc-
tors transitioning into new roles used medical apps to resolve dicult clinical cases
and that this resulted in improved patient outcomes. Medical app use was also asso-
ciated with greater engagement with senior colleagues, suggesting that mobile tech-
nology inuences interprofessional relationships, such as those between junior and
senior sta. However, medical apps can be used in unintended ways - a notion known
as “interpretive exibility” (Pinch and Bijker, 1984) - making it dicult to predict their
outcomes on patient care without further quantitative and qualitative research.
In one of the largest studies of clinical smartphone use, Franko and Tirrell (2012)
surveyed 3306 students and doctors attached to the Accreditation Council for Gradu-
ate Medical Education in the US. 85% of respondents owned a smartphone and about
every other respondent reported that they used it in their clinical practice. They also
reported that respondents felt that there is a lack of high quality apps, especially for
medical textbooks and treatment algorithms. This suggests that there is demand for
high quality clinical decision-support and learning materials in the form of apps.
Finally, in one of the rst major studies of medical smartphone use in the UK,
Payne et al. (2012) surveyed 257 medical students and 131 junior doctors. They found
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that just under 80% of respondents owned a smartphone. This was a higher rate of
adoption than the population at large at the time
1
. Most respondents had between one
and ve medical apps installed on their smartphones and reported using them several
times every day, but for less than 30 minutes per day. The study concluded that medical
students and junior doctors are demanding more apps that could support their medical
education and clinical practice.
Perhaps encouraged by the demand of medical professionals and the potential to
increase the dissemination of their guidelines, several professional medical bodies have
now published apps intended to be used by healthcare practitioners in clinical decision-
making.
2.2.2 “Appication” of medical guidelines
Medical decision-making is a critical process that is inuenced by cognitive processes
and biases (Stiegler and Tung, 2014). The use of evidence-based medical guidelines
and heuristics can lead to better decisions (Grimshaw and Russell, 1993; Gigerenzer
and Kurzenhauser, 2005; Marewski and Gigerenzer, 2012). However, Tanenbaum (1999,
762) argues that standardised medical guidelines challenge the experiential knowledge
of health professionals and may promote detrimental rule-bound thinking. There are
also issues associated with disseminating and promoting the use of medical guidelines,
1
In 2013, less than two-thirds of UK adults owned a smartphone (Google/Ipsos, 2013), and only about
25% owned a tablet device (Ofcom, 2014b)
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such as raising awareness and changing existing practices (Lugtenberg et al., 2009).
The portability, searchability and the ease of distributing and keeping information
updated through mobile apps could potentially improve the dissemination and use
of medical guidelines. Charani et al. (2013) oers data, collected from the adoption
of an app with the antibiotics policy of the Imperial College Healthcare NHS Trust,
which lends some support to these assertions. The Imperial Antibiotics Prescribing
Policy (IAPP) app was promoted at several teaching sessions for junior doctors, via
an email and on the Trust’s intranet and newsletter. Within one month, 40% (374) of
junior doctors had installed the app. By twelve months, it was adopted by all (990)
junior doctors. User tracking suggested that the app was being accessed ten times
more frequently than the existing intranet version of the policy, and 81% of a sample
of 59 doctors felt that the app helped them adhere to the Trust’s policy.
This adaptation (or “appication”) of guidelines into app format is well under way
in other areas too. For example, all trust-approved hospital guidelines at the Notting-
ham University Hospital (NUH) are available as an app.
2
Furthermore, apps based on
national evidence-based guidelines have been published by bodies such as the National
Institute for Health and Care Excellence (NICE), the Scottish Intercollegiate Guidelines
Network (SIGN), the Royal College of Obstetricians and Gynaecologists (RCOG) and
the British Society for Haematology (BSH).
2
https://www.nuh.nhs.uk/nuh-guidelines-app/
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2.2.3 Mobile learning in medical education
Another area where apps have made inroads is in medical education. Popular medical
textbooks are widely available on mobile devices and Davies et al. (2012) trialled the use
of handheld iPAQ PDAs preloaded with reference textbooks among medical students.
Nearly 400 undergraduate medical students at a UK medical school took part in the
study, which was based on survey data and four focus groups.
Although the survey response rate was low, about half the students reported using
the devices at least weekly to access reference materials, such as drug and anatomy
textbooks. Barriers to mobile learning identied by students included negative atti-
tudes from colleagues towards using the devices on the ward, poorly designed and
unreliable technology, and the need to carry another device. Many participants also
expressed a preference for using a smartphone instead of a PDA.
In line with Traxler (2007, 7), the authors argue that mobile devices can enable
situational and “just in time” learning, and oer freedom to access resources in the
home or workplace place during low demand. The utility of smartphone devices in
medical learning has also been demonstrated in the Welsh “iDoc” initiative (Hardyman
et al., 2013; Bullock et al., 2015; Dimond et al., 2016). iDoc is a smartphone app which
provides o-line access to a selection of popular medical reference textbooks.
The app was rst made available to Welsh junior doctors in 2009 through the Wales
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initiative is notable for its evaluation focus. The Cardi Unit for Research and Evalua-
tion in Medical and Dental Education has evaluated the initiative repeatedly and have
furthered understanding of how junior doctors make use of apps in their practice.
Hardyman et al. (2013) oer qualitative evidence from real clinical situations en-
countered by junior doctors suggesting that the iDoc app enabled more expedient pain
management and assessment of patients. The app was also used to facilitate ad hoc
teaching and learning between patients and sta, for improving communication be-
tween practitioners, and for agging up complications during care planning.
Despite these positive outcomes, app-based textbooks and educational materials
are not supported and evaluated at an institutional level in many areas of medical ed-
ucation. For instance, desktop-based e-learning systems have dominated blood trans-
fusion education in the UK (Graham, 2015; Smith et al., 2014, 2011).
In the US, some medical schools have been early adopters of mobile devices in
the curriculum. For example, at the University of Utah, the Health Sciences Library
have supported the use of mobile devices since 2003 (Le Ber and Lombardo, 2012, 151).
Similarly, one year after the rst release of the Apple iPad tablet in 2010, the Yale
School of Medicine started providing their students with individual iPads and mobile
apps in an eort to move towards digital curricular delivery and to reduce paper waste
(Skomorowski et al., 2013, 22).
Other US institutions have since followed their example, and between 2011 and
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2012 all 119 residents at the Riverside Methodist Hospital were provided with iPads.
However, a survey of the clinical and educational utility of the iPads answered by
102 of the residents (86% response rate) found that the utility was low, partly due to
connectivity and technical problems (Skomorowski et al., 2013, 22).
US medical libraries have also explored the use of apps in learning and research. For
instance, the Pennsylvania Hospital Library provided iPads to patrons and analysed the
use of apps by clinicians for information seeking and patient education (Witman, 2012).
Similarly, the Mobile Technology Team at the University of Florida Health Science
Center Libraries have examined how they can support healthcare professionals’ use of
mobile devices and apps (Bushhousen et al., 2013, 67). In a study of 432 patrons, they
found that over 40% of respondents used apps to support their clinical duties, such as
looking up drug information or accessing journal articles (Bushhousen et al., 2013).
Furthermore, nearly all respondents expressed a desire for a list of vetted or quality
assured apps, suggesting a possible future role for medical libraries (Bushhousen et al.,
2013, 66). Other studies have also discussed the diculty for practitioners to identify
and decide on which apps to use (Wiechmann et al., 2015; Aungst et al., 2014; van
Velsen et al., 2013). Developing external review mechanisms to quality assure medical
apps is an issue that I return to at the end of the chapter. However, quality assurance
could also be viewed as an integral part of the design process and I will now consider
prior work relevant to the design of medical apps.
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2.3 Design of medical apps
Weaknesses in healthcare information technology and medical apps are frequently at-
tributed to limitations in the design process, such as failure to engage suciently with
users and medical experts, and to conduct and learn from timely evaluation research
(Pagliari, 2007; Car et al., 2008; Masters, 2014; Visvanathan et al., 2012; Hamilton and
Brady, 2012; Haey et al., 2013b; O’neill and Brady, 2012; Zhou et al., 2012).
What design work entails, and who is qualied to carry it out, is contested. The
study of design is fragmented (Margolin, 1989, 5) and attempts at narrowly dening
design may serve the interest of “professional” designers and exclude others – an ac-
tivity known as “boundary work” Gieryn (1983). In contrast, the denition by Simon
(1996, 111) argues that design is a process common to many professions:
“Everyone designs who devises courses of action aimed at changing existing situa-
tions into preferred ones. The intellectual activity that produces material artifacts
is no dierent fundamentally from the one that prescribes remedies for a sick pa-
tient or the one that devises a new sales plan for a company or a social welfare
policy for a state. Design, so construed, is the core of all professional training...”
According to this denition anyone with expertise relevant to a problem, including
patients and healthcare providers, could participate in design, regardless of whether
the end product is an app or another product. This perspective underpins the view that
users should be encouraged to participate in the design of healthcare information tech-
nologies (Berg, 1999). For example, Car et al. (2008, xxvii) argue that user engagement
is critical throughout the development of healthcare information technologies:
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“End-user consultation and feedback should be viewed as an on-going process and
should therefore continue after deployment to ensure that problems are identied
early [and] solutions [...] can be incorporated into system upgrades.”
However, many app developers appear to be out of touch with their users. In a
survey of over 3000 international app developers, only one quarter reported that they
planned apps in discussions with their customers (Vision Mobile, 2013a). Furthermore,
app stores are geared toward consumption and discovery of apps, rather than two-way
communication and collaboration between developers and users (Pagano and Walid,
2009). Interactions are typically limited to downloading, leaving comments and rating
apps. One approach to improve the quality of medical apps is then to make develop-
ment processes more open and collaborative to encourage healthcare practitioners to
become active participants or even take the lead during the design process.
2.3.1 User-centered design, lead users and co-design
Involving users in the development process is at the heart of user-centered design
(UCD). UCD is an approach to software development that can be traced back to the
1960s socio-technical systems approach (Ritter et al., 2014, 41). It advocates close col-
laboration between software developers and users to ensure that the resulting product
aligns with the needs and capabilities of users and the context in which they operate
(Kling, 1977; Norman, 1988).
There is a substantial UCD literature with several schools of thought and contin-
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uing debate about how to best apply UCD principles, not least in the creation of new
applications using contemporary web and mobile technologies (Williams, 2009; Peis-
chl et al., 2015). Lawler et al. (2011) includes user-centered design among ten human
factors recommendations for improving the design of healthcare information tech-
nologies. The recommendations are applicable to medical apps and also emphasise
software testing, training, risk assessment, continuous improvement and evaluation,
anticipation of future needs, eective workplace conguration and system usability.
Complementing UCD, work in innovation studies have demonstrated that compa-
nies can benet from identifying, learning from and involving so called “lead users” in
the design process (von Hippel, 1986). These are advanced users who are well-placed
to contribute to new products because they have an unmet need, intimate knowledge
of the context of use, and have often started to design a solution to resolve the problem.
In a medical context, lead users can be patients (Oliveira et al., 2015), nurses, doctors
(DeMonaco et al., 2006) and others. Another common label for a process where users
and developers work together to create a product is “co-design”. Sanders and Stappers
(2008) traces the history of co-design back to earlier work in user-centered design,
arguing that role of the “professional designer” is shifting towards that of a facilitator
and researcher.
The changing relationship between the user/consumer and designer/producer is
further analysed by Humphreys and Grayson (2008, 1) who argue that “‘co-creation’,
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‘co-production’, and ‘prosumption’ refer to situations in which consumers collaborate
with companies or with other consumers to produce things of value”. However, facili-
tating user collaborations can be dicult and there are few studies of how to apply such
principles in practice (Ram et al., 2007, 69). In the context of online consumer health
information, Norman and Skinner (2006, para. 1) argue that digital literacy skills (or
“eHealth literacy”) is critical to reap the benets of technology:
“Electronic health tools provide little value if the intended users lack the skills [...]
Engaging with eHealth requires a skill set, or literacy, of its own.”
This argument could readily be extended to healthcare practitioners. Digital skills
are vital to assess the quality of medical apps and to allow healthcare practitioners to
become critical consumers of medical apps (Haey et al., 2013a). Such skills are also
necessary to enable practitioners to become active contributors to medical apps, and
healthcare information technology more generally (Henwood and Hart, 2003, 264).
In Denmark, Thorell et al. (2015) surveyed 8000 medical students at the University
of Copenhagen to understand how they used information technologies, and whether
they felt that they were taught sucient ICT skills during their training. Of the 1165
students who responded (12% response rate), over half expressed interest in additional
training to ensure they acquired the ICT skills required in their profession.
In addition to facilitating skills development, the use of appropriate tools and meth-
ods is important for eective collaboration. von Hippel (2001) discusses how “user in-
novation toolkits”, including computer aided design software applications, have lead
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to new products in many industrial sectors. These are tools that make it easier for
users to create or customise products that suit their needs.
Collaborative software tools have been pioneered in the free libre/open source soft-
ware movement. For instance, Git is a distributed version control system that pro-
vides an eective way of handling changes to les made by multiple authors. It was
created to facilitate cooperation on the GNU/Linux operating system kernel, which is
embedded in mobile devices and Internet infrastructure (Perez-Riverol et al., 2016, 1).
Used by millions of projects, Github.com is a web-based service that extends Git
by oering social networking and community features (Ram, 2013). Dabbish et al.
(2012) interviewed 24 Github users and concluded that the service can improve col-
laboration, innovation, transparency and learning in knowledge-based projects. Sim-
ilarly, Ram (2013) argues that Github could improve reproducibility and transparency
in research. The core tenet of the free/libre open source movement - enshrined in its
license agreements - is that collaboration is more eective when resources, such as
source code, are made freely available for use, modication and reuse (an argument
expounded in Eric Raymond’s seminal book The Cathedral and The Bazaar).
However, open source tools and principles have so far had limited impact on health-
care software outside of niche areas (Janamanchi et al., 2009), although this may be
changing (Benson, 2016). For example, Perez-Riverol et al. (2016) provides ten rules for
improving collaboration practices in bioinformatics using Git and GitHub. Addition-
2.3. DESIGN OF MEDICAL APPS 55
ally, as the number of available medical apps are growing and the market is becoming
dicult to navigate for consumers, van Velsen et al. (2013) argue that there is a need
to develop a collaborative open source model to coordinate eorts.
While participative methods and tools could enable co-design and user innovation
in healthcare, such initiatives have faced barriers, including existing power relation-
ships, resistance to change and the drive for standardised healthcare (Batalden et al.,
2015). However, there are examples of projects where medical students and healthcare
practitioners have been supported to learn about and develop medical apps (Masters,
2014; Youm and Wiechmann, 2015).
These studies also show that it is important to inspire and empower practitioners
to become interested in the topic, as they may otherwise feel that they lack the mo-
tivation, condence and technical skills to get involved (Lindsey, 2007; Henwood and
Hart, 2003). Safe spaces for learning and experimentation, such as NHS Hackaday
4
,
could promote participative design in healthcare. Having explored the opportunities
and challenges associated with more participative and open approaches to medical app
design, I will now attempt to draw lessons from previous apps and design guides.
2.3.2 Case studies and design guides
There is a shortage of studies and systematic reviews that investigate how medical
apps are, or should be, designed at a generalisable level. However, there is a growing
4
http://nhshackday.com/
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number of studies which report ndings from the design of specic medical apps. I
will briey consider design lessons from three such studies, related to apps intended
to aid prescribing, decision support and care planning.
The National Centre for Infection Prevention and Management (CIPM) developed
a smartphone application to promote restrictive antibiotics prescription (Imperial Col-
lege, 2012, 2013; Charani et al., 2013). After establishing the need for the app, the au-
thors developed it and promoted it as part of a broader initiative to improve antibiotics
prescribing. One of the design challenges they encountered was that it was dicult
to push updates after the app had been installed by users and when new guidelines
became available. They also identied a range of cultural, technical and individual
barriers to adoption, such as organisational policies which restrict the use of mobile
devices in hospital environments.
Moreover, Yuan et al. (2013) discusses the design of an app aiming to provide acute
care decision support for nursing sta to identify patients who are deteriorating (a
topic explored in a PhD thesis at Sheeld University by Stevenson, 2016). They con-
ducted usability evaluation based on violations of Nielsen & Molich’s 1990 user in-
terface heuristic, task completion and timing, and the NASA Task Load Index. The
authors concluded that the design of the app’s user interface is t for purpose. How-
ever, they also acknowledge that training and cultural acceptance remain important
(and at the time of the paper outstanding) aspects to address to ensure uptake.
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Adopting an iterative development process involving a cross-functional team of
experts in medicine, ergonomics and software engineering, Ehrler et al. (2013) de-
scribes the creation of an app intended to enable nurses to plan their daily workload.
The authors identify and propose solutions for several challenges facing medical app
designers, including nancial constraints, hardware limitations, interoperability with
healthcare systems, data security and usability.
For example, they highlight the need for clear governance to overcome the inherent
conict between the typically “cheap and cheerful” approach associated with consumer
mobile apps and the requirement in medicine for reliable and high quality software.
The authors also oer recommendations for ensuring a high degree of usability in
medical apps and reducing the likelihood of user error by having a predictable and
familiar user interface that structures information sensibly.
In summary, although the examples are diverse and context-specic, studies of this
kind are useful for informing future work. They oer lessons that can preempt unfore-
seen challenges. They can also help identify methods for assessing apps and provide
suggestions for how barriers could be overcome. However, it is hard to consolidate
knowledge from individual studies and there are few systematic reviews. Medical app
development guides that aim to promote good design practices could help ll this gap.
Unfortunately, the availability and quality of current guides is limited. One of the
most extensive resources targeting those interested in medical app development in the
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UK is the 2014 NHS Guide for Developing Mobile Healthcare Applications (NHS Innova-
tions South East, 2014). Following a linear eight-step medical app development process,
the guide spans pre-development, design and development, user testing, stakeholder
review, medical device approval and deployment to app stores through to marketing
and “monetisation” (i.e. a discussion of dierent business models for medical apps).
The guide is a useful and easy to use introductory resource for gaining an overview
of the medical app development process. However, it does not address the importance
of planning and budgeting for software maintenance and evaluation research. It also
provides little in-depth advice for anyone who are looking to resolve technical ques-
tions or issues related to evaluation methodology. For example, the guide does not
help to answer questions such as which technical framework to use or what might be
appropriate evaluation methods and endpoints.
Another perspective on the medical app development process is oered by John-
ston et al. (2015) who have proposed the “CDE” model. It involves three steps, each
corresponding to a letter of the abbreviation: C - Clarify the task; D - Design the app;
and E - Evaluate it. While it is a simple to remember acronym that places empha-
sis on key aspects, such as evaluation, the model could be criticised for adopting an
incomplete and non-iterative bird’s eye view of the development process.
For example, it omits key steps in the app life-cycle, such as bug xing or promo-
tion. It also does not consider the importance of broader socio-technical issues, such as
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securing clinician and management support. Naturally, the development of a medical
app is not just concerned with the look or feel of the nal product – aspects treated
in generic mobile app design advice oered Google (2015) and Apple (2015) – but also
the way in which it is promoted and implemented in the workplace.
2.3.3 Implementation design and organisational change
Good product design - characterised by ease of use, high task completion, appealing
aesthetics and pleasure from use - is important but insucient to ensure the uptake of
healthcare innovations (Greenhalgh et al., 2004; Silverstone and Haddon, 1996). This
insight has prompted Karsh (2004) to develop what he calls “implementation design
principles”. These emphasise the importance of creating a structured implementa-
tion approach or “roadmap” to ensure appropriate training programmes, pilot testing,
management support, organisational communication structures, feedback and other
aspects are in place to ensure a successful adoption process.
A concrete example is oered by Murphy et al. (2009) who provide a detailed
account of the development and staged implementation of an end-to-end electronic
transfusion system in three hospitals in Oxfordshire over the course of ten years. They
identify several critical success factors, such as time, resources and expertise, team-
work, staged implementation, management and clinician support, investing in training
and a determination to overcome organisational issues and technical problems.
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Table 2.3: Aspects inuencing the adoption of healthcare innovations, adapted from
Greenhalgh et al. (2004, pp. 13-15).
Aspect Desirable properties and circumstances
1. Relative advantage Clear eectiveness advantage recogised by all key players.
2. Compatibility Match the norms, values and perceived needs of adopters.
3. Complexity Simple to use.
4. Trialability Easy for users to try out and experiment with.
5. Observability Benets are visible to the users.
6. Re-invention Modiable by the adopter to t their needs.
7. Task relevance Relevant to the user’s work responsibilities.
8. Task usefulness Improves the performance of the user.
9. Feasibility Workable in the intended setting of use.
10. Implementation Can be used immediately without overcoming barriers.
11. Divisibility Support incremental adoption.
12. The nature of the
required knowledge
Implementation knowledge is codied and transferable to
new settings.
Similarly, Edmondson (2003) analysed the introduction of new cardiac surgery
technology in four hospitals. The study shows that the success of the implementa-
tion was contingent on team work, dynamic leadership and a framing of the project
as learning journey that involved trial and error. Moreover, Greenhalgh et al. (2004),
extending the Diusion of Innovation Theory (Rogers, 2003) to health services organ-
isations, have identied key factors inuencing the uptake of healthcare innovations
(summarised table 2.3). They place particular emphasis on ensuring user acceptance
(items 3, 4, 5, 7, and 8 in the table) and achieving a good “t” between the innovation
and the organisational setting of use (items 1,2, 9 and 10).
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Furthermore, Berg (1999) argues that the implementation of healthcare information
technology is a political process of organisational change. This process is “messy” and
dees simplistic linear accounts. Rather it requires “...an iterative approach, in which
the distinctions between ‘analysis’, ‘design’, ‘implementation’ and ‘evaluation’ blur”
(Berg, 1999, 87). Hence, the widespread notion of an upfront “design” phase is mislead-
ing as design work continues during the implementation process. For example, design
work may take the form of healthcare practitioners coming up with “workarounds” to
ensure electronic healthcare record systems better meet their needs (Berg, 1999, 97).
This continuation of design during implementation has been labelled “innofusion”
(a contraction of innovation and diusion) by Fleck (1994, 638). The notion extends
domestication theory, which highlights the work that users carry out to make sense of
and incorporate innovations in their lives (Silverstone and Haddon, 1996).
Finally, formative evaluation plays a critical role in the development of eHealth in-
terventions (Granlien, 2010, 49). Separating “evaluation” from “design” is thus a false
dichotomy as these activities are closely related and ideally feed o one another, al-
though they of course also compete for limited resources (Pagliari, 2007, p.5):
“... economic drivers prioritize the production of resources that meet key func-
tionality criteria and client-dened requirements within commercially viable time
frames. Evaluation often takes a lower priority, and rapid application develop-
ment using small convenience samples of users is common”
However, one cannot neglect one activity over another other because as Craig et al.
(2006) argue there is a need to balance all stages of the process:
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“Developing, piloting, evaluating, reporting and implementing a complex inter-
vention can be a lengthy process. All of the stages are important, and too strong
a focus on the main evaluation, to the neglect of adequate development and pi-
loting work, or proper consideration of the practical issues of implementation,
will result in weaker interventions, that are harder to evaluate, less likely to be
implemented and less likely to be worth implementing.”
I return to this tension between design and implementation versus the need to
generate strong evidence by conducting rigerous evaluations in in chapter four. I will
now turn to the evaluation of medical apps, relating it to prior work on evidence-based
medicine, risk management, quality assurance and regulation.
2.4 Evaluation of medical apps
Evaluation has connotations to a wide range of critical issues related to medical apps,
including evidence-based medicine (should apps be used in medical practice?), research
methodology (how should apps be evaluated?), risk management (how should apps be
risk assessed?) and regulation (how should apps be regulated?). I will begin by giving
an account of the state of current evidence for medical apps.
The clinical use of medical apps has sparked considerable debate because most lack
strong supporting evidence (Boulos et al., 2014; McCartney, 2013; Buijink et al., 2013;
Kamerow, 2013; Ozdalga et al., 2012; Nolan, 2011). Furthermore, studies have iden-
tied weaknesses in medical apps intended to be used by professionals in specialties
such as cardiology (Kumar et al., 2015), dermatology (Hamilton and Brady, 2012), en-
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docrinology (Eng and Lee, 2013), microbiology (Visvanathan et al., 2012), oncology
(Bender et al., 2013; Wolf et al., 2013), pharmacology (Haey et al., 2013a,b), urology
(Pereira-Azevedo et al., 2015) and women’s health (Derbyshire and Dancey, 2013).
For instance, Hamilton and Brady (2012) reviewed 79 dermatology-themed apps
and found that only 20 disclosed the authors’ medical qualitications. While acknowl-
edging the potential of apps for improving dermatology practice – for example by
applying vision algorithms to classify skin pigmentations – the authors expressed con-
cern over apps that claim to diagnose skin lesions and oer a false sense of security.
The authors call for more transparent disclosure of the app creators, and for external
quality review processes to guarantee the accuracy of the apps.
Haey et al. (2013b) reviewed mobile apps that aid opioid prescription. They as-
sessed 23 apps intended to support dose conversion when switching between opioids,
using criteria such as output dose recommendation and the level of professional med-
ical involvement in the design. In this study, about half the apps clearly signaled pro-
fessional medical involvement and referenced sources.
Additionally, eight apps did not warn the user about dose reductions, which is a
standard practice when switching opioid. The study authors call for stronger regula-
tion of medical apps to prevent potential harm to patients. Similarly, Visvanathan et al.
(2012) reviewed 94 apps in microbiology. They found that only one in three provided
information about the medical expertise of the authors or contributors, once again
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raising questions about the quality of the medical content.
In a subsequent review of drug prescription apps more generally, Haey et al.
(2013a) analysed over three hundred apps (including “appied” medical textbooks).
They concluded that there are medical apps that could potentially improve prescription
practice, but that the medical expertise of the app developers must be made available
so that clinicians can make informed choices about which apps to use.
Pereira-Azevedo et al. (2015) conducted a systematic review of 150 urology apps for
Android and iOS devices. Their ndings mirror the previous studies in that a signi-
cant portion of apps lacked evidence of healthcare professional input. Only just over
one third of apps were developed by a scientic urology association. To address this
issue, Pereira-Azevedo et al. (2015, 2) suggest that “... urologists become stakeholders
in mHealth, shaping future app design and promoting peer-review app validation.”
Studies of apps for patients also oer important lessons. For example, Kumar et al.
(2015) reviewed 107 apps for self-management of hypertension. They found that 14%
purported to provide reliable measure of blood pressure, yet none of the apps used a
blood pressure cu or other validated method for measuring blood pressure.
Diabetes is a popular topic for self-help apps and Demidowich et al. (2012) con-
ducted a review of 42 Android apps intended to help diabetics manage their blood
sugar, medications and insulin doses. Two evaluators scored each of the apps inde-
pendently according to features and usability criteria. The apps were ranked and the
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authors concluded that clinicians may want to recommend the top ones to patients.
Likewise, West et al. (2012) reviewed a wide range of apps aiming to enhance public
health through exercise, healthy eating and other positive behavioural changes. They
evaluated the apps against the Precede-Proceed Model of behaviour change, nding
that few apps address all stages recommended for behavioural change (predisposing,
enabling, and reinforcing), and therefore are less likely to be eective.
Finally, Eng and Lee (2013) analysed endocrinology apps intended for either pa-
tients or healthcare practitioners. They found several insulin calculator apps that
would be classied as medical devices, but which lacked any indication of having gone
through FDA regulatory approval. Additionally, they concluded that “... it is certainly
possible that use of these apps could lead to adverse events.” (Eng and Lee, 2013, 6).
Although studies such as the above are useful in gaining an overview of currently
available apps, one limitation is that they tend to consider a large number of apps
relatively shallowly. There is a shortage of peer reviewed evaluations that examine
a smaller number of apps in greater depth, and that are written by authors who are
independent from the development team.
One exception, however, is the study by Morris et al. (2013). They conducted a small
RCT to evaluate two competing smartphone apps for calculating uid replacement
in burns victims. 34 trainee and consultant surgeons in Burns and Plastic Surgery,
anaesthetists and nursing sta were asked to carry out simulated uid calculations
66 CHAPTER 2. RELATED WORK
using a standard calculator, the “uBurn” app and the “Mersey Burns” app.
No signicant dierence was discerned between the interventions in terms of the
accuracy of the calculations or the ease of use. However, participants completed the
calculations quicker when using the apps. The authors therefore concluded that both
apps are suitable for clinical use. The Mersey Burns app is also one of the rst apps
that have been registered as a medical device in the UK.
The lack of evidence of the eectiveness of medical apps extends to other health-
care information technologies. The report entitled The impact of eHealth on the quality
and safety of healthcare (Car et al., 2008) was the culmination of an ambitious research
project investigating the impact of eHealth interventions. Having reviewed 284 ran-
domised controlled trials and 67 systematic reviews, the authors concluded contrarily:
“... eHealth applications have the potential to dramatically improve the quality of
healthcare delivery [...] [and] the safety prole of medicine through elimination of
both latent and active errors [—] The major nding from reviewing the empirical
evidence - which is of variable quality - however, is that there is very limited
rigorous evidence demonstrating that these technologies actually improve either
the quality or safety of healthcare.” (Car et al., 2008, xxv)
A lack of evidence does not imply that use is necessarily inappropriate however.
There are multiple reasons why good evidence about the impacts of eHealth interven-
tions is lacking. Car et al. (2008, xxvi) have identied several causes, such as a general
lack of primary research, serious methodological aws and failures to consider the
socio-technical context of healthcare information technology projects. Furthermore,
high quality evaluations of eHealth interventions can be time-consuming, expensive,
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dicult to conduct and may rank low on the agenda. The evaluation of healthcare
information technologies also raises methodological and epistemological challenges.
2.4.1 Methodological and epistemological issues
Understanding the consequences of medical interventions, including computer-based
interventions, is a central concern for medical research. Evaluation research is nec-
essary to assess the impact of interventions. There are ample examples where such
research has established that previously accepted medical practices have caused more
harm than benet, such as with the routine use of corticosteroid in adults with head
injury (CRASH trial collaborators, 2005). Conversely, research has strengthened the
evidence for the eectiveness of treatments. For instance, the use of tranexamic acid, a
cheap and widely available drug that improves blood clotting by preventing the break-
down of brinogen, has been demonstrated to reduce mortality in bleeding trauma
patients (Roberts et al., 2011, 2010).
These examples illustrate that, like Popperian science where knowledge takes the
form of conjectures which are upheld until falsied (Miller, 1983), medical practice is
tentative and must be revised in line with new scientic evidence. A dominant thought
in western medicine embodies this principle. Evidence-based medicine (EBM) is “the
conscientious, explicit, and judicious use of current best evidence in making decisions
about the care of individual patients” (para. 3 Sackett et al., 1996).
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While the core principle underlying EBM paradigm is sound, it is not unprob-
lematic (Greenhalgh, 2014) and dogmatic insistence on published evidence from ran-
domised controlled trials (RCTs) have been parodied (Smith and Pell, 2003). Further-
more, there are concerns over publication bias and there have been calls to increase
transparency in clinical trials given the substantial commercial interests at stake when
developing new drugs and treatments (Dunn et al., 2012).
There are also criticisms pertaining to the hierarchical rating systems, such as
GRADE (GRADE working group, 2013), that are used in evidence-based medical guide-
lines and systematic reviews (Cochrane, 2013) to rank the quality of available scientic
evidence. These systems enable judgements to be made between observational stud-
ies, usually more qualitative in nature, and quantitative studies, such as randomised
controlled trials (RCTs).
RCTs are resource-intensive, dicult or even impossible to apply to certain prob-
lems and are largely incompatible with the interpretivist research paradigm (Treasure,
2009; Smith and Pell, 2003; Rees, 2000, 2002, 2008, 2010; Wadman, 2013). For exam-
ple, Treasure (2009) argues that surgeons rely on knowledge accumulated on a case
to case basis which cannot be easily demonstrated using randomised controlled trials.
Similarly, evaluating eHealth interventions is very dierent from evaluating a drug.
Identifying the most appropriate way to evaluate computer-based interventions is
dicult and contentious. Assessing the impact of eHealth interventions using RCTs is
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thus not always possible and risks missing the signicance of context-specic aspects
of the intervention, such as their uptake in actual workplaces:
“Systematic reviews of RCTs [randomised controlled trials] are, on account of
their ability to control for known and unknown confounders, the "gold standard"
evidence source in relation to studying the eectiveness of interventions. Whilst
RCTs and systematic summaries of these are ideally suited for studying drug treat-
ments, they are [—] unable to shed detailed insights on whether systems will be
used or indeed how they will be used - factors which greatly inuence the eec-
tiveness (as opposed to ecacy) of interventions when implemented in routine
practice.” (Car et al., 2008, 20)
To discuss the role of RCTs in establishing the eectiveness of medical apps, it is
useful to consider an example. The developers of iResus, a smartphone app based on
the UK Resuscitation Council’s resuscitation guidelines algorithms, conducted an RCT
to assess the impact of their app (Low et al., 2011). 31 junior doctors with life support
training were randomly allocated into two groups. One group was provided with ac-
cess to the iResus app and the control group was not provided with any cognitive aid.
Performance was scored on the simulated cardiac arrest simulation test (CASTest).
The app arm performed signicantly better in the test and the authors concluded
that the app signicantly improved performance. The authors justify the research de-
sign by arguing that “... most cardiac arrests do not occur near a wall poster, and most
healthcare professionals do not carry card-based cognitive aids. Thus, we considered
a study group using iResus compared with a control group with no cognitive aids to
be most representative of the real world.” (Low et al., 2011, 260).
This reasoning can be criticised as, using the same logic, one could argue that most
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clinicians will not have the iResus app installed on their phone. Furthermore, the app is
very similar to the paper-based owchart guidance issued by the Resuscitation Coun-
cil, suggesting that this is an obvious control intervention. If the control group had
access to the paper-based intervention (such as a printed ow chart of the bradycar-
dia algorithm), the comparison arguably would have been more meaningful because it
would have provided insight into how the type of medium impacts performance.
For example, a recent study have suggested that paper-based cognitive aid are
favoured over the electronic version by trainee anaesthetists in a simulated pediatric
cardiopulmonary resuscitation setting (Watkins et al., 2016). These criticisms of the
iResus study highlights the diculty of designing RCTs for medical apps.
Heatheld et al. (1998) identify key challenges for evaluating healthcare informa-
tion technology interventions using RCTs; namely, RCTs are dicult to generalise and
have low validity as they rarely establish the acceptability of interventions. They ad-
vocate the use of methods that combine qualitative and quantitative approaches.
Having discussed methodological and epistemological issues, oered examples from
current evaluation studies and highlighted the general lack of independent and peer
reviewed supporting evidence for medical apps, it is appropriate to consider potential
risks associated with medical app use and how these could be mitigated.
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2.4.2 Risks and unintended consequences
Although it is hard to nd published examples of medical apps that have caused direct
harm, the use of untested, incorrect or misleading apps can conceivably pose risks.
Charles Perrow, a prominent scholar in human factors, argues that unintended conse-
quences and accidents involving complex and tightly coupled technological systems
are inevitable (Perrow, 1999).
Many healthcare processes can be characterised as complex and tightly coupled as
they involve many actors and specialist knowledges, are time critical with little built-
in slack, and inadvertent errors at key stages can have serious consequences down the
line. For example, in transfusion medicine the mislabelling of a blood sample (“wrong
blood in tube”) is a serious mistake that can be potentially catastrophic for the patient.
Preventing the consequence of this error requires vigilant sta who can detect the
error in time and stop the transfusion (Bolton-Maggs et al., 2015b). This is particularly
challening in time critical situations and during periods of high workloads and sta
shortages.
Hence, as the adoption and level of sophistication of medical apps increase, the like-
lihood of introducing unanticipated negative impacts also increase. The current lack
of evidence of negative impacts could be due to under-reporting, publication bias and
a shortage of evaluations. What is clear is that the impacts of healthcare information
technologies are complex and cannot be assumed as “given”. For example, a study of
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clinical decision support systems by Campbell et al. (2006) suggests that computerised
decision aids have unintended consequences, such as increasing workload, introduc-
ing new kinds of errors and making healthcare practitioners excessively dependent on
technology.
Some of these negative impacts derive from the limited capacity of humans to pro-
cess information, and are applicable to the introduction of most information and com-
munication technologies in the workplace (Lawler et al., 2011). For instance, mobile
technologies, such as smartphones, are a potential source of distraction (Gill et al.,
2012) and could reduce patient safety in certain situations, such as in the operating
theater (Jorm and O’Sullivan, 2012).
The American Association of Nurse Anesthetists issued a statement on mobile
phone use which ag up a range of potential problems related to mobile devices (AANA,
2012). These include reduced clinical vigilance, hygiene issues due to bacterial contam-
ination of the phone (further explored in Albrecht et al., 2013), privacy concerns related
to misuse of the phone’s camera, interference with medical equipment, lack of valida-
tion of the clinical content of apps and the evolving state of regulation. These issues
raise questions about the roles and responsibilities of medical app developers and pub-
lishers, app stores, individual healthcare practitioners, professional institutions and
government bodies in regulating and quality assuring medical apps.
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2.4.3 Regulation and quality assurance
There is debate and uncertainty over the regulation of medical apps (Visvanathan et al.,
2012; Kamerow, 2013; Haey et al., 2013b; Cortez et al., 2014). Lewis and Wyatt (2014)
propose a four-level framework for assessing the risks of medical apps, ranging from
individual self-assessment, professional peer review and formal review by local health
organisation through to central government regulation for those apps that pose the
highest risks. How such a risk model could be applied in practice remains to be seen
and I will therefore consider existing measures. I have termed these the “market-based”,
the “centralised regulation” and the “trusted intermediaries” approaches.
The “market-based” approach is the modus operandi of app marketplaces where
users purchase and download apps, such as Google Play or Apple’s Appstore. It is
based on the principle that the market self-adjusts: given competition, unsatisfactory
apps fail because consumers favour the better apps. This approach is somewhat analo-
gous to evolution through natural selection. It assumes that consumers have the infor-
mation, knowledge and skills to make good decisions, and the power and motivation
to inuence markets. While consumers have some inuence, consumer power has
become a cliché and is limited unless it is well-organised (Denegri-Knott et al., 2006).
As discussed previously, not all app developers reach out to their users and app
stores oer little to encourage collaboration. Consumers can also be misled into pur-
chasing and using low quality apps. For instance, the Federal Trade Commission (FTC),
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the US consumer protection agency, have investigated apps with unsubstantiated or
misleading health claims. The company behind the “UltimEyes” app was ned $150,000
for claiming that it improved users’ vision (FTC, 2015a). Another company claimed
their app cured acne with the light emitted from a mobile device display (FTC, 2011).
The FTC have also taken down apps that claim to diagnose melanoma (FTC, 2015b).
Recognising the importance of intervening regulatory bodies, such as the FTC, the
“centralised regulation” approach to improving medical apps builds on existing legal
frameworks. This includes product safety and consumer protection, but also medical
device regulation. Although the legal denition of a “medical device” dier depending
on jurisdiction, simply put it refers to healthcare products, such as medical equipment
or drugs, that are subject to strict quality control because they could endanger patient
health if they operate incorrectly or are unreliable.
The regulation of medical devices in the UK falls under the authority of the Medicines
and Healthcare products Regulatory Agency, which have issued guidance for medical
apps that is harmonised with European legislation (MHRA, 2010, 2014). In the US, the
Food and Drug Administration (FDA) updated its advice regarding the regulation of
medical apps in September 2013, and again in February 2015 (FDA, 2015).
According to the FDA (2015, 8), only those medical apps that are deemed to meet the
criteria for a medical device (e.g. intended “for diagnosis of disease or other conditions,
or the cure, mitigation, treatment, or prevention of disease”) and “whose functionality
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could pose a risk to a patient’s safety if the mobile app were to not function as intended”
are actively regulated. The MHRA have also made it clear that they will only actively
regulate a small proportion of available medical apps.
Consequently, there are relatively few public cases where apps for healthcare prac-
titioners have been withdrawn. For example, a medical imaging app for reviewing MRI
and CT imagery was taken o the Apple app store for two years while it was being
cleared by the FDA (Dolan, 2010). The FDA also informed Biosense Technologies that
their “uChek Urine analyzer” app requires clearance (FDA, 2014; Dolan, 2013) and it
has since been unavailable on the iTunes app store. Furthermore, a rheumatology app
aimed at clinicians was withdrawn by Pzer due to software bugs that caused inam-
matory diseases activity to be scored incorrectly (Jelle Visser and Bouman, 2012).
Kamerow (2013) argues current regulatory policies reect the huge eort required
to regulate a changing sector. In the updated regulatory policies, a large portion of
clinical apps are classed as “low-risk” and therefore outside the oversight priorities of
regulators. Thus, the vast majority of medical apps fall outside the remit of regula-
tors and require a dierent quality review mechanism. One alternative is the “trusted
intermediaries” approach, where medical apps are “vetted” by a trusted third party.
There are several examples of such initiatives, including some medical libraries, the
NHS Health Apps Library, iMedicalApps, Happtique and other websites. NHS England
launched the Health Apps Library (HAL) website in March 2013, listing apps that are
76 CHAPTER 2. RELATED WORK
“safe and trusted” for patient use (NHS Choices, 2013). HAL claim it will not approve
apps that are likely to cause harm to patients. It is unclear how this is determined,
although HAL apply the Information Standard branding to certain apps.
This is a certication scheme for health and social care information commissioned
in 2009 also by NHS England. The certication is intended to show that healthcare in-
formation is clear, accurate, impartial, evidence-based and up-to-date (NHS England,
2013). To achieve certied status, products require adequately documented informa-
tion writing processes, use of referencing, user testing and commitment to review ma-
terial at least every three years (NHS England, 2013).
Predating HAL, the iMedicalApps website have published reviews of medical apps
since 2009 (iMedicalapps, 2013). Unlike HAL, it focuses on apps intended for healthcare
professionals rather than patients. The website appears to be updated more frequently
and oers more details of the strengths and weaknesses of the reviewed apps compared
to HAL. However, it is dicult to know how they decide which apps to review and
whether the reviewer possesses sucient expertise in the area. iMedicalApps supports
free text search and there are several reviews of apps related to blood transfusion and
haematology at the time of writing (August 2016). The website is US-based and its
reviews are therefore not always applicable to medical practice in the UK.
Intermediaries have met with limited long-term success as conducting in-depth
reviews of medical apps is dicult and resource-intensive, and the business model
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is unclear. Huckvale et al. (2015) showed that nearly 80% of the HAL-approved apps
suered from signicant privacy limitations. For example, the apps sent information
to third parties and did not store data using encryption. Since October 2015, the HAL
website is no longer operational. Another notable certication programme, Happtique,
was similarly decient and even more short-lived:
“Happtique recently announced the suspension of their App Certication Pro-
gram after [...] security aws in apps [...] from Happtique’s rst round of ’cer-
tied’ apps. [...] these ndings were an embarrassing setback for a program [...]
intended to help patients and clinicians feel condent about their app selections.
[—] Happtique took a year and a half to certify 16 apps from 10 developers. Sim-
ilarly, the NHS Health Apps Library, which evaluates apps to ensure they are
clinically safe, launched in March 2013 with about 70 apps; nearly a year later,
its at about 100 apps. But these certied apps are a drop in the bucket compared
to the nearly 50,000 apps in the iOS App Store Health/Fitness and Medical sec-
tions alone. These kinds of intensive programs are simply not scalable. And in a
pay-for-certication model, it’s not necessarily the best that become certied but
rather those with suciently deep pockets.” (para. 1, 7 Misra, 2014)
2.5 Chapter summary
The purpose of this chapter was to situate the thesis in the existing research landscape
and to identify key issues pertaining to the use, design and evaluation of medical apps
for healthcare practitioners. It proved challenging to gain a complete overview of the
state of research for several reasons. The literature is fragmented, there is a shortage
of comprehensive systematic reviews and seminal work in eHealth predates current
mobile technologies that have expanded rapidly in the last few years. Nonetheless, a
number of conclusions can be drawn from this review.
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Recent innovation and uptake of mobile apps have been fueled by gains in device
manufacturing, faster network infrastructures and new commercial services that make
it easy to publish software to billions of devices, as well as shifts in social and cultural
norms and values. Earlier work in eHealth and social studies of technology provide a
nuanced view of these developments.
Unlike hyped-up and technologically determinist accounts of how medical apps is
“impacting on” healthcare in simple ways, the use, design and evaluation of medical
apps can be understood as uid socio-technical phenomena that are embedded in com-
plex and politically-textured change processes taking place in the healthcare sector.
What sets medical apps apart from earlier generations of centrally imposed tech-
nology initiatives, such as the NHS National Programme for IT, is that apps can be
adopted on an individual and “pick and mix” basis. This oers great exibility to users,
but makes it dicult to control access centrally. For the same reason, it is also dicult
to study and draw conclusions about the impacts of app use in healthcare settings.
Surveys oer some insight into the clinical use of medical apps, although it should
be noted that ndings may be biased towards adopters due to the widespread use of
participant self-selection.
Numerous studies suggest that smartphone adoption is approaching a saturation
point among some categories of healthcare practitioners. For example, the smartphone
is a highly valued tool among junior doctors as it can support work tasks and increase
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condence when carrying out duties. Furthermore, both national evidence-based med-
ical guidelines and local hospital guidelines are available in app form. Many of these
initiatives have not yet been carefully evaluated (and possibly never will be), but there
is some evidence that apps could promote the use of medical guidelines and improve
clinical decision making. For example, the IAPP improved the dissemination of antibi-
otics prescription policies among junior doctors.
The use of apps in medical education is well under way. The mobile learning ap-
proach is advocated by some scholars as it could extend earlier e-learning initiatives by
oering “just in time” and situated learning experiences in and beyond the classroom.
Although textbooks and other learning resources are available as apps, institutional
support for using apps as part of medical education vary. Utilisation is low in some
areas of medical practice and technical problems have hampered initiatives in the past.
Furthermore, apps spanning a wide range of specialties have been found to suer
from important shortcomings, and there is quite vocal concern among some scholars
and commentators that their use could be detrimental to patient safety. Others, such
as the American Association of Nurse Anesthetists, have warned that the clinical use
of mobile devices in general could have serious side eects, such as reducing clinical
vigilance by creating distractions, causing an over-reliance on technology, jeopardising
patient condentiality and contributing to spreading bacterial infections.
Mitigating these risks is not trivial and requires multiple interventions. Attempts
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at top-down regulation of medical apps have met with limited success as the majority
of medical apps fall outside the remit of regulators. Indeed, some of the most publicised
examples of apps that have been withdrawn from the market originate from consumer
protection agencies targeting consumer-oriented apps which make misleading mar-
keting claims, rather than from the bodies that regulate medical device safety.
Repeated calls from scholars and medical professionals for a “certied selection”
or “white-list” of trusted medical apps also look increasingly unlikely to gain traction.
Notable initiatives, such as the defunct NHS “Health Apps Library” and Happtique,
which both intended to oer comprehensive app certication programmes, have failed
to review apps in a transparent, eective and timely fashion.
A more promising approach is to invest in training to enable healthcare practi-
tioner to manage the opportunities and perils of (untested) medical apps. The notion
of an “eHealth literacy” (or “medical app literacy”) is pertinent as practitioners retain
responsibility to patients and must exercise caution whether they rely on a paper-based
medical guideline or an “appied” version. Although some medical schools have en-
couraged their students to learn about and create apps, other educational programmes
may be failing to provide students with the necessary IT skills and knowledge.
A novel way to attempt to tackle this issue is to develop mechanisms that encourage
healthcare practitioners to participate actively in the design and evaluation of medical
apps. Failure to involve healthcare practitioners in the development process, together
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with a general lack of medical app evaluation research, are among the most frequently
cited causes of deciencies in apps. Thus, there is a need for collaborative app design
and evaluation research across professional boundaries.
The open source and open science movements could oer lessons for such an en-
deavor. These seek to promote increased transparency and openness in software de-
velopment and medical research by opening up access to computer code and research
data, including data from clinical trials. These approaches could potentially make it
easier to inspect how apps work, and to assess their correctness. However, there are as
yet few examples where this strategy has been successfully used. Apart from a small
number of counter-examples, political and cultural barriers, such as entrenched power
structures, have previously impeded these approaches in medicine.
Additionally, it is critical to develop a more integrated approach to app develop-
ment that incorporates iterative design with evaluation research. Perspectives from
user-centered design, co-design, user innovation and evaluation research are valuable
in furthering this agenda. As are insights from the social studies of technology and
innovation that suggest that design, implementation and innovation should be under-
stood as interleaving processes. Thus, simple linear models of the software life-cycle
are misleading and brush over the potential for innovations by users. Additionally,
there is a need to develop appropriate app evaluation methods that strike a balance
between validity, reliability, cost and rigour, and which generates data that can be
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used to improve the quality and credibility of apps.
To summarise, the growing adoption of apps by practitioners raise questions about
the extent to which medical apps are safe to use and how one would determine this.
It also raises questions about how development and evaluation processes should be
carried out to ensure medical apps are “t for purpose”. There is little research evidence
to answer these questions with condence. Indeed, the impacts of medical app use on
clinical outcomes is rarely known and few studies have demonstrated the mechanisms
by which apps may have contributed to improvements in actual patient outcomes.
Until stronger evidence is available, the use of medical apps will remain contentious.
Chapter 3:
Blood transfusion in the UK
This chapter aims to provide a concise introduction to blood transfusion in a UK
context. Knowledge of the composition, manufacture and clinical use of blood compo-
nents underpin the assumptions, rationale and research strategy of the thesis. In this
chapter, I discuss these topics with particular emphasis on the correct care of patients
who require irradiated and Cytomegalovirus (CMV) negative blood components. The
last part of the chapter draws on learning materials that I developed for the Special
Blood Components app, and which has been reviewed by the research collaborators
acknowledged in the preface of the thesis. The chapter concludes with a summary of
the main ndings.
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3.1 Composition and function of human blood
Blood is a tissue that interacts with many systems within the body, such as the circu-
latory, immune and respiratory systems. It is vital for the transportation of nutrients,
gaseous exchange, defending against infections, healing wounds and regulating tem-
perature (Schaller et al., 2008, 8). Moreover, blood is separable into four main com-
ponents. Plasma makes up about 55% of human blood by volume and is composed
mostly of water, together with small amounts of mineral salts, ions, carbohydrates,
amino acids, gases and products of metabolism (Schaller et al., 2008, 12). Suspended in
the plasma are three types of blood cells (gure 3.1).
Figure 3.1: Scanning electron microscope (SEM) image of a red blood cell, an activated
platelet cell and a white blood cell (t-lymphocyte). Public domain image by National
Cancer Institute (2011).
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Red blood cells (erythrocytes) account for about 45% of human blood by volume.
They contain haemoglobin, a protein that binds oxygen required for cell metabolism
(Schaller et al., 2008, 8). Red blood cells are essential for the oxygenation of the body’s
tissues and for removing carbon dioxide produced by cellular respiration. Platelet cells
(thrombocytes), together with brinogen and other proteins (clotting factors), are in-
volved in the formation of blood clots that stop bleeding. White blood cells (leucocytes)
is an umbrella term for granulocytes, monocytes, macrophages, lymphocytes, and sev-
eral subclasses of immune cells. They are an essential part of the immune system which
prevents disease by identifying and destroying pathogens (Schaller et al., 2008, 10-11).
3.2 Blood component manufacture
Rather than transfusing whole blood, a single blood component, such as “packed red
blood cells”, is normally used in the UK. This allows for more ecient use and stor-
age of donated blood (Norfolk, 2013, 18). Thus, the production of high quality blood
components is essential to oer safe, eective and sustainable healthcare services that
fulll legal requirements and public scrutiny (McClelland et al., 2010, 4). To meet the
demand for blood, many countries have developed national systems for its collection,
processing, storage, use and traceability. The “Guidelines for the Blood Transfusion
Services in the UK” (known as the Red Book) provides a good overview of the system
in place in the UK (JPAC, 2013).
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UK blood donors are recruited on a voluntary basis. To prevent introducing unsafe
blood into the national supply, donors are carefully screened and tested for blood-
borne diseases (see ch.3 JPAC, 2013). Once approved, whole blood is collected through
venesection or a specic blood component, such as red blood cells, is collected from
the donor’s bloodstream through apheresis whereby it is isolated by density using
centrifugation and the other blood components are returned to the donor’s circulation.
After collection, the blood components are processed to reduce the risk of trans-
fusion complications (see ch.6 JPAC, 2013). A key stage is the removal of white blood
cells from red blood cell, platelet and plasma components through ltration, a process
known as leucodepletion (also termed leukoreduction). It was introduced 1999 in the
UK to prevent transmission of variant Creutzfelt-Jacob Disease (vCJD) (SaBTO, 2012a,
2). Since then all cellular blood components produced in the UK are routinely leu-
codepleted with the exception of granulocytes components (white blood cells) (Massey
et al., 2014).
The eectiveness of the process is veried using statistical control. 90% of leucode-
pleted components in the UK have a white blood cell count of less than one million
per unit with 95% statistical condence (SaBTO, 2012b, 9). Failure rates vary between
the national blood services and depending on the type of component. For example,
in 703 tested units of pooled platelets produced by the SNBTS in October-December
2010, seven units exceeded ve million white blood cells per unit (SaBTO, 2012b, 10).
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Although, the eectiveness of the process cannot be 100% guaranteed as not ev-
ery bag is tested, leucodepletion has proved eective in reducing the risk of several
transfusion complications, including febrile transfusion reactions (Bassuni et al., 2008),
cytomegalovirus (CMV) infection (SaBTO, 2012a) and Transfusion-Associated Graft
versus Host Disease (TA-GvHD) (Bolton-Maggs et al., 2015a, 24). It has also reduced
platelet transfusion failures (platelet refractoriness) (Murphy, 2015).
Blood components intended for patients at-risk of transfusion complications are
further processed. For example, cellular blood components intended for patients at
risk of TA-GvHD are exposed to a dose of 25-50 Gy (gray) of Gamma or X-ray irradi-
ation (Treleaven et al., 2010, 41). Blood for fetuses, neonates and infants is separated
into smaller “paedipacks” which contain irradiated blood from a single CMV-negative
donor. Advances in chemical and photochemical treatment, known as pathogen inac-
tivation, could further improve the safety of blood components (Prowse, 2013).
After processing, the blood components are packaged, labelled and stored in a con-
trolled environment in blood establishments until they are released to stock and dis-
tributed to hospital blood banks for use. Individual blood bags (referred to as “units”)
are bar-coded and tracked throughout their life-cycle in an information system. The
system keeps a record of individual units of blood, associated donors and recipients. It
enables units to be traced and recalled if a problem is discovered (a process known as
’look-back’) (see ch.10 JPAC, 2013).
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3.3 Clinical transfusion process
This section outlines the main steps of the clinical transfusion process, following the
stages set out in gure 3.2. The process begins with a doctor or another healthcare
practitioner who prescribes blood, such as a nurse authoriser (Pirie and Green, 2010),
determining in consultation with the patient if the benets of transfusion outweigh the
risks (step 1). For example, patients who are ill as a result of a chronic, congenital (in-
herited) or acquired medical conditions, or who have lost blood in an accident or after
an operation, may require one or more blood transfusions to recover. However, re-
strictive use of blood components is critical for preventing inappropriate transfusions
and achieving a high level of safety (Hofman et al., 2011).
Figure 3.2: Visual representation of the six stages in the clinical transfusion process,
adapted from McClelland et al. (2010, 4).
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If a blood transfusion is prescribed, a request form stating the reason for the trans-
fusion, the number and type of blood components required, and other details, such as
any special transfusion requirements, is completed (step 2). A sample of the patient’s
blood, usually drawn by a nurse or phlebotomist, is sent together with the request
form to the blood bank to ensure that compatible blood is issued. Laboratory sta
analyse the blood sample to determine the patient’s ABO blood group and other key
information (step 3). This includes the presence of Rhesus D (RhD) antibodies, which
is particularly important for preventing haemolytic disease of the newborn (HDN) (Ur-
baniak and Griess, 2000).
Prior to the discovery of major blood groups, incompatible blood matching limited
the safety and usefulness of transfusions. The development of the ABO system in 1901
by Karl Landsteiner lead to an increase in the use of transfusions, especially during
the rst World War (Watkins, 2001, 243). Although the genetics and biochemistry of
blood groups remain active research areas (Watkins, 2001, pp. 258-259), the ABO and
subsequent Rhesus blood grouping systems enable compatible donors to be identied
(table 3.1). The sux minus sign indicate that no antibodies for the Rhesus D (RhD)
antigen is present (i.e. the screen for RhD is negative). Antigens are proteins and car-
bohydrate structures on the surface of cells that the immune system use to distinguish
between the body’s own cells and foreign cells. They determine whether a tissue, such
as blood, will be rejected or not by the recipient (i.e. histocompatibility).
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When incompatible cells are transfused into a patient they trigger the production
of antibodies and an immune response that destroy (haemolyse) the cells. The sever-
ity of such a haemolytic transfusion reaction (HTR) vary from initially relatively mild
symptoms (chills, dread, increased pulse and temperature) through to disseminated in-
travascular coagulation (DIC), multiple organ failure and death, unless the transfusion
is stopped promptly (Strobel, 2008).
Compatibility testing is the laboratory process of determining that a blood com-
ponent can be safely transfused into a patient
1
. In addition to blood group typing,
compatibility testing includes antibody screening and cross-matching (American As-
sociation for Clinical Chemistry, 2015, para. 6).
1
Interested readers should consult textbooks on the subject as only a brief overview of the laboratory
processes can be oered here.





Antibodies present in the
blood plasma Compatible donors
O- None anti-A, anti-B and anti-D* O-
O+ RhD anti-A and anti-B O- or O+
A- A anti-B and anti-D* O- or A-
A+ A and RhD anti-B O-, O+, A- or A+
B- B anti-A and anti-D* O- or B-
B+ B and RhD anti-A O-, O+, B- or B+
AB- A and B anti-D* O-, A-, B- or AB-
AB+ A, B and RhD none Donors of any group
* Antibodies to RhD (anti-D) are only present in RhD negative patients sensitised
to RhD positive blood, such as via transfusion or pregnancy (Norfolk, 2013, 9).
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Thus, a “group and screen” is the ABO and RhD typing of the patient’s blood and
the screening of it against other signicant antibodies that could cause a haemolytic
reaction (McClelland, 2007, 17; Norfolk, 2013, pp. 10-11). Furthermore, prior to the
issue of a blood component, a serological or computerised cross-match is conducted
(Norfolk, 2013; Chapman et al., 2000, 10). In the former, a sample of the patient’s plasma
and the blood component is tested. Observing agglutination – the formation of one or
more solid masses of clumped together red cells – in the test tube indicates a haemolytic
reaction due to incompatible blood groups.
In the computerised cross-match (also referred to as electronic issue), compatible
blood can quickly be issued without further serological testing based on information
held in the patients electronic record, provided that (McClelland, 2007, 17):
• there are multiple robust records of the patient’s blood group type;
• the patient’s antibody screen is negative and;
• the patient’s identity, transfusion and testing history is reliably established.
Finally, to ensure that the correct unit is issued, blood bank sta also checks for
any special requirements (discussed below). Once issued, the unit of blood is delivered
to the patient’s ward by a porter where it is typically collected by a nurse (step 4). The
nurse will check the blood bag (label details and signs of contamination) and match it
against the patient’s identity and the prescription, and record the patient’s vital signs
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(Gray and Illingworth, 2013, 8) before administering the unit of blood (step 5). This is
a critical step as an undetected mistake up to this point can lead to an incompatible
transfusion.
During the transfusion, the patient should be monitored (step 6) so that if there
are signs of a transfusion reaction, the transfusion can be stopped promptly (Gray and
Illingworth, 2013, 8). When an uneventful transfusion is nished, a nurse completes
a form recording the blood bag identier, date and patient. This information is stored
for traceability purposes to aid investigations in the event of an incident. Incidents and
near-misses are reported to UK haemovigilance schemes.
3.4 Safety and haemovigilance
The scientic understanding of human blood and safe blood transfusion practice has
evolved considerably in the last century (Bain, 2005; Alter and Klein, 2008; Schnei-
der and Drucker, 2006; Watkins, 2001). In the last decades, not least following the
HIV/AIDS and Hepatitis C crises of the 1970s and early 1980s, major improvements
have been implemented, such as better donor screening and recruitment, as well as
more eective diagnostic tools and treatments to manage complications.
Prior to these advances, it is estimated that thousands of patients in Scotland alone
contracted Hepatitis C or HIV/AIDS via unsafe blood transfusions (Penrose, 2015). The
collection of blood from prison inmates, who had a higher incidence of Hepatitis C and
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HIV/AIDS as a result of intravenous drug use and the sharing of needles, introduced
tainted blood into the national supply. At the time, these conditions were not well
understood, and diagnostic tests and treatments were unavailable (ibid).
A recent example highlighting similar issues is the Zika virus outbreaks. The virus
spreads via the Aedes family of mosquito and can cause microcephaly in fetuses born
to infected mothers (Mlakar et al., 2015). It has also recently been associated with
other serious complications, such as Guillain-Barré Syndrome (Cao-Lormeau et al.,
2016) (a neurological condition causing muscle weakness). The virus has been detected
in asymptomatic blood donors in the South Pacic, raising concerns of transfusion-
transmitted Zika infection via contaminated blood donations (Musso et al., 2014).
These examples vividly illustrate some of the challenge of ensuring, monitoring
and improving the safety of blood transfusions. Making sure that the nearly three
million annual transfusions in the UK (Bolton-Maggs and Cohen, 2013b) are as safe
as possible is an ongoing eort that require that patients, doctors, nurses, blood bank
sta and other professionals work together.
The professionally-led haemovigilance scheme Serious Hazards of Transfusion (SHOT)
was founded in 1996 to facilitate this work in the UK (Williamson et al., 1998). SHOT
collects and analyses “... anonymised information on adverse events and reactions in
blood transfusion from all healthcare organisations that are involved in the transfu-
sion of blood and blood components in the United Kingdom [...] recommendations are
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put into its annual report which is then circulated to all the relevant organisations...”
(SHOT, 2017, para. 1). SHOT owns the copyright to the data, which is not available
in raw format or permitted to be reproduced without the organisation’s prior consent
(Bolton-Maggs et al., 2016, 3).
Since monitoring began, SHOT have found that many of the current transfusion
risks originate from limitations in workplace processes and practices, slips, mistakes
and lapses in knowledge of healthcare sta (Bolton-Maggs et al., 2016, 22). For example,
in 2014, Bolton-Maggs et al. (2015a, 31) attributed 750 out of 764 (98%) serious adverse
events (SAE) to human error at any stage of the transfusion process. An SAE is dened
as an:
“untoward occurrence associated with the collection, testing, processing, storage
and distribution, of blood or blood components that might lead to death or life-
threatening, disabling or incapacitating conditions for patients or which results
in, or prolongs, hospitalisation or morbidity.” (Bolton-Maggs et al., 2015a, 31)
The reason why so many SAEs are attributed to human factor errors is that the
manufacture, storage, distribution and clinical use of blood depends on a complex
socio-technical system which involves many actors with specialised roles and knowl-
edges. Studies of such systems, including modern medicine (Carayon and Wood, 2010)
and nuclear power (Perrow, 1999), show that they are vulnerable because they are
tightly coupled and have many points of failure which are dicult to predict, detect,
prevent and recover from.
3.4. SAFETY AND HAEMOVIGILANCE 95
Table 3.2: Steps, possible errors, consequences and causes in the rst three stages of
the clinical transfusion process, abridged from McClelland et al. (2010, pp. 5-7).
Stage 1. Assess patient and decide whether to transfuse

































Stage 2. Order the blood component




































Stage 3. Pre-transfusion testing
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Table 3.3: Steps, possible errors, consequences and causes in the last three stages of
the clinical transfusion process, abridged from McClelland et al. (2010, pp. 5-7).
Stage 4. Deliver the blood component
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Stage 5. Administer the blood component
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Tables 3.2 and 3.3 provide an overview of the steps, errors, causes and adverse
outcomes that may occur in the clinical transfusion process. There are many things
that can go wrong and errors can propagate throughout the system. For example, a
misidentied patient can lead to the wrong patient getting the wrong blood unless
the error is detected. Given the tight coupling between the sampling, laboratory test-
ing, blood issuing, collection and transfusion, and the high workload, sta shortages
and challening working environments, this system shares many characteristics with
Perrow’s analysis of industrial accidents.
Fortunately, as a result of SHOT’s work and measures to improve safety, the risk
associated with blood transfusions in the UK have decreased greatly in the last decades
(Cohen and Bolton-Maggs, 2012). Monitoring statistics suggest blood transfusions in
the UK today carry a very low probability of serious complications (Bolton-Maggs and
Cohen, 2013b). Furthermore, cost-eectiveness considerations and better understand-
ing of the adverse eects associated with the liberal use of blood has promoted more
restrictive transfusion policies (Holst et al., 2015; NHSBT, 2014), thereby side-stepping
the inherent risks of a blood transfusion.
However, an area where mistakes continue to be frequently reported – albeit for-
tunately very rarely leads to serious complications – is in the supply of irradiated and
cytomegalovirus (CMV) negative blood components to vulnerable patients who have
special transfusion requirements.
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3.5 Use of special blood components
Failures to provide patients with irradiated and Cytomegalovirus (CMV) negative blood
components according to guidelines are reported to SHOT at a steady rate of about
one hundred incidents per year (see gure 1.1 in chapter one). These incidents put
patients at risk of Transfusion-Associated Graft versus Host Disease (TA-GvHD) and
Transfusion-Transmitted CMV infection (TT-CMV), but fortunately only very rarely
have a clinical impact. Only 14 cases of TA-GvHD (all fatal) (Bolton-Maggs and Cohen,
2013a, 135) and one (unconrmed) case of TT-CMV (Bolton-Maggs et al., 2015a, 125)
have been reported in the UK since 1996.
TA-GvHD is a rare, almost universally fatal disease caused by the transfusion of cel-
lular blood (red cells, platelets and granulocytes) components containing viable lym-
phocytes. The transfused donor lymphocytes engraft and attack the recipient, causing
skin rash, diarrhoea, liver disease, bone marrow failure and death from infection often
within two-three weeks of the transfusion (McClelland, 2007, 41). The risk of develop-
ing TA-GvHD depends on three factors (Treleaven et al., 2010, 37):
• The number and viability of lymphocytes transfused;
• The susceptibility of the recipient’s immune system to their engraftment and;
• The degree of immunological (HLA) disparity between donor and recipient.
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In most cases, the recipient’s immune system is capable of detecting and destroy-
ing the donor lymphocytes before they engraft. Immunodecient patients (whether
congenital or as a result of immunosuppressive treatment) are therefore at risk of TA-
GvHD. However, TA-GvHD can also occur in immunocompetent recipients. If the
donor and recipient share an HLA (Human Leucocyte Antigen) type, the recipient’s
immune system is unable to distinguish the donor lymphocytes from the body’s own
cells, allowing the donor lymphocytes to engraft. Shared HLA haplotypes are much
more likely to occur in directed donations from relatives than between random donors
and recipients. They are also present in HLA-matched transfusions.
As there is no eective treatment, current national guidelines require that all pa-
tients at risk of TA-GvHD receive cellular blood components that have been exposed
to a dose of 25-50 Gy of Gamma or X-ray irradiation, thus inactivating the donor lym-
phocytes that give rise to the condition (Treleaven et al., 2010, 41). Additionally, all
granulocyte transfusions must be irradiated as they contain a high concentration of
lymphocytes, cannot be leucodepleted and are often given to immunodecient patients
(Massey et al., 2014, 7).
Cytomegalovirus (CMV), on the other hand, is common herpes virus that is harm-
less in healthy individuals, but can lead to lifelong disability or death in vulnerable
patients, such as neonates (SaBTO, 2012b, 16). Providing patients at risk of CMV in-
fection with blood components manufactured from donors who screen negative to
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CMV can prevent transfusion-transmitted CMV (TT-CMV) infection SaBTO (2012a).
In 2012 the indications for CMV-negative blood components were updated in light of
evidence showing that the removal of leucocytes from red cells and platelets through
leucodepletion signicantly reduces the risk of TT-CMV (SaBTO, 2012b,a).
Furthermore, there is growing evidence to suggest that leucodepletion has reduced
the incidence of TA-GvHD (for a recent discussion see Hui et al. (2015)). Despite al-
most a thousand failures to provide irradiated components according to guidelines,
there have only been two cases of TA-GvHD in the UK in the decade after universal
leucodepletion was introduced (Treleaven et al., 2010, 41). However, just as there are
patients for whom leucodepletion does not oer sucient protection against CMV in-
fection (SaBTO, 2012b, 11), leucodepletion cannot be relied upon to prevent TA-GvHD:
“Leucodepletion [...] provides some degree of protection but must not be relied
upon since not all units are tested to ensure adequate reduction in leucocytes and
there are some failures. In addition, there is no scientic evidence that for the
most immunosuppressed, LD is adequate, and indeed animal evidence that LD
is not adequate. [...] therefore irradiation continues to be indicated for at-risk
groups for the forseeable [sic] future and it is important that clinicians work to
ensure that this guidance is met.” (Bolton-Maggs et al., 2015a, pp. 23-24)
Until new evidence or component manufacturing methods are available, the correct
use of irradiated and CMV-negative blood components according to current guidelines
is essential. Irradiated and/or CMV-negative components are indicated only to those
at risk of TA-GvHD or TT-CMV. Such patients are a minority of transfusion recipients
and fall under the umbrella term of patients with “special requirements”.
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3.6 Causes of mistakes and mitigation strategies
There are multiple reasons why special requirements fail to be provided to at-risk pa-
tients including: incorrectly completed blood request forms (Taylor et al., 2008, 46),
failures to check medical records (Bolton-Maggs and Cohen, 2012, 32), poor handover
during shared patient care (Cohen et al., 2010, 41), inadequate bedside checks (Taylor
et al., 2008, 31) and errors in the laboratory systems (Bolton-Maggs and Cohen, 2012,
56). Protecting patients with special requirements is another reason that it is vital that
the right patient receives the right blood component (Gray and Illingworth, 2013).
Overcoming these issues requires multiple interventions. Root cause analysis indi-
cates that inadequate practitioner knowledge is a recurring and preventable cause of
mistakes (Bolton-Maggs and Cohen, 2012, 33). Practitioners involved in blood transfu-
sion must be aware of the rationale and indications for irradiated and CMV-negative
blood to be able to request it as appropriate. Furthermore, they must have sucient
knowledge to critically assess clinical decisions and spot potential mistakes elsewhere
in the transfusion chain (depicted in gure 3.3). SHOT have also identied several
additional measures for improving practice, including:
• ensuring blood components are ordered correctly and that systems for ordering
facilitates this (Knowles and Cohen, 2011, 26).
• educating patients with special requirements, including providing them with a
card that they can show to healthcare sta (Bolton-Maggs and Cohen, 2012, p.34).
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• conducting thorough pre-transfusion bedside checks, ensuring such checks are
uninterrupted (Knowles and Cohen, 2011, 61) and and supported with a checklist
(Bolton-Maggs and Cohen, 2013a, 62).
• the appropriate use of computerised alerts and ags (Bolton-Maggs and Cohen,
2012, 7), taking care to ensure that setting ags is carried out carefully and veri-
ed by multiple members of sta (Bolton-Maggs and Cohen, 2012, 51).
Figure 3.3: Process map for special requirements, adapted from National Patient Safety
Agency (2006, 20). The three middle boxes marked with strong black borders indicate
steps where the need for special requirements should be identied. Any units will addi-
tionally need to be veried at other points in the process, such as during pretransfusion
checks, to ensure special requirements are met.
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Furthermore, there are many interventions aiming to improve transfusion practice
and knowledge, including: videos, such as 2002 production The Strange Case of Penny
Allison, starring Hugh Laurie and Imelda Staunton; animated short lms, such as a
recent production highlighting critical stages in the transfusion process (gure 3.4);
paper-based aids, such as pocket-sized cards (gure 3.5);and digital aids, such as the
NHSBT Platelets App reviewed in chapter four (Estcourt et al., 2013).
However, as discussed in the introduction, despite recommendations by Knowles
and Cohen (2011, 28) and Cohen et al. (2010, 55) to improve this area of blood transfu-
sion education, there are few dedicated learning resources available to practitioners. In
particular, the Learn Blood Transfusion e-learning program (gure 3.6), which forms a
mandatory part of professional development of practitioners involved in blood trans-
fusions in many parts of the UK, does not address special requirements in detail in the
modules on safe transfusion practice.
Figure 3.4: Screenshot from an animated lm highlighting sources of error (“hotspots”)
in the pre-transfusion sampling process. Courtesy of SNBTS.
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Figure 3.5: Cards summaring the do’s and don’ts at each step of the clinical transfusion
process. Courtesy of SNBTS.
Figure 3.6: Screenshot from the Learn Blood Transfusion e-learning platform used by
healthcare practitioners in the UK. Courtesy of SNBTS.
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3.7 Chapter summary
The purpose of this chapter was to provide an overview of the manufacture and clinical
use of blood components in the UK. The review demonstrated that current practices
are the result of evolving scientic advances on multiple fronts. This include under-
standing of human blood (single component therapy, grouping and antibody testing),
blood-borne diseases (HIV, Hepatitis C, Zika, etc), blood transfusion safety (e.g. donor
screening, haemovigilance, patient blood management and management of transfusion
reactions) and human factors (e.g. to mitigate errors in the workplace).
A pertinent issue that merits further research is the role (and cost-eectiveness)
of component manufacturing processes, such as pathogen inactivation, in eliminat-
ing the need to separately manufacture special components for certain patient groups.
However, until such developments, the correct use of irradiated and Cytomegalovirus
(CMV) negative blood components remains critical to prevent two very rare and seri-
ous conditions in vulnerable patients: transfusion associated Graft versus Host Disease
(TA-GvHD) and transfusion-transmitted Cytomegalovirus (TT-CMV) infection.
Preventing mistakes in the use of these components is dicult as there are multiple
causes requiring targeted interventions. Many problems can be traced back to the
working environment, such as understang. Inadequate knowledge in practitioners
is a preventable cause of mistakes. Creating educational resources for the correct use
of these components is necessary as there are few dedicated learning interventions.
106 CHAPTER 3. BLOOD TRANSFUSION IN THE UK
In summary, this review of the composition, manufacture and use of blood com-
ponents has provided a foundation for which to attempt to intervene in a complex
medical system. It has informed subsequent stages of the research which seeks to im-
prove the correct use of irradiated and CMV negative blood components by creating a
mobile learning intervention for healthcare practitioners.
Chapter 4:
Methodology
This chapter provides an overview of the research methodology adopted in the
thesis. It begins by discussing the main assumptions underpinning the research, and
the aims, objectives and research questions. This is followed by a discussion of the
methodological and theoretical framework, epistemological and ethical considerations,
as well as software development process. Details of specic methods adopted in each
of the ve empirical studies are provided in their respective chapters.
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4.1 Aims and assumptions
Many of the medical apps currently available to healthcare practitioners suer from
notable shortcomings due to weaknesses in the design and evaluation processes that
gave rise to them. Eective interdisciplinary collaboration and mixed-methods evalu-
ations have been identied by scholars in eHealth as critical to the success of health-
care information technology interventions. Thus, the aim of the research was to
explore how the quality and credibility of medical apps might be improved
through collaborative design and evaluation processes.
To investigate this question, I reected on transferable lessons from the collabo-
rative development and evaluation of a new mobile app in transfusion medicine. I
adopted a working denition of “quality” that encompassed three main aspects: the
clarity, correctness and traceability of medical information contained in an app (1); the
accuracy of calculations or recommendations returned by an app, such as drug dosing
(2); and the ease of use, including the ability to avert, rather than induce, errors (3).
Furthermore, I dened the “credibility” of a medical app as a judgement of its trust-
worthiness based on published evidence. “Weighing up the evidence” is a central part
of such a judgement. However, as the absence of published evidence is the rule rather
than the exception for many medical apps, other aspects will naturally inuence judge-
ment. For example, endorsement from institutions or peers could profoundly inuence
the decision to adopt or reject an app.
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To limit the scope, I focused on the use, design and evaluation of medical apps
intended to improve blood transfusion practice and education in a UK context. I set
out specic research objectives (presented in chapter one, table 1.3), which included
reviewing prior work, analysing and evaluating the Special Blood Components (SBC)
mobile learning app at several stages, and creating tools and methods to support col-
laborative development and evaluation with healthcare professionals.
The research objectives were addressed in two literature reviews (reported in chap-
ters two and three) and ve empirical studies (presented in chapters ve through nine).
The empirical studies relied on a mix of qualitative and quantitative methods to answer
specic research questions, which are summarised in table 4.1. As they are discussed
in their respective chapters, I will not detail the methods adopted in each study here.
Instead, I will now discuss and justify my research approach, including theoretical,
methodological and ethical considerations.
4.2 Theoretical and methodological framework
Although there are many well-established software development methodologies, such
as Soft Systems (Checkland, 2000), I have been unable to identify any which are di-
rectly applicable to the collaborative design and evaluation of medical apps. Further-
more, bridging dierences in the priorities, methods and epistemologies of technical
development, and the rigorous evaluation of healthcare information technology inter-
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Table 4.1: Research questions by study number and chapter.
Study 1 - Review of an Existing Transfusion App (Chapter 4):
1a. What strengths and weaknesses do practitioners identify in an existing app aiming
to improve a specic area of blood transfusion practice?
1b. To what extent could their observations transfer to other medical apps?
Study 2 - Concept Validation of the Proposed App (Chapter 5):
2a. What are dierent practitioners’ experiences of “special blood components”?
2b. What are their views on the causes of mistakes and eective interventions?
2c. What strengths and weaknesses do they identify in the proposed app?
Study 3 - Collaborative App Design with the WAE (Chapter 6):
3a. To what extent is the Web App Editor an eective and easy to use tool that enables
novice app developers to acquire technical and collaborative skills?
Study 4 - Usability Evaluation of the SBC App (Chapter 7):
4a. How do medical students rate the usability and content of the revised SBC app?
4b. What further improvements to the app do they identify?
Study 5 - A Randomised Controlled Pilot of the SBC App (Chapter 8):
5a. To what extent is the updated SBC app eective in improving the knowledge of special
blood components in sta with recent transfusion training?
5b. How do sta rate the app in terms of the ease of nding information, enjoyment of
use, likelihood to use again and to recommend to others?
5c. How does the ecacy and ratings of the app compare to existing local hospital guide-
lines?
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ventions is challenging and require interdisciplinary understanding (Pagliari, 2007).
For this reason, it was necessary to assemble a heterogenous framework by identify-
ing methodological and theoretical building blocks from several disciplines through a
process of “bricolage” (Turkle and Papert, 1991, 168).
4.2.1 Action research
Foundational building blocks of the methodological framework originate from the ac-
tion research tradition. This is an interventionist approach to conducting research
that is concerned with creating, evaluating and rening solutions to practical prob-
lems through active involvement of stakeholders. It can be traced back to work in the
1940s by the social psychologist Kurt Lewin, here summarised by Adelman (1993, 9):
“Action research for Lewin was exemplied by the discussion of problems fol-
lowed by group decisions on how to proceed. Action research must include the
active participation by those who have to carry out the work in the exploration of
problems that they identify and anticipate. [...] The group would decide on when
a particular plan or strategy had been exhausted and fullled, come to nothing,
and would bring to these discussions newly perceived problems.”
Although the validity of action research is contested by “positivists” for its in-
terventionist and pluralistic underpinnings, it is an established methodology in elds
such as nursing (Meyer, 1993, 2000), education (Carr and Kemmis, 2003), information
systems development (Checkland and Poulter, 2010) and human computer interaction
(Hayes, 2011). Because it is used in such a wide range of contexts and there are many
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Figure 4.1: Visual representation of the iterative action research cycle, adapted after
Susman and Evered (1978).
forms of action research, there is no single accepted denition (Reason and Bradbury,
2006, 1). However, most denitions place emphasis on the following characteristics:
• A dual objective of intervening to initiate some “desirable” change, while simul-
taneously generating answers to research questions through the application of
scientic methods;
• A participative approach to the research process, dependent on close collabora-
tion with stakeholders; and
• Learning and theorisation through a repeating cycle of planning, acting, observ-
ing and reecting (g. 4.1).
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Furthermore, Greenhalgh et al. (2004, 30-31) singles out action research as an ap-
propriate method for healthcare innovation research as it “focuses on change and im-
provement; explicitly and pro-actively involves participants in the research process;
is educational for all involved; looks at questions that arise from practice; involves a
cyclical process of collecting, feeding back, and reecting on data; and is a process that
generates knowledge.”
Thus, the development and evaluation of the Special Blood Components app was
structured so as to enable clinicians and other stakeholders to critique ideas and pro-
totypes throughout in the design process. The decision to work closely with potential
users in an iterative manner hint at two other important building blocks of the method-
ological framework, namely user-centered design and agile development.
4.2.2 User-centered design and agile development
The development work was organised into iterations involving planning, development,
evaluation and re-development based on user feedback. The Special Blood Component
(SBC) app went through three main iterations that were relatively short in duration to
allow changes in user requirements and research direction, particularly at the start
of the project. Towards the end of the project, the iterations were longer due to the
increasing burden of conducting the research, including data collection and analysis
of ndings.
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Organising the work in short iterations borrows from agile software development
methodologies (Abrahamsson, 2002). Agile approaches promote early delivery of func-
tioning, but incomplete software to users to allow unexpected changes to be identied
early in the design process when the cost of making signicant changes are still low.
One of the unexpected changes in research direction – that only became clear after
the second study – was the need for better app development tools to allow work in
progress to be shared eectively with collaborators to ensure the nal product was
accurate, easy to use and met the needs of users.
Thus, signicant eort went into creating a web-based collaborative app editor to
support processes of learning about, modifying and creating mobile apps with others.
This system, called the Web App Editor (WAE), became an important tool for creating
the SBC app, and for exploring how collaborative development and evaluation could
improve the quality and credibility of medical apps.
Inspired by concepts from user innovation (von Hippel, 1998, 2005), and calls to
adopt open source principles to better organise the development of medical apps (van
Velsen et al., 2013), this aspect of the research went beyond most user-centered design
methodologies as creating tools for the collaborative development of apps could be
said to amount to a “transformation” design approach:
“Transformation design acknowledges that ‘design is never done’ [...] the chal-
lenge is not how to design a response to a current issue, but how to design a
means of continually responding, adapting and innovating. Transformation de-
sign seeks to leave behind not only the shape of a new solution, but the tools,
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skills and organisational capacity for ongoing change. This builds on the reality
that ‘everybody is a designer in everyday life”’ (Burns et al., 2006, 21)
That is to say, the tool is general enough to not only help develop the SBC app, but
has also been used in other projects (some of which are discussed in chapter seven).
4.3 Epistemological position
Like many studies involving the design and evaluation of computer software or health-
care interventions, the research questions reect a commitment to both “practical” and
“theoretical” concerns (Hevner et al., 2004), which historically have not enjoyed equal
status in academia (Simon, 1996, 112). The interventionist and practically-oriented na-
ture of action research can raise concerns about validity, reliability and generalisability.
As a methodology, action research has been criticised for its lack of “objectivity”
and rigor compared to positivist methodologies. However, these criticisms have been
addressed by Susman and Evered (1978), Checkland and Holwell (1998), Meyer (2000)
and others. Nevertheless, it is important to consider the epistemological position I
adopted in this project. Epistemology is concerned with what counts as “knowledge”,
and by which means or methods knowledge claims can be supported (or refuted).
Drawing on the tradition of Popper, Kuhn and feminist critiques of science and
technology, this research subscribes to a post-positivist (i.e. interpretivist), social con-
structivist and pluralist epistemology (Miller, 1983; Racher and Robinson, 2002; Kuhn,
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1970; Haraway, 1988). Critical research in the post-positivist tradition does not claim
to be “objective” as it acknowledges the “situatedness” of the researcher (Haraway,
1988).
That is to say, researchers are not isolated from the social and cultural context they
operate in (Bloor, 1991), and their work is also shaped by professional socialisation
(Kuhn, 1970) and personal experiences (Haraway, 1988). Acknowledging these social
dimensions of research as sources of potential bias, and adopting a reexive approach
(Finlay, 2002), contrasts approaches where the researcher is portrayed as an outside,
invisible, objective and dispassionate observer waiting for the world to reveal its true
nature.
Like most work in the social sciences, I reject the notion of a single discoverable
“truth”. Instead, I prefer the notion that there are many possible narratives about the
world (falsiable conjectures in Popper’s terminology) that are socially constructed
and mediated through personal, cultural, language and technological lters. Of course,
operating in an interdisciplinary space, I must shift between epistemologies and play
by the rules and conventions established in dierent research communities.
This position also embraces the pluralistic view that there are several way of know-
ing and inquiring into the world, each with strengths and weaknesses, and that multi-
ple perspectives are important to understand real-world problems (Miller et al., 2008;
Rittel and Webber, 1973). It is a worldview resonates with the socio-technical com-
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plexity associated with the development, evaluation and implementation of healthcare
information technologies, where mixed-methods research is common.
4.4 Ethical considerations
All researchers must examine the ethical implications of their proposed research to
ensure participants’ interests are respected and no harm is caused. At the start of the
project and prior to commencing study one, I completed the University of Edinburgh
ethics self-audit procedure. The outcome of this process was that no signicant ethical
issues could be identied that could not be mitigated by standard good practices, such
as the anonymisation of participants.
Participating in the studies was voluntary and deemed unlikely to cause stress,
negative feelings or harm to participants. Participants were provided with accurate
information about the purpose of the research and what they were being asked to do
and asked for their consent to participate prior to taking part (see appendices for copies
of the participant information and consent sheets). The main burden on participants
was the time that it takes to complete the research tasks. I hence designed the tasks to
be fast to complete by reducing the number of questions and streamlining the partic-
ipation process. For example, the Web App Trial system went through several stages
of prototyping and piloting with this aim. Moreover, participants were encouraged to
take part at a time and in a location that was convenient to them.
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Furthermore, as far as possible all results were reported in aggregate to ensure
participants’ anonymity. Names, contact details and any personal information relating
to individual participants was not disclosed, unless express written permission was
granted by the participant. When using quotes, statements were reported so as to
preserve the respondent’s anonymity.
At the time of the fourth study, I learned that research involving the National
Health Service (including its sta) may require additional permissions, such as man-
agement approval. The rst route I explored for obtaining NHS ethical review and
clearance was through the Health Research Authority (HRA) research ethics commit-
tee (REC) system. The HRA provides an online self-assessment tool to determine if a
research project requires ethics permission from a REC (HRA, no year). Thus, on July
19 2013, I completed the HRA self-assessment tool. The result of the self-assessment
was that the fourth study did not require review by a research ethics committee as
it involved students. As the study targeted medical students and was conducted on
university premises in close collaboration with university sta, written management
clearance from the healthboard was not sought.
For study ve, which involved NHS sta rather than medical students, I submitted
an Integrated Research Application System (IRAS) application on August 19 2014. I
then applied for permission from the relevant NHS healthboard to recruit NHS sta.
The result of the IRAS application was that REC approval was not required as the
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study did not recruit patients. However, management permission was required and I
submitted a project registration on September 26 2014 to the chair of the local quality
improvement team. Approval was granted in early November 2014 from the health-
board Clinical Governance and Risk Management Support Team.
On reection, the ethical governance of research involving NHS sta can be slow
and dicult to navigate unless you have an existing aliation with the NHS. It in-
volved signicant amount of waiting, extensive paperwork and communication with
sta within the NHS. The advice I accessed was not always consistent and clear, and
there appeared to be dierences in procedures at the national, regional health board
and local hospital level. Furthermore, the ethical assessment would likely have changed
if the app could be classed as a Medical Device. It would have required approval by the
Medicines and Healthcare Products Regulatory Agency. Similarly, if the research had
involved patient data, it would have required full REC approval.
4.5 Software development process
The research and software development process is summarised in tables 4.2 and 4.3.
Beyond this, I also developed a collaborative app editor and a system to conduct an
online randomised controlled trial of the SBC app. The process, which began with
paper mockups and prototypes, was more chaotic than these organised tables convey.
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Table 4.2: Activities related to the development and evaluation of the Special Blood
Components app, February to December 2013.





When developing ideas Dr McClelland, medical advisor to the project,
acted as a proxy user and domain expert. Our initial ideas changed over
time as our understanding of the problem, stakeholders and contexts





Where there were particular design challenges, resorting to pen and
paper helped explore the choices quickly. For example, alternative





The use of the jQuery Mobile framework allowed rapid construction of
functional wireframes with graphical user interface elements. This en-
abled early testing and renement of key interactions like navigation,
search and ltering list items.






To identify improvements and design lessons, clinicians were invited
to review the usability and contents of several third party transfusion
apps and our rst prototype about special transfusion requirements




At this point, I had a long list of possible topics and urgently needed
to decide on one. The comments from the clinicians, together with
my own assessment of the feasibility and demand for dierent topics,
led to the decision to pursue the topic of irradiated and CMV-negative
blood components.






Completing a full version of the app required much work: program-
ming new features, summarising medical articles and guidelines, ren-
ing data structures for the clinical indications, improving the visual de-
sign, enhancing usabilty, incorporating analytics, refactoring, testing





The app was then circulated for review to the clinicians who had been
approached earlier and a few other critical friends. Most of them used
the app’s new feedback mechanism, which prompted them to submit






After the review, I presented the app at the British Blood Transfusion
Society’s (BBTS) annual conference. Attendees were encouraged to try
it out and comment through the evaluation system. This resulted in a
few responses and a research opportunity to evaluate the SBC app with
medical students.
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Table 4.3: Activities related to the development and evaluation of the Special Blood
Components app, January 2014 to September 2015.





The app was evaluated by 54 nal year medical students during
a compulsary training day (see study 3). No special approval was
required since the ethical issues of involving students were cov-
ered by standard university procedures and the training organis-
ers gave their permission. I was well-prepared since I had already
developed and tested the app’s feedback mechanism. These were
fortunate circumstances as the timing coincided with my Major





The analysis of the students’ responses was straight-forward. Al-
though most were unfamiliar with the topic, they identied sev-
eral usability improvements and a need to expand the learning




I presented the ndings from the student evaluation at the Seri-
ous Hazards of Transfusion (SHOT) annual symposium and re-
ceived favourable feedback, suggesting the choice of topic res-
onated with the community.





I decided to rewrite the app from scratch because a new version
of jQuery Mobile was released and I wanted to improve the code.
Furthermore, I wanted to simplify the presentation of the indica-
tions and learning materials. Editing and quality-assuring the
new learning materials was challenging and time-consuming,





My collaborators and I had identied a need to assess the impact
of the app in a more systematic way with a larger number clini-
cians. Thus, I began to construct patient scenarios to validate the
app. To comply with the ethical and management rules govern-
ing research involving NHS sta, we prepared an extensive IRAS
application. With the assistance of a respected senior clinician,






Using a randomised pre-post study design, I evaluated the impact
of the app on clinicians’ knowledge about special blood compo-
nents, comparing it to existing local hospital guidelines.






The last part of the project have been dedicated to analysing the
ndings of the nal study and writing up the PhD thesis and
publications.
Promotion Ongoing
I continue to work with collaborators to promote adoption of the
app and maintain it.
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4.5.1 Technical architecture, design decisions and stakeholders
There are many technical and design decisions that went into the making of the SBC
app, and it is necessary to touch on some of these. Already at the start of the project I
was faced with the important choice between a “native” or web-based architecture. The
decision of native or web-based apps is contentious and the decision reects individual
developers’ taste and requirements (Huy and vanThanh, 2012).
HTML is the language of the Web and with the latest revision it has become more
oriented towards the mobile domain. HTML5 includes application programming inter-
faces (APIs) for a range of previously unavailable functionality (Aghaee and Pautasso,
2010). For example, webcam and audio support, le handling, advanced graphics using
webGL and the canvas tag, access to embedded device sensors such as GPS, gyroscope
and accelerometer, and real time peer-to-peer communication (webRTC). Some of the
benets of HTML5 over native apps are interoperability and greater familiarity for
developers with prior experience of web design. The main drawbacks are slower per-
formance and a more limited range of APIs compared to native platforms.
My methodology greatly inuenced my decision. Developing web apps with the
Web App Editor made it possible to quickly iterate designs and share them with col-
laborators in real-time. This would have been more dicult using native apps, as they
would have to be compiled and published before testing (and for iOS devices this re-
quires commercial server infrastructure that was unavailable to me).
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Other reasons I chose to work with web technologies, over native programming
languages, include that the hyper-text markup language (HTML), cascading style sheets
(CSS) and Javascript are vendor neutral, open and viable technologies for creating apps
(Korkmaz et al., 2011). For instance, in 2013 over half of more than 6000 surveyed app
developers reported that they use HTML5 to create apps (Vision Mobile, 2013b, 3).
Having briey explored the key technological choices, I will now turn to some of the
design challenges that I encountered and how I resolved them.
Safety, accuracy, speed and usability were some of the key considerations that
shaped the design process. A considerable amount of time was allocated to ensur-
ing that the content of the app accurately reected the best available evidence-based
guidelines. Similarly, it was important to ensure that the information was presented
clearly so as to minimise the risk of misinterpretation and potentially inducing new
forms of errors. For the same reason, ensuring a high level of usability was a key pri-
ority and resulted in evaluations of this aspect at several stages of the design process.
One of the most challenging design aspects was the level of complexity of the topic
and the need to present information in a way that made it easy for a newcomer to gain
an overview quickly, while also oering a comprehensive summary that allowed users
to dive into details when necessary. For instance, I experimented with using graphical
icons based on the trac light system to indicate when irradiated or cytomegalovirus
negative blood is required. Clicking on the icon would then expand a specic indication
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and give the user a short summary of current guidelines.
At a broader level this design problem relates to the speed and accuracy dimensions
of clinical decision making, which is often solvable by triage, heuristics, decision trees
and similar techniques. After initially testing these techniques with limited success, it
became clear that oering a list of summarised clinical indications and separate learn-
ing materials was a more eective design in this case. It was also a more appropriate
design as the purpose of the app shifted from the initial aim of providing a quick deci-
sion support to instead oering educational materials where solving the time/accuracy
trade-o was a less pronounced design goal. The main stakeholders involved in the
project are presented in table 4.4.
Table 4.4: Stakeholders in the SBC app project.
Patients requiring blood tranfusion, and their carers.
Healthcare professionals (doctors, nurses, blood bank sta and others).
The core research team (PhD candidate and supervisory team).
Collaborative partners, contributors and research participants.
Various local, national and international organisations and communities of practice






Study 1: Review of an Existing
Transfusion App
This study oers a critical review of a recently published app in transfusion medicine
based on interviews and usability testing with a small group of healthcare practition-
ers. The app under review aims to promote conservative use of platelets and targets
clinicians who prescribe blood components.
The chapter begins by introducing the rationale for the study together with the
objectives and methods. In the results section, participants comments are analysed
thematically and the clinical content, dose calculator and usability of the app is dis-
cussed in detail. The chapter concludes by reecting on the key issues that the study
has raised and the extent to which they may be applicable to the design of the Special
Blood Components app, as well as medical apps more generally.
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5.1 Introduction
As was noted in chapter two, there is a general shortage of evaluations of medical apps
undertaken by researchers who are independent from the development team. This has
resulted in a situation where the use of many medical apps is unsupported by evidence.
The lack of published independent evaluations extends to other forms of eHealth
initiatives too, which often lack high quality evidence supporting their use (Black et al.,
2011). This failure to evaluate existing apps not only reduces their credibility, but is
also a lost opportunity to identify and correct problems. For example, usability issues,
inaccurate information or unintended impacts could be corrected in software updates.
Given the dearth of evaluations of healthcare information technologies generally,
and blood transfusion apps in particular, the purpose of this study was to identify
existing apps in transfusion medicine and review them with potential target users.
The rationale for the study was to learn from what has gone before and to identify
lessons, such as good practices and pitfalls, that could inform the design of the Special
Blood Components app. Specically, the study sought to answer two related research
questions:
1. What strengths and weaknesses do practitioners identify in an existing app aim-
ing to improve a specic area of blood transfusion practice?
2. To what extent could their observations transfer to other medical apps?
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5.2 Methods
Searching for suitable apps to review in the Google and Apple app stores revealed that
there were few appropriate apps in transfusion medicine at the time of study (April
2013). After discovering the recently published web-based “Platelets app” (NHSBT,
2013), which is unavailable through the app stores, it was apparent that it would be a
suitable candidate to review.
The Platelets app was a good comparator to the Special Blood Components (SBC)
app for several reasons. It had a similar purpose and audience since it aimed to improve
the use of blood components and targeted healthcare practitioners. Like the SBC app,
it was designed as an interoperable web app for a range of devices and platforms and
appeared to be based on current UK national transfusion guidelines.
To provide some context, the platelets app (shown in gure 5.1) is promoted as
a bedside tool to aid clinical decision-making during the prescription of platelets and
aims to reduce the inappropriate use of platelets (Estcourt et al., 2013). It was developed
by a team at NHS Blood and Transplant (NHSBT), but had not been evaluated in detail
previously. Members of the development team explained that the Platelets app had
been created under challenging time and budget constraints. They also hoped to secure
additional funding to continue its development.
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Figure 5.1: Screenshots of the NHSBT Platelets app. Left: welcome screen with the
main menu options. Right: the “indications for platelet transfusion” page oers the
user recommendations for prescribing platelets to adults or children. The app is avail-
able at: http://hospital.blood.co.uk/safe_use/platelet_education_resources/bbt/
About ten healthcare practitioners involved in blood transfusion were identied
and invited via the Scottish National Blood Transfusion Service (SNBTS) to take part
in the study. Seven participants agreed to participate on the basis of interest in the topic
and meetings were arranged with three haematologists (1 consultant and 2 registrars),
three anesthetist consultants and one transfusion practitioner nurse. In addition, the
medical advisor to the research project took part in the interviews.
5.2. METHODS 131
Evaluation was conducted using four semi-structured interviews (Gillham, 2005).
The anaesthetists and haematologists were interviewed separately. To accommodate
the commitments of participants, two interviews were group interviews (focus groups),
with two and three participants respectively. The remaining were single interviews.
Interviews lasted between one and two hours, and took place in the hospital workplace
of participants.
Abridged “technobiographies” (Kennedy, 2003, 129) are summarised in table 5.1
and illustrate the experience of information technologies that the participants shared.
During the interviews, participants were encouraged to freely explore the Platelets app
using a supplied iPad and to “think aloud” while doing so. Thinking aloud is a simple
and widely used technique for identifying usability problems:
“By verbalizing their thoughts, the test users enable us to understand how they
view the system, which makes it easier to identify the end users’ major miscon-
ceptions [—] revealing why users do something; providing a close approximation
to how individuals use the system in practice; [—] early clues can help to antici-
pate and trace the source of problems to avoid later misconceptions and confusion
in the early stage of design.” (Holzinger, 2005, 73)
The interviews were based on the schedule in appendix A.2, but diverged from
this as required. As can be seen in the interview schedule, in addition to reviewing the
Platelets app, all participants were asked to test and give feedback on the rst prototype
of the Special Blood Components app. Results from this activity is discussed in study
two (the next chapter).
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Table 5.1: Role, age range and thumbnail technobiography of participants. Names have
been changed to preserve anonymity.





Procient user of smartphone and tablet





“I am not an IT freak. I have just got a
basic Android phone, and the only app I






Android user who uses his smartphone
in clinical practice. During the interview,





iPhone owner. She condently used an
app on her phone to make a calculation






Knowledgeable about several hospital in-
formation systems which she uses to





Enthusiastic about medical apps: “I think
apps are the perfect form of owchart.
Because you just tick ’yes’, ’no’, ’next
screen’, ’yes’, ’no’, ’next screen’. Much





Develops web based software in his spare
time. His brother is a software engineer




20-34 Condent iPad user.
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Additionally, the anaesthetist consultants were invited to explore and comment on
a free game-based learning app developed by the Mayo Clinic called “TransFuse”. One
of the haematology registrars was also asked for her views on the Australian Blood
Service’s website about the indications for irradiated blood. However, the clinicians’
feedback relating to the TransFuse app and the Australian Blood Service’s website is
outside the scope of this chapter.
The interviews were recorded, transcribed, coded and analysed by hand, loosely
following a grounded theory approach (Glaser and Strauss, 1967; Strauss and Corbin,
1998). After reviewing the transcript and coding patterns several times, participants’
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5.3 Results
In this section, I present and discuss the comments raised by the participants. On the
whole, the reception of the Platelets app was mixed. Participants felt that the app
addressed an important issue, but that there was scope for improvement:
“There’s potential for it being useful [...] ideally [as part of] a transfusion app
incorporating red cells, platelets and plasma. [...] from the point of view of re-
stricting inappropriate use of red cells, plasma and platelets, actually having an
app that has fairly restrictive thresholds that people may look at once or twice
might just help the culture of avoiding excessive transfusions.” (James, consul-
tant anaesthetist)
“I personally haven’t fallen in love with it. I think it is too cumbersome. And it
doesn’t necessarily give the right answer.” (Jane, consultant haematologist)
“I wouldn’t nd it very helpful to be honest. I would probably reject that at rst
pass, and probably just ask a friend or something.” (David, consultant anaes-
thetist)
To better understand the reasons why respondents held these views, I will discuss
their comments related to the quality of the clinical content of the app, problems with
the built-in platelet dose calculator and issues related to usability.
5.3.1 Clinical content and presentation
Participants identied several issues with the contents of the Platelets app, ranging
from inaccuracies of the clinical recommendations and possible omissions to failing
to accommodate user preferences about how the information in the app should be
written, structured and presented.
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For instance, the thresholds for prescribing platelets is perhaps the single most
important information that users of the app are likely to look for. However, the value
and provenance of the transfusion threshold presented in the app was unclear:
“Where did the 75 threshold [75x10
9
/L platelet count] come from? [...] No guide-
line that I have read, as far as I remember, has ever mentioned 75. There’s 50,
100 and 80. 75 is completely random, not necessarily wrong, but random.” (Jane,
consultant haematologist)
“I’m not sure where these numbers come from. For example, patients with multi-
ple trauma [are recommended a] platelet count of a hundred. There are European
guidelines for patients with trauma which recommend keeping the platelet count
above fty. [—] So I am not sure if a hundred is a BCSH [British Committee for
Standards in Haematology] thing?” (James, consultant anaesthetist)
That said, another participant found the app’s threshold for epidural anaesthesia
acceptable, as illustrated in this following extract:
“[Let’s say] I want to transfuse pre-procedure, except eyes and brain. So this is
like a central line, a procedure we would do. Put a line into someone’s neck. We
often worry about platelet count because they might bleed.” (David, consultant
anaesthetist)
[looks up threshold in app]
“Ah, there we go. Oh, epidural anaesthesia. Oh, that’s good. 80 [...] All other
procedures 50. That’s fair enough.” (David, consultant anaesthetist)
State the aim and sources used by the app
Although the app had been designed to promote conservative use of platelets, one
participant felt that the purpose was unclear because the app’s thresholds were higher
than those used in current practice:
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“Is the reason for this app to help people decide when to give platelets [...] because
there is a perception that we’re giving platelets inappropriately and [the app is
trying] to stop it?” (James, consultant anaesthetist)
“My sense is that it was the latter. But I don’t know the full background.” (Andrew,
medical advisor to project)
“I’m sure that’s true, but some of the thresholds there are actually higher than
we’re sometimes following.” (James)
Transparency about the objectives and sources that an app draws on is important
to allow users to independently verify the recommendations embedded within an app,
and make an informed choice about whether to use the app or not. Participants recog-
nised that universal agreement on thresholds may not be feasible, and suggested that
the app should cite its references:
“The numbers are always going to be controversial.” (James, consultant anaes-
thetist)
“Well yes, but if they are controversial and the controversy lies within a range of
numbers, then the app needs to reect that. Or if there is a UK guideline which is
sensible in terms of the current play of the controversy, they should reect that.
But in something as dynamic as this it needs to be very clear about what [it is
based on].” (Andrew, medical advisor to project)
Oer clear and consistent information
In terms of the presentation, participants expressed uncertainty about whether the
value stated in the app represented the target platelet count or the threshold for pre-
scribing platelets:
“Prophylactic use involving eyes or brain... [Does it mean we should] transfuse if
it is a hundred or less? Or aim for a hundred?” (Mary, haematology registrar)
5.3. RESULTS 137
“We know what it means, but that implies if they are at a hundred you need to get
them platelets. Rather than that if they are nearly a hundred you are ne.” (Jane,
consultant haematologist)
“That’s a threshold value. If below ’x’, give platelets.” (Andrew, medical advisor
to project)
“It should say less than a hundred rather than a hundred.” (Jane)
The need to clarify whether the platelet count value in the app is a minimum or
maximum value was echoed by one of the anaesthetists. Furthermore, in the recom-
mendations for massive bleeding, both the minimum and maximum values were stated
in the app. This is dierent from the single platelet count threshold that is used in the
table with indications. Again, the decision to include two values led to some confusion:
“Keep platelets above 50 and aim for 75... I nd that a little bit dicult. I want to
have a target. If I keep it above 50, then I am happy with 51. If I want 75, then I
aim for 75.” (James, consultant anaesthetist)
It would perhaps remove some confusion if the same value, or set of values, were
presented consistently for all indications, with appropriate labels. One of the anaes-
thetists also commented that some of values were imprecisely labeled:
“That [table column with threshold values] should say platelet count or threshold
platelet count. [...] One adult unit. It should say one unit of platelets. You really
need to be clear about these things.” (David, consultant anaesthetist)
Help the user complete their task
For indications where it was not possible to state a threshold, it was not clear why the
indication was included in the app since that information did not appear to help the
user complete their task:
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[Reading indication for irreversible bone marrow failure]:
“So it is not possible to state threshold, which is probably right.” (Neil, consultant
anaesthetist)
“Yeah, [for] that one, irreversible bone marrow failure. So it’s not very helpful, is
it?” (David, consultant anaesthetist)
This raises a broader question about how apps should deal with cases where there
are no clear recommendations or where a treatment is not indicated. The extent to
which this kind of information is included or left out is an important editorial judge-
ment that should be made explicit. Furthermore, to make the recommendations easier
to apply, some participants felt that the app should be more prescriptive:
“But [the app] doesn’t actually tell me what I am supposed to be doing.” (David,
consultant anaesthetist)
The following dialogue, drawing on a hypothetical scenario involving an obstetric
patient, illustrates how the recommendations provided by the app were sometimes
dicult to interpret and caused confusion:
“All other procedures except epidural stays at [a platelet count of 50x10
9
/L]. In-
teresting, I thought the guidelines said [80]... it doesn’t tell you actually if it is
[appropriate for] an obstetric [patient]? No. If it is for anything else, yes.” (Jane,
consultant haematologist)
“I thought they [the guidelines] said 80?” (Mary, haematology registrar)
“But if you need to support an obstetric [patient] [with a platelet transfusion]
then you wouldn’t [do an epidural].” (Jane)
“Oh sorry. Because if it wasn’t 80 and above?” (Mary)
“For an obstetric, as far as I can remember, if you had to support to get to 80, you
wouldn’t do epidural.” (Jane)
“But then this is suggesting that if you are running at 80 and you’re doing an
epidural, you need to give platelets. Because this is the prophylactic use [pre-
procedure except eyes and brain]. Isn’t that what it is saying?” (Mary)
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The app contains pages with guidance about indications for platelet transfusion
and alternatives to platelet transfusion. At the stage of prescribing platelets in the app,
the user is asked questions about these topics, but there is no link back to the guidance.
The user can therefore easily miss the information, as this example shows:
[reads o screen:] “Prior to prescribing platelets for transfusion, what are the
indications for transfusion, are there alternatives? But then it doesn’t really help
answer those, does it?” (Sarah)
In the context of surgery, two of the anaesthetists made the general point that
thresholds are of limited use when a patient’s condition is changing quickly, or when
antiplatelet drugs are used:
“The other issue with major bleeding is of course the fact that with your platelet
count, by the time it is back, the patient has either lost a lot of blood or you’ve
given some treatment. So it is not necessarily particularly relevant.” (James, con-
sultant anaesthetist)
“The thing about these thresholds is [...] you’re not dealing with a static situation
[...] it is not as clear cut as an one snapshot in time. What has happened, what is
happening now and what is going to happen?” (Neil, consultant anaesthetist)
Take existing working practices into account
Further to the thresholds, participants identied issues with other parts of the contents
of the app. For example, the app recommends taking a full blood count after transfu-
sion, but this does not reect current clinical practice according to the participants:
“It is a bit odd that they suggest that [you should] remember to take FBC [full
blood count] after transfusion has been completed. That is not the clinical prac-
tice, only if there’s [a special reason]... We wouldn’t usually ask for that.” (Mary,
haematology registrar)
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“It depends on what you are doing. If you are going to do an epidural I think it
would be common sense to conrm that what you have done has had the neces-
sary eect. But if, for example, the patient is having [...] surgery [or] splenectomy,
you’d give them platelets and run with it.” (Jane, consultant haematologist)
“And also it says this exact same sentence with every single indication, even with
the prophylactic with a platelet count of 10. Which we don’t do.” (Mary)
Furthermore, in the section in the app dedicated to alternatives to platelet transfu-
sion, participants felt the prescription of DDAVP (Desmopressin, a drug that reduces
bleed time) should involve haematology:
“[for patients with uraemia] consider DDAVP with specialist renal advice. Really?
I think that [should be] haematology.” (Jane, consultant haematologist)
“Well, I see they’ve got specialised haematology advice down here [next item in
list].” (Andrew, medical advisor to project)
“For inherited platelet function disorders only.” (Mary, haematology registrar)
Signal important omissions
On the issue of relevant medical treatments, antiplatelet drugs, such as aspirin and
Clopidogrel, are widely used and can cause excessive bleeding. However, this topic is
not included in the app:
“What I haven’t found yet is antiplatelet drugs which in surgical patients, partic-
ularly in cardiac surgery patients, is a huge issue, particularly aspirin and Clopi-
dogrel. Which obviously isn’t picked up by the blood count. Some people are
using point of care aggregometry or modied thromboelastography to get an as-
sessment of the drug eect, but in terms of bleeding during surgery that is a huge
issue.” (James, consultant anaesthetist)
The app contains instructions about how to carry out platelet transfusions. For
example, it states the rate of transfusion and that platelets can be given through a
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standard set. However, it does not answer if it is acceptable to reuse a set that has had
red cells given through it, a question that one of the clinicians raised:
“One thing that isn’t here and perhaps this is something you could help me with.
It is often said that platelets shouldn’t be given through a set that has already had
red cells given through it. But I don’t know why and it is not in here. So I am not
sure if it is important.” (James, consultant anaesthetist)
“I personally don’t think it is important. There is no evidence for it, but I think
it is still in the BCSH guidelines. [...] So I think that’s probably an omission.”
(Andrew, medical advisor to project)
The app also does not provide information about how the rate of transfusion would
change in a paediatric setting (20-30ml/kg/h) (BCSH, 2003, 17), nor does it link to the
guidelines so that the user could easily nd out for themselves. Based on these com-
ments, it would be useful if the app stated clearly what was included, and any notable
limitations, such as anti-platelet drugs.
5.3.2 Platelet dose calculator
The dose calculator feature initially excited participants. Perhaps because it can be
confusing as this anecdote where the consultant haematologist tries to explain platelet
dosing to a registrar illustrates:
“I tried giving a unit of platelets recently and heard this registrar say:
’Well, this transfusion consultant wants to just give us a unit [although] I explained
that it is 15ml per kilo!”.
I tried to explain to the [registrar] that 15ml per kilo is much more than a standard
unit [150-300ml].” (Jane, consultant haematology)
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However, participants discovered several issues with the dose calculator. The list
of indications do not update to reect the entered weight. For example, the indications
for neonate and infants are still displayed for a 17kg child:
“Go back to the original list. Did you go into child?” (Jane, consultant haematol-
ogist)
“No, not yet. ” [taps on ’child’ button] (Mary, haematology registrar)
[on seeing weight input box:] “Oh okay, interesting. ” (Jane)
“We’ll just pick a small one” [types in 17 kilos] (Mary)
“Prophylactic, patent not bleeding” [taps on ’prophylactic without risk factors’].
(Mary)
“That’s quite an interesting idea.” (Andrew, medical advisor to project)
“Calculation 1 unit of platelets.” [reads out indications for neonate and infants]
(Mary)
“None of which are likely to weigh 17 kilograms.” (Andrew)
Further testing revealed that no validation is done on the entered weight. A typo
or simple user error, such as accidentally entering non-numeric character, leads to an
incorrect recommended dose. For example, entering “2kg” erroneously returns one
adult unit of platelets, a dangerously high dose. Table 5.2 contains a few simple test
cases and the recommended doses returned by the app. A sample calculation is shown
in gure 5.2.
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Table 5.2: Recommended doses for valid and invalid test cases returned by the Platelets
app, last tested 26 October 2015.
Input (weight [kg]) Recommended dose [ml] Correctness
15 and over 1 adult unit (150-300ml) Correct
12 120-240 ml Correct
6 60-120 ml Correct
3 30-60 ml Correct
0 0 - 0ml Incorrect (should fail)
-2 -40 - -80 Incorrect (should fail)
Non-numeric (e.g. “2kg”) 1 adult unit Incorrect (should fail)
Figure 5.2: Example of an erroneous platelet dose calculation. Left: the user inputs the
weight a paediatric patient, specifying kilograms. Right: The app incorrectly returns
a recommended dose of 1 adult unit. A simple bug in the calculator (failure to validate
input data) causes non-numeric values such as “10kg” to always return 1 adult unit.
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Because the app is web-based and relies on Javascript, it is easy to inspect the
code and identify the incorrect portion. In this case, the error is in the setChildWeight
function:
1 setChildWeight: function () {
2 this.weight = $(’#childs-weight-textbox’).val();
3 /*
4 Three unimportant lines removed to improve legibility
5 */
6 this.calculation = (this.weight < 15) ? (this.weight *




On the second line, the value entered by the user is retrieved without any kind
of verication that the value is within a valid range or of a correct data type (i.e. a
number). On line six, this unvalidated value is used to generate a recommended dose
calculation, which is then returned to the user on the next line.
The conditional (ternary) statement on line six reads: if the entered weight evalu-
ates as below 15 kilos, the recommended dose is calculated as a range, starting from the
weight multiplied by ten to the weight multiplied by twenty. However, if the condition
evaluates as false, the dose always defaults to one adult unit.
The programmer’s intention was to ensure that weights over 14 kilos yields one
adult unit. However, as Javascript is a loosely typed language, code execution will not
stop if a user enters a bad value, such as non-numeric text string when a numeric value
is expected. Instead, the Javascript interpreter will continue to evaluate the condition.
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In this case, this results in a behaviour where if a weight is entered as “2kg” (the
’kg’ letters makes this value a Javascript string and not a numeric value), the condi-
tion will evaluate as false and the code will incorrectly return a recommended dose of
one adult unit. This behaviour can easily be corrected by checking that the entered
value is a valid numeric value, for example using Javascript’s built-in function isNaN()
where NaN stands for “not a number”. The entered value could further be validated by
checking that it is within an acceptable range (e.g. non-negative).
These ndings highlight the importance of studying interactive cognitive aids in
their context of use context to uncover problems and suggest design improvements
(Furniss et al., 2015, 338). Moreover, the dose recommended by the app does not change
depending on whether the patient is bleeding or if it is for prophylactic use, although
the national guidelines suggest it should:
“When platelets are given therapeutically to treat active bleeding, a larger dose of
platelets may be indicated; the dose and frequency of administration depends on
the individual circumstances, and it is not possible to give general advice.” (BCSH,
2003)[17]
The BCSH guidelines also recommend 10-15ml/kg, not 10-20ml/kg, and the cut o
point for one adult unit is 20kg, not 15kg (ibid):
“One platelet concentrate is usually given to most adult patients. In small children
(under 20 kg), 10–15 ml/kg up to the adult dose of one platelet concentrate is used;
in older children, an adult dose of platelets should be used.”
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5.3.3 Usability
Interactive apps running on smartphones and tablets place dierent demands on the
design compared to desktop computer software or medical guidelines. For example,
apps should be easy to use on small screens, and they should allow users to stop and
resume a task easily. This is important in situations where the user is splitting their
attention between other tasks and may be distracted, which is likely when using mobile
devices. Thus, manufacturers of mobile devices have issued guidance for creating high
quality apps. These include the iOS Human Interface Guidelines (Apple, 2015) and the
Android design documentation (Google, 2015).
Dene purpose and scope of the app
A key point raised in both iOS and Android design guidelines is the rule that an app
must have a clear, narrowly dened purpose. The clinicians who evaluated the Platelets
app expressed some confusion about its purpose:
“I’m sometimes not sure what [the purpose is]. Is the reason for this app to help
people decide when to give platelets?” (James, consultant anaesthetist)
“It is almost like a sort of major haemorrhage protocol isn’t it? [—] It is not totally
clear who it is aimed at. [—] Maybe it is more of an educational thing really.”
(Sarah, haematology registrar)
The iOS Human Interface Guidelines stresses the importance of dening the scope
of the app, such as supported tasks and target audience (Apple, 2013)[9]:
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“When you’re starting with an idea for an app, it’s crucial to decide precisely
which features you intend to deliver, and to whom. [—] It’s essential to keep the
user experience uppermost in your mind as you design every aspect of your app,
from the way you enable a task, to the way your app starts and stops, to the way
you use a button.”
Thus, users would likely benet if the Platelets app communicated its purpose and
scope more clearly, such as what topics are within and outside its scope, who the in-
tended audience is and where in the transfusion process the app should be used. Clarity
about the purpose and scope would also make it easier for the user to assess if the app
is likely to meet their needs. This could take the form of a brief mission statement
shown on the home screen of the app.
Prioritise the key task
The design guidelines also highlight that an app should have one or more “killer” or
“hero” task that users of the app are likely to want to carry out. The app must be de-
signed in such a way that users can complete these tasks eciently, and with minimal
frustration. Most participants thought that the main purpose of app was to show indi-
cations and thresholds for platelet transfusions. One of the rst questions asked about
the Platelets app was: “So does it give a platelet count?”
The design should therefore make this feature much more prominent and faster
to complete. For a new user, it is not obvious that the thresholds are listed on the
“indications” page because they have to go through many steps before they can see
the thresholds, as this extract from the interviews demonstrates:
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[After opening ’conditions that require platelet transfusion’ page:] “To me, if I
read that and I am a junior doctor and I have a patient with a platelet count of 40
and it is bone marrow failure, should I be giving them platelets? [...] At this point
[...] it’s not saying.” (Jane, consultant haematologist)
[suggests pressing ’Indications for use of platelet transfusions’] (Mary, haematol-
ogy registrar)
“Yeah try that.” (Jane)
[taps button and skims screen:] “Who would you like to transfuse...” (Mary)
[taps ’adult’:] “If for prophylactic use, give 1 adult unit and reassess patient.”
(Mary)
“If you click on prophylactic does it give you [the threshold value]?” (Jane)
[Expands section which shows two new buttons:] “It doesn’t give a platelet count!
[taps the rst of the newly appeared buttons] Ah, it does there. Finally!” (Mary,
emphasis added)
“My goodness! What did you guys think of this? Because for me I would expect ...
you had to go through too many pages to get to anything that tells you whether
it is yes or no.” (Jane)
The app should make it very clear how to nd the platelet count thresholds. Ev-
erything else should be given lower priority:
“If the question is: should you give platelets, how much and when? Then maybe
you should concentrate on that”. (James, consultant anaesthetist)
Structure the app around the key task
It is important to identify the key task that the app must get right to please most users.
To achieve this, the app must be structured so that the user can easily carry out the
task they have in mind. This means understanding the user’s way of thinking, and
reducing the gulf of execution (Norman, 1988): "The gulf is small when the system
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provides information about its state in a form that is easy to get, is easy to interpret,
and matches the way the person thinks of the system" (Norman, 1988, 51).
Participants’ comments gave the impression that the app had been written without
sucient input of an experienced, practising clinician, familiar with the daily ins and
outs of platelet therapy. The app takes the user through the stages of platelet transfu-
sion, from conditions requiring platelets, alternatives, indications, counter-indications,
administration and risk factors for bleeding. But one participant commented that the
app had the wrong starting point and suggested an alternative ow:
“It is almost starting in the middle of the question, because you really want it to
be [structured like this]... Patient with low platelets. Patient who is bleeding. Or
patient who is for a procedure.” (Sarah, haematology registrar)
“Then, maybe if you picked patient who is bleeding, it could say normal platelet
count, low platelet count or whatever. And if you pick normal platelet count, it
[would ask] has the patient been given anti-platelet agents? Still consider giving
platelets. If not, [platelets are] probably not required.” (Sarah)
“And then if you picked, patient with low platelets, it would take you through:
are they low because they have an irreversible bone marrow failure; or are they
low because they have had chemotherapy [...] Or is it Heparin, or something all
together dierent.” (Sarah)
“Or then it could say... Patient going for procedure. What is their platelet count?
What is the procedure? Is it one that is high risk or low risk for bleeding. Have
they got other issues, such as antiplatelets agents? (Sarah)
Avoid getting in the way
Medical apps are typically accessed for short periods of time and must therefore allow
users to complete their tasks quickly. Comments from participants indicate that the
app could be made more succinct:
150 CHAPTER 5. STUDY 1: REVIEW OF AN EXISTING TRANSFUSION APP
“It looks as though you need to sit down and really work it through. It wouldn’t be
anything that you’d be looking at in the ward.” (Laura, transfusion practitioner)
“Some people like things that are text based.” (Andrew, medical advisor to project)
“Not when people are panicking.” (Jane, consultant haematologist)
“Yeah, there’s too much to read.” (Mary, haematologist registrar)
Moreover, participants felt that the app contains information which was superu-
ous to the core task of determining indications and thresholds for platelet transfusion:
“[The app] has clearly come from a sort of blood transfusion background with lots
of caveats about [making] sure you’ve got consent and recorded things in notes,
and lled in forms. [All of] which are important. But [...] they [the instructions]
give way to some of the ow. [...] Getting consent and lling in paperwork is for
somewhere else.” (James, consultant anaesthetist)
“If you are someone from another specialty [than haematology], you are like:
’why are they asking me about risk factors for bleeding’, ’what has that got to
do with it?’ Whereas maybe what you want to say is something more to do with
your platelet threshold for transfusion.” (Sarah, haematology registrar)
Simplify navigation
In terms of navigating the app, it provides some cues about where the user is through
page headings and occasionally through vertical button breadcrumbs. However, the
app is suciently complex for a new user to get lost:
“Where are we?” (Jane, consultant haematologist)
“We’re in therapeutic use, which is the last of the indications.” (Mary, haematol-
ogy registrar)
The navigational structure could be made simpler and clearer, for example by num-
bering headings and subheadings and by exposing page hierarchy. One of the most
important navigational aids is the back button, which is missing from some screens:
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“Can I go back? Because I am not sure what I clicked to get to this.” (Jane, con-
sultant haematologist)
“So how do I get back? There isn’t a back button, which is bad. Because you get
kind of stuck in the middle of it, going around in circles.” (Sarah, haematology
registrar)
In rare combinations, the back button is present, but non-functional (nothing hap-
pens when you click it). For example, the back button on the “risk factors for bleeding”
page is not working when the user is coming from a page showing a calculated child
or adult platelet dose.
The app lacks a “home” button and there is no way of getting to the front screen
once you leave it, except by reloading the app. Although the quick menu shows largely
the same information, the decision to not provide a method of getting back to home
screen can make the user feel that they are missing something:
“It [the menu] doesn’t look the same as before. What have I done?” (Sarah, haema-
tology registrar)
More consistent use of navigation buttons would improve user experience. Google
and Apple design guidelines have recommendations for handling navigation. The user
is likely to be familiar with these conventions and the app should seek to emulate these.
For example, by putting the back button in the top left corner of every page.
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5.4 Discussion
Although the app garnered a mixed reception, most participants felt that it was rel-
evant and addressed an important issue. It was perceived as potentially improving
access to thresholds and dosing advice, and could perhaps contribute to improving
prescribing culture. However, a number of important weaknesses were identied in
the app, making it less likely to be used. The interviews revealed a range of issues to
do with the content, dose calculator and usability of the Platelets app.
5.4.1 Thresholds and recommendations
The thresholds for prescribing platelets is something that users of the app are likely
to look for, but the value and provenance of the platelet threshold for major bleeding
in the app (75x10
9
/l) was questioned by participants. Although the app promotes con-
servative use of platelets, some thresholds were sometimes higher than those used in
current clinical practice. As universal agreement on thresholds is unfeasible, the app
should cite its sources.
Additionally, the presentation of the thresholds was sometimes unclear. For ex-
ample, there was confusion about whether the states values represented the target
platelet count or threshold for prescribing platelets. In the recommendations for mas-
sive bleeding both the minimum and maximum values are given. This was dierent
from the single platelet count threshold used in the indications table.
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It was also not always clear how the recommendations should be interpreted. For
example, the app recommends that a full blood count should always be taken after
transfusion, but this does not reect current clinical practice. Another problematic
area is antiplatelet drugs, such as aspirin and Clopidogrel, which are widely used and
can cause excessive bleeding. However, the app’s recommendations did not appear to
take this aspect into account at any point.
5.4.2 Potential for errors
The calculator feature, which initially excited participants, recommends one unit of
platelets for adults and calculates an adjusted dose for children based on weight. It
has a threshold set at 15kg. If the weight is above this, the dose defaults to one adult
unit. If it is below, the dose is calculated as a range in milliliters based on the weight.
Participants found some issues with the calculator. For paediatric dosing, the list of
indications are not updated to reect the entered weight. For example, the indications
for neonate and infants are still displayed for a 17kg child.
More seriously, no validation is done on the inputted weight value. A typo, such
as an accidentally entered non-numerical character, could lead to an incorrect dosage
being recommended. For example, entering “2kg” erroneously returns one adult unit.
This has potential to lead to medical error and serious patient harm. Additionally, the
dose recommendation does not change depending on whether the patient is bleeding
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or if it is for prophylactic use, although the national guidelines on the use of platelets
suggest it should. Furthermore, the same guidelines recommend a 10-15ml/kg dose for
children under 20kg (not 10-20ml/kg for children under 15kg as recommended by the
app).
5.4.3 User experience
Smartphones and tablets place dierent demands on design compared to desktop com-
puters or printed guidelines. Apps must be easy to use on small screens, be optimised
for short interaction time and work in situations where the user may be distracted.
Mobile app design guidelines therefore stress the importance of clearly dening the
scope, such as supported tasks and target audience. However, participants expressed
confusion about the aim of the Platelets app.
Thus, users would benet from clearer information about the purpose of the app,
what is included and excluded from its scope, who the intended audience is and when
in the transfusion process the app should be used. This could take the form of a brief
mission statement at shown on the home screen of the app. Clarity about the purpose
and scope would also make it easier for the user to assess if the app is likely to meet
their needs. Indeed, one of the rst questions asked about the app was “so does it give a
platelet count?” The design should make this feature much more prominent and faster
to complete. For a new user, it is not clear that the “indications” page is where to look
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for thresholds, nor that they have to go through several steps to get to the thresholds.
Furthermore, there was an impression that the app had been written without suf-
cient input from an experienced, practicing clinician. Indeed, one participant com-
mented that the app had the wrong starting point and suggested an alternative ow
based on more clinically focused questions. Medical apps are typically accessed for
short periods of time and to allow users to complete tasks quickly, they must follow
the user’s way of thinking to reduce the gulf of execution (e.g. make it clear to user
how to use the app to achieve the task at hand).
In terms of navigation, the app provides cues about where the user is through page
headings and occasionally through vertical button breadcrumbs. However, the app is
suciently complex for a new user to get lost. The navigational structure could be
made clearer. For example, by numbering headings and subheadings, and exposing
menu hierarchy. One of the most important navigational aids is the back button. This
was missing on some screens and occasionally it did not work.
The app also lacked a “home” button so there was no way to get to the front screen
once you leave it (other than reloading the app). Although the quick menu shows
largely the same information, the decision to not provide a method of getting back to
home screen made user feel that they were missing something.
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5.5 Conclusion
The objective of this study was to review an existing blood transfusion app target-
ing healthcare practitioners in order to learn from what has gone before. The study,
among the rst independent reviews of an app in transfusion medicine, revealed no-
table weaknesses in the clinical content, dose calculator and usability of the NHSBT
Platelets app. The ndings highlight how medical apps released with bugs and usabil-
ity problems are not only likely to be rejected by practitioners, but could potentially
also contribute to medical errors.
This study demonstrated that it is relatively straightforward to identify weaknesses
in medical apps and that reviewing existing interventions can identify important de-
sign lessons, such as following conventions that users are familiar with. Table 5.3
summarises the main areas of improvement and possible enhancements. Most of these
are general points that transfer readily to the design any medical app.
This was a small qualitative study conducted without giving participants an explicit
clinical task, and reecting the view of mainly senior clinicians. It did not involve
junior doctors or medical trainees who are also in the target audience for the app. With
these limitations in mind, practitioners’ comments made it quite clear that app could
be signicantly improved. Furthermore, unless the budget, skills and organisational
processes are in place to detect bugs and roll out software xes, it can be challenging
to make corrections in a timely manner.
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Table 5.3: Summary of areas of improvement for the Platelets app.
Maximise task eciency and
minimise user frustration
Promote the key task (looking up thresholds). Make
this task more obvious and faster to complete.
Validate the dose calculator
Check input to prevent erroneous results. Develop
test cases to verify accuracy of the calculation. Show
the user how the resulting dose was derived.
Content and structure
Add a brief mission statement to clarify the purpose
and scope of the app. Label and present thresholds
consistently. Make recommendations more explicit.
Layout information according to the users’ way of
thinking.
Usability
Simplify the navigational structure (possibly by re-
ducing scope); Ensure navigation buttons are present
on every page and functional.
Evidence base
Add references to allow users to verify of the source
of the information.
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Chapter 6:
Study 2: Concept Validation of the
Proposed App
This chapter explores challenges pertaining to the use of irradiated and Cytomegalovirus
(CMV) negative blood components through the perspectives of healthcare practition-
ers involved in blood transfusion at two Scottish hospitals. The study also solicited
their feedback on the initial working prototype of the Special Blood Components (SBC)
app intended to address this topic.
The chapter begins by detailing the research methods and objectives. The results
and discussion section is presented thematically and a summary of the main ndings
is oered in the conclusion.
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6.1 Introduction
The purpose of the research collaboration was to create and evaluate a mobile app
for practitioners involved in blood transfusion. It is an attempt to intervene to reduce
mistakes in the use of irradiated and CMV-negative blood components. As with the
all action research projects, the project must be guided by an accurate understanding
of the problem. This requires identifying the stakeholders and soliciting their under-
standing of the problem and their views it to address it.
As discussed in chapter three, failures to provide special blood components ac-
cording to guidelines is a challenge that requires several interventions and collabora-
tion across disciplines. Additionally, Checkland and Poulter (2010) argue that dierent
stakeholders may approach a problem in multiple ways based on their view of the
world (’weltanschaung’). It is thus essential to engage with a range of actors and ap-
proach the project in an open and collaborative manner.
With these considerations in mind, this study aimed to test my assumptions, which
were predominantly based on published haemovigilance data. I also hoped to gauge
to what extent an app could be an acceptable approach and sought to solicit early
practitioner feedback on the initial working prototype (shown in gure 6.1). Before
proceeding, I will briey describe the version of the SBC app used in the study.
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6.1.1 Initial SBC prototype
As discussed in the methodology chapter, the Special Blood Components (SBC) app
was iteratively developed, using an approach inspired by action research, co-design
and agile software development. This meant that the app underwent several re-designs
based on feedback from healthcare practitioners. This chapter reports on the initial
prototype.
The rst version of the SBC app was conceived of as a cognitive aid and simple
decision support tool covering dicult to remember indications of blood transfusion
(some of which were discussed in chapter three). It was intended primarily for doctors
involved in prescribing blood transfusions.
The scope included not just irradiated and CMV-negative blood components, but
also haemoglobinopathies, such as sickle-cell and thalassemia, transfusions in patients
with clinically signicant antibodies, use of emergency blood, massive haemorrage
transfusions and recommendations for Rhesus-D negative women of childbearing age
at risk of haemolytic disease of the newborn. Thus, this early version contained clinical
indications for a broad range of special transfusion requirements (g. 6.2). It also
featured a simple knowledge quiz (g. 6.3).
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Figure 6.1: Welcome screen and associated dialogues in the Special Blood Components
prototype. Clockwise: main screen; about page; help page; and the settings page.
6.1. INTRODUCTION 163
Figure 6.2: Indications section of the Special Blood Components prototype. Clockwise:
the complete list of indications; detailed view of the recommendations for intrauterine
transfusions; options for ltering the list of indications; subset of the indications list,
showing only items for which taking advice is recommended.
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Figure 6.3: Quiz section of the Special Blood Components prototype, showing an ex-
ample question and feedback dialogue for selecting the correct answer.
6.2 Methods
This study was conducted in a similar manner to the review of the Platelets app, which
was discussed in the previous chapter. That is to say, it involved the same research par-
ticipants and they were interviewed using the same process (see schedule in appendix
A.2). There were four semi-structured interviews (Gillham, 2005) with three haema-
tologists (one consultant and two registrars), three anesthetist consultants and one
transfusion practitioner nurse. Participants’ professional roles, approximate age range
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and “thumbnail technobiography” is summarised in the previous chapter (table 5.1).
The interviewees were recruited through the Scottish National Blood Transfusion
Service (SNBTS) and were self-selected. Two of the interviews were group interviews,
with two and three participants respectively. The remaining were single interviews.
The length of the interviews varied between one and two hours.
Participants were encouraged to freely explore the prototype and to think aloud
during the interviews to help identify usability problems (Holzinger, 2005, 73). The
interviews were recorded, transcribed, coded and analysed by hand, loosely following
a grounded theory approach (Glaser and Strauss, 1967; Strauss and Corbin, 1998). The
ndings were organised into the themes summarised in table 6.1.
Table 6.1: Themes identied in the interviews.
Theme Aspects covered
Problem denition
Extent, reasons and severity of problem; exist-
ing local solutions and limitations in these; per-
ceived possible solutions.
Appropriateness of an app
Questions about scope, audience and purpose
of the app; app as a learning aid; familiarity and
acceptability of using apps; likely limitations of
an app.
Collaboration
How and who to collaborate with; ways of
evaluating and disseminating the app;
Contents
What indications to include; what sources to
draw on; what search terms to include; discus-
sion of scientic evidence.
Usability
Presentation of information; use of language;
possible decision algorithms; visual design; fa-
miliarity.
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After the interviews, the clinicians who I interviewed, and three additional collabo-
rators with blood transfusion backgrounds, were emailed an invitation to preview and
comment on the revised app. The email contained a brief progress update and instruc-
tions for how to leave feedback (see appendix A.3 for a copy of the email invitation).
All follow-up feedback data was captured remotely via email, phone or the online
survey. In addition, the app contained integration with Google Analytics, enabling
tracking and analysis of how users accessed the app. The app’s terms of use, presented
to the user when opening the app, explained which data was collected and why. The
feedback questionnaire included information about the research aims and conditions
for participation. A copy of the questionnaire is provided in appendix C.3. Participants
also helped pilot the questionnaire, which would later be used for an evaluation of the
app with nal year medical students – the topic of chapter eight.
6.3 Results
The interviews conrmed the incidence of mistakes in the use of irradiated and CMV-
negative blood. The haematologists that I spoke to gave several examples where non-
irradiated blood had incorrectly been transfused to patients with special requirements:
“We’ve had errors which we have reported to SHOT [Serious Hazards of Transfu-
sion]. We had a child who was harvested [for stem cells] and got non-irradiated.”
(Jane, consultant haematologist)
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In another case, failure was caused by incomplete handover of information when a
haematology patient received care at another hospital that used a dierent IT systems:
“One of the haematology patients from here had to have a transfusion at a dier-
ent hospital, and that information wasn’t on their system. I think [the patient]
actually got non-irradiated red cells. That was agged up as an [—] incident in
the system.” (Sarah, Haematology Registrar)
Sometimes, special components were also requested inappropriately:
“We’ve had a case where a sick kid was requested irradiated, when they didn’t
need it. The reason they requested irradiated was because this patient was pan-
cytopenic [decient in all blood cell types] from leukaemia therapy. So, it is in
a way equally important to identify [situations that] doesn’t need irradiated. In
this case, it depends on the type of chemo or underlying diagnosis.” (Jane)
Unnecessary requests for irradiated blood components could harm patients in time-
critical scenarios. Knowing when irradiated blood is not required can avoid delay:
“I can tell you of someone who requested irradiated when they didn’t need it. It
was in a [...] major haemorrhage situation, and it got them tied up in knots. And
despite explaining it 24 hours later, I was having the same discussion with them
again.” (Jane)
These examples illustrate failures to request and to communicate special require-
ments during shared care, as well as the inappropriate request for special blood compo-
nents in situations which could be time-critical. Considered together, these examples
conrm the case reports published by SHOT and provide rst hand accounts of the
types of mistakes, causes and impacts they have on patients and practitioners.
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6.3.1 Systems for managing special requirements
Ensuring that patients with special requirements are identied and always given the
correct blood component is challenging. This issue led to the introduction of a formal
process in one of the hospitals whereby the blood bank is notied of any patients with
special requirements:
“For the very same reason that you have been thinking about this app – there
had been quite a few near misses if you’d like where all non-irradiated products
were requested, and it was only picked up by the lab – we’ve actually changed
the system within the haematology department.
So, when a patient is newly diagnosed – and that’s a consultant decision – a
form goes down to the haematology lab so that it is documented on the blood
transfusion lab system. So we as juniors are not required to tick any boxes, and
it is given that the information is already down in the lab.
It is really up to the senior team, so the consultants, if they are giving a new drug,
such as udarabine or whatever. And if that changes then that information has
to go down in a new form. [—] That form is then led with the patient’s notes.”
(Sarah, Haematology Registrar)
As the haematologist registrar explained that there have been near misses, where
mistakes were detected and prevented before patients were aected. This lead to the
introduction of the special requirements notication system. A similar system was
introduced for the same reasons in the hospital where Jane is haematology consultant:
“[The use of irradiated blood components] is such a problem, and they get it
wrong so often, that we actually have a system where, if a patient is identied
as requiring irradiated products, the blood bank is informed. And we put that on
[...] our IT system for SNBTS [Scottish National Blood Transfusion Service]. So
that any time that a patient comes through an SNBTS blood bank, nobody needs
to think about it. [...] That’s how bad this is.” (Jane, consultant haematologist)
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While Sarah felt that the system had worked well in her department, Jane explained
that their system have potential to lead to a false sense of security because it was being
perceived as fail-safe. Jane highlighted the danger, using an example of a consultant
who suggested it was unnecessary to always complete the special requirements on the
blood request form as the system would catch errors involving special requirements:
“My understanding is that it is the consultant who proposed [...] that you don’t
actually have to request irradiation every time because they know that there is a
fail-safe system. [—] I think this is wrong. They should always request irradiated
because if there is a visitor from England it falls through.” (Jane)
“Or if the IT system is down, like ours was the other day.” (Laura, transfusion
practitioner)
These views are echoed in a SHOT recommendation based on a case where a preg-
nant woman was not provided with CMV-negative blood for an elective operation.
This incident was caused by a failure to complete the request form fully and SHOT
recommends that : “It must never be assumed that the laboratory sta will know what
the patient’s requirements are and they should be conrmed by selecting the appro-
priate option on every request form.” (Bolton-Maggs et al., 2015a, 61).
SHOT have also highlighted that failures to provide special blood components can
happen because of missing, incorrect or ignored ags in the hospital or blood bank
information systems (Bolton-Maggs et al., 2015a, 62), adding to Jane’s point that these
systems are not fail-safe.
The transfusion practitioner commented that it was some time since an incident
was raised in the system for detecting mistakes, suggesting either that practice has
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improved or perhaps that the system is not detecting mistakes:
“There used to be an incident if it agged up on [the laboratory IT system] and
[...] I’ve not had [a notication of an incident] for long time.” (Laura, Transfusion
practitioner)
One of the haematologists had a dierent explanation. She explained that there is
likely to be under-reporting since mistakes can go unnoticed due lacking awareness:
“It is only those who realises they have made a mistake and comes back to us that
we can pick up.” (Jane)
6.3.2 Causes of mistakes
Over the last ten years, the SHOT reports have identied several causes of mistakes
involving irradiated and CMV-negative blood components, including a lack of clini-
cian knowledge, inadequate communication during shared patient care and IT system
failures. The interviews conrmed many of these ndings. For example, Jane felt that
there was a poor level of knowledge for some of the indications for irradiated blood:
“[Clinicians] keep falling down on [Campath and ATG] [—] [They are] not nec-
essarily making the connection that they need to be using irradiated products.”
(Jane, consultant haematologist)
James, one of the anaesthetists, also felt that there was limited knowledge of the
indications, as well as a general the lack of awareness of the rationale for using special
blood components:
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“Obviously there is a diculty of remembering what [the indications for irradi-
ated and CMV-negative blood components] are. But I think the common problem
is that [clinicians] won’t even think about it. Patients come into ITU [intensive
treatment unit] who have previously been at an other hospital, and that there
is an indication for special requirements doesn’t cross anybody’s mind.” (James,
consultant anaesthetist)
He went on to compare this issue with the challenges related to implementing
medical guidelines – such as promoting their use and changing medical practice:
“One of the big problems that we have with guidelines – and I guess it will be
the same for the app – is not that people don’t follow them, but that they don’t
know of their existence. They don’t get to the stage of even looking at them. By
the time they think ’maybe this patient has a special requirement’, you’re almost
there. You just need a little bit of help to clarify it. It is not having realised it, that
is the issue.” (James)
Furthermore, Andrew commented that checking whether a patient has special re-
quirements is a low priority for most clinicians:
“The fact that a patient needs irradiated blood is low on the list of priorities of
things that anybody has to remember when they see almost any patient. It just
happens to be very important if you get it wrong. We know its an area where
lots of mistakes are made. We got plenty of evidence for that.” (Andrew, medical
adviser to project)
Disparate IT systems between hospitals and departments is another reason for why
mistakes can happen. One of the haematologists explained how this situation prevents
information from being automatically shared between caregivers:
“Unfortunately, the computer system here is not directly linked to other hospitals
[...] The plan was to have those [irradiated blood] forms communicated to other
hospitals, so it would be on the same system. But it has to be done on an individual
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basis, and sent through as a purposeful act, rather than it automatically getting
linked up. So there is always room for error, unfortunately.” (Sarah, haematology
registrar)
The national guidelines for irradiated blood recommends that patients should be
given a card stating that they require irradiated blood and instructed to show the card
to healthcare sta (Treleaven et al., 2010). However, Sarah felt that patients cannot be
relied upon to communicate their special requirements and that linking up IT systems
would improve safety:
“The link up of dierent labs is important for some of the patients. For those with
Hodgkin’s [lymphoma] it’s a life-long [condition], and for the stem-cell [therapy
patients] it is becoming a life-long period. [—] I suppose Hodgkin’s [patients] do
so well so they forget they’ve had it twenty years ago, and they don’t mention it.”
(Sarah)
6.3.3 Professional knowledge boundaries
Assessing if a patient should receive irradiated and/or CMV-negative blood compo-
nents require detailed knowledge of the clinical indications. Unless one sees patients
with special requirements on a regular basis, making the correct decision can be hard:
“It is [a complex decision] if you are not a haematologist. It is bread and butter
for us, but it is [a complex decision] if you are not a haematologist, yes.” (Jane,
haematologist consultant)
This view was mirrored in a comment by David who felt that the clinical indications
are mostly irrelevant to the majority of doctors - until they encounter a patient where
it becomes relevant:
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“So, what you’ve got here [referring to the SBC app prototype] is a long list of
reasons for transfusing [irradiated and/or CMV-negative] blood products, most of
them fairly rare. Because most transfusions are going to be red cell transfusions
for non-haematology patients for anaemia or bleeding [—] for most doctors, most
of this is not relevant. [...] it is the one specialised patient that comes into a
general ward with another problem that is the highest risk. If it is a specialist
ward, then it’s ne. Everybody knows.” (David, consultant anaesthetist)
Non-haematologists do of course prescribe, request and administer blood com-
ponents to patients with special requirements occasionally. This is the reason that
SHOT recommends that “The existence [...] of special transfusion requirements must
be taught to junior doctors in all hospital specialities.” (Cohen et al., 2010, 55). How-
ever, Jane felt that the SBC app should not only target junior doctors:
“I would not just aim this at junior doctors. We have many senior consultants who
have genuinely said: “Do I need irradiated products?” (Jane, consultant haema-
tologist)
“Right. I’m not surprised to hear that.” (Andrew, medical adviser to project)
“But these are people who I personally would have expected them to know.” (Jane)
“Would they use something like this, do you think?” (Andrew)
“I don’t know.” (Jane)
“Their registrars might.” (Mary, haematology registrar)
“Yes, but the mistakes were made by consultants. If they’ve made a mistake once,
they know to go back and check next time.” (Jane)
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6.3.4 Suggestions for improving existing procedures
The anesthetists suggested that having a way of alerting clinicians at the time of re-
questing blood could be eective since remembering special requirements is dicult:
“The other point, which you touched on, is that if people think of using the app,
then they will have thought through already, maybe this patients needs irradi-
ated.” (Andrew, medical adviser to project)
“Yes, so you are halfway there. You’ve already got the red ag waving. Something
is out of the ordinary here. And actually that is half the battle. What we are trying
to avoid here is somebody saying: ’Oh I just give them a couple of red cells’
without thinking. Which is very easy to do.” (David, consultant anaesthetist)
An idea that came up repeatedly was incorporating decision support prompts at the
time of prescribing blood components. This has been explored by Turner et al. (2003)
who evaluated a handheld bar code scanner with built-in prompts. They found that
prompts improved adherence to special requirements checking. A similar approach has
since been incorporated into an end-to-end system electronic transfusion management
system (Murphy et al., 2012). However, such a system was not implemented in any of
the hospitals included in this study and no prompts related to special requirements
were in place:
“If you put in an x-ray, you get a prompt saying might the patient be pregnant [...]
but blood transfusion has been avoided from being incorporated into that system.
[—] At the moment it is dicult to impose a sort of question every time anyone
requests a blood transfusion.” (David)
“We are a bit atypical. The majority of hospitals are in a position to do that. I don’t
know how many have done it. It is something we should explore. Because the
blood bank data is handled through the main laboratory system, which is not the
case here, they have the facility to put all kinds of haematology alerts on there, if
they want to.” (Andrew)
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6.3.5 Improvements to the SBC prototype
The interviews also identied areas of improvement in the Special Blood Components
app prototype (summarised in table 6.2). When addressing these points, it was dicult
to nd a good way to feed changes back to the research participants. For example,
sending a spreadsheet was a clunky way of collaborating on changes to the app:
“...what would be the best way to provide the new text to anybody who would be
prepared to look through it and make some edits. Would you send the app and
say give us notes with anything that needs to be changed? Or how would you
handle that?” (Andrew)
“The database behind it is basically a spreadsheet. So that might be the easiest
way; to circulate a spreadsheet. [—] [but] it would be hard for you to see the
dierences if I just sent you the next version. It would be good to set up some
kind of editorial system. I’m not sure how to do that at the moment.” (Karl)
After investigating this problem further, it became clear that there were few suit-
able tools for easily sharing changes to the app with collaborators.
6.4 Discussion
The interviews provided perspectives on why the correct use of special blood compo-
nents is challenging, and how it could be improved. For example, the haematologists
who regularly worked with patients with special requirements, were able to give ex-
amples of when and why incidents occurred, and how these were managed.
They emphasised the importance of having robust systems for capturing and com-
munication special requirements, and for raising knowledge of the issue among prac-
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titioners in other specialties, including at consultant level. The view was shared by
the transfusion practitioner nurse who was responsible for improving the local hospi-
tal transfusion process by monitoring transfusion incidents and training sta. These
comments strongly reect the key recommendations provided in the reports by SHOT.
The anaesthetists provided another angle on the problem. Unlike the haematolo-
gists, they rarely knowingly encounter patients with special requirements, were less
familiar with the topic and somewhat hesitant to admit gaps in their knowledge.
Table 6.2: Areas of improvement for the Special Blood Component app.
Area of improvement Required action
Score, audience and
purpose
Limit scope to irradiated and CMV-negative blood. Remove
haemorrhage, emergency blood, RhD-D negative blood compo-
nents, sickle cell disease, thallasaemia and signicant antibodies.
Content
Update indications for CMV-negative components according to
the guidance from SaBTO. Ensure that the indications follow the
national guidelines to the letter. Improve taxonomy of search
terms by adding common misspellings, relevant clinical diag-
noses and the names of increasingly used chemotherapy drugs
(e.g. Campath/Alemtuzumab). Add a section that explains the
rationale for the use of irradiated and CMV-negative blood com-
ponents. Expand the use of references and rely directly on the
national guidelines instead of secondary sources.
Features
The list of indications is quite long. Re-investigate the feasibil-
ity of adding a decision support algorithm to make it faster and
easier to check if there are any indications that might apply to a
given situation.
Usability
Make the search feature for the indications more prominent. Im-
prove the icons as their meaning was not intuitive. Use colour-
coding, possibly based on a trac lights system, to make the in-
dications easier to scan. Group and prioritise the indications list
carefully, perhaps by specialty or frequency.
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However, they agreed it was a challenging topic, and that poor awareness of the
indications for special blood components was an important cause of the problem. They
also felt that it was hard to remember when irradiated or CMV-negative blood is re-
quired, and that special blood components ranked low on their list of priorities.
A recurring comment was that any decision support provided in an app is un-
likely to improve the situation because by the time a user opens the app, they were
“nearly there”. What was needed was an “externally triggered” reminder, such as a
prompt at the point of ordering blood components. This assertion is supported by a
systematic review of 20 studies concerning the impact of decision support systems on
blood ordering by Hibbs et al. (2015). Although the review did not consider special
requirements, they found good evidence that such systems promote appropriate use
of red cells. However, this did not exist in the hospital involved in this study because
the blood ordering system, which was separate from the main hospital information
system, lacked support for decision support prompts.
Their comments encouraged me to think more broadly about the problem and the
purpose of the app. As well as oering easy access to the indications, it could function
as a learning aid to raise awareness of the problem. There are SHOT cases illustrating
the importance of wider awareness of the issue among nurses and patients, as they
have prevented mistakes made by clinicians. It could to increase the likelihood that
mistakes could be picked up at other stages of the clinical transfusion process besides
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the prescription of blood components, such as at pre-transfusion checking. It is there-
fore important to increase general knowledge and awareness of the topic among sta
involved in key stages of the blood transfusion process.
6.5 Conclusion
In conclusion, interviewing participants from dierent hospitals, specialties, and with
dierent professional responsibilities and priorities, deepened my understanding of
the problem that the SBC app sought to address. This included of the challenges of
providing continuity of care given variations in information systems and processes
between hospitals. A limitation of this study was that it only captured the views of a
small number of practitioners.
However, it was large enough to observe dierences and similarities in how the
participants dened and analysed the problem, and how they identied potential so-
lutions. This early input from clinicians was essential for developing a better under-
standing of the problem from multiple viewpoints, for identifying inaccuracies in the
app’s data model, for improving the usability, and most importantly for rening the
purpose and audience of the app. It also became apparent that it an issue that requires
more than one interventions to tackle.
Finally, the comments oered by participants helped to improve the SBC prototype
and convinced me that it was worth continuing its development. I did, however, en-
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counter diculties in eectively sharing work in progress with participants to verify
I had corrected the issues that they had identied. This diculty prompted the third
study, where I create and demonstrate a collaborative app editor. The Web App Editor
would become a vital tool for sharing work.
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Chapter 7:
Study 3: Collaborative App Design
with the WAE
This chapter shifts focus from the blood transfusion domain to the software engi-
neering and collaboration processes involved in the development of mobile apps. It
discusses the design and testing of the Web App Editor (WAE), a web-based tool de-
signed to make it easier to collaboratively develop apps.
The rst part of the chapter draws on data collected during two courses in mobile
app development where the WAE was used. It builds on work previously reported
in Monsen (2013). The second part is based on an interview with a Master student
who used the WAE to develop an app for stroke patients. This work is the basis for
Mamalaki et al. (forthcoming).
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7.1 Introduction
Carayon and Wood (2010) argue that healthcare practitioners, human factors experts
and systems engineers must collaborate and learn from each other in order to im-
prove patient safety. As I discussed in chapter two, interdisciplinary collaboration is
also critical to create high quality medical apps that are supported by evidence. For
instance, Car et al. (2008, xxvii) argue that there is a need for “... a methodological
toolkit to facilitate evaluation of eHealth applications throughout all aspects of the
development and deployment life cycle of these technologies”. Similarly, von Hippel
(2001) demonstrates how “user innovation toolkits”, including computer aided design
software applications, have lead to new products in many sectors.
I observed at the end of chapter six that there is a lack of collaborative tools for
co-designing medical web apps. For example, resorting to emailing spreadsheets to
collaborators is not conducive to agile and iterative app development. The objective
of this study was thus to create a collaborative authoring tool to facilitate eective
participative app design and explore its usefulness beyond the context of the SBC app.
It sought to explore to what extent and how the Web App Editor (WAE) could enable
novice app developers to create mobile apps. Before describing the study methods, I
will elaborate the background to why and how I created the editor, and how it compares
to prior art.
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7.1.1 Origin as a constructivist learning tool
As was mentioned in chapter two, digital literacy is important to allow users to become
involved in the medical app development process. An obvious method for improving
digital literacy is to teach app development to learners who are interested in this topic,
but unfamiliar with software development.
The precursor to the WAE was created for the delivery of a course on app de-
velopment for beginners that I rst taught in 2013. It aimed to explain how HTML5
apps work and encourage beginners to learn to create apps through examples. Conse-
quently, I created a very simple code editor that could load and modify code templates
(table 7.1). These were designed to separate the content from the logic to enable learn-
ers to change to the content without having to make extensive changes to the code,
although students were encouraged to experiment to support deeper learning.
This pedagogical approach was inspired by the constructivist approach to teach-
ing programming concepts to beginners, pioneered by Papert et al. (1979). Their sem-
inal work on the Logo programming language has since inspired beginner-friendly
visual programming environments, including Scratch (Resnick et al., 2009), Catroid
(e.g. Slany, 2012) and MIT’s App Inventor. These have enabled a diverse range of users
to create apps, including children (Slany, 2012), university students outside of com-
puter science (Wolber, 2011), teachers (Liu et al., 2013) and healthcare practitioners
(MacKellar, 2012).
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jQuery Mobile scaolding necessary to create
and link pages within an app.
Geolocative map
Plots the user’s physical location determined
using GPS and a custom map layer with user
dened points of interest onto a Google map.
JSON data
structure
Dynamically creates page content and menus
from a JSON (Javascript object notation) data
structure using jQuery.
News reader
Downloads and displays a single RSS (really
simple syndication) newsfeed.
Battery meter
Shows power consumption based on Firefox’s
power API.
Web requests
Creates and handles asynchronous Javascript
(AJAX) requests to third party web services.
Physics
simulation
Demonstrates the Javascript port of Erin
Catto’s Box2D physics engine.
While visual programming environments lower barriers for beginners, they do
have some important limitations. The inability to switch easily between graphical code
blocks and the source code makes the transition to text-based programming harder.
Another drawback of both Catroid and MIT App Inventor is that the resulting apps
will only run on Android. More specically, testing these apps require access to An-
droid hardware, or an emulator that can be slow and frustrating to work with on other
processor architectures, such as desktop computers.
In contrast to “native apps”, HTML5 web apps are interpreted or compiled at near
run time speed (using just in time compilation), making it is possible to get a near real-
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time preview of the app on any device with a recent browser. This can make it faster
and easier to debug web apps, which is benecial for beginners. Indeed, Subhi et al.
(2014) argue it can be very easy to create apps using these web technologies and they
encourage clinicians to learn how to use them.
Furthermore, there are a number of online services
1
which allow novices to create
HTML5 apps by dragging and dropping visual elements. These editing environments
are quite easy to use, but restrictive because they are based on predened designs
and lack the ability to change the underlying templates. For example, Masters (2014)
discuss how medical students at Sultan Qaboos Univesity, Oman were taught to create
medical apps using the iBuildApp web service. The large majority of students favoured
a more sophisticated system as they felt constrained by the drag and drop interface
(Masters, 2014, 885). Hence, I decided against creating a visual editor for native apps
and developed a text-based editor for creating HTML5 apps.
Compared to native development using object-oriented languages such as Java or
Objective-C, app development with HTML5 can be an easier route for beginners. There
is no requirement for software development kits (SDKs), integrated development en-
vironments (IDEs) like Eclipse or Apple’s Xcode, or access to specic hardware or em-
ulators for testing.
The interactivity of HTML5 apps is down to Javascript. It is a widely used, but
1
e.g. www.appypie.com, www.como.com, www.ibuildapp.com, www.appmakr.com, last visited 25
June 2015
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far from perfect programming language (Crockford, 2008). Compared to native app
languages, it could be considered a more suitable language for beginners because it is
loosely typed, variables have global scope and the use of object-oriented concepts is
optional.
Additionally, web design with Javascript is widely taught as an introductory pro-
gramming language. For example, Mozilla runs initiatives to teach the basics of HTML










and to teach game programming to children (Strom, 2013). I will now briey
describe the technical architecture of the latest version of the Web App Editor.
7.1.2 Technical architecture
The WAE is based on the open source Cloud 9 ACE editor, which allows code to be
modied in a web browser. The code editor, together with a live preview of the inter-
preted code, was initially embedded inside a split-screen layout. Changes were stored
locally in the browser cache, using the HTML5 localStorage feature. This allowed cod-
ing sessions to be stopped and resumed, but did not provide robust permanent storage.
The updated version of the system, shown in gure 7.1, was modied according to
2
https://p2pu.org/en/groups/schools/school-of-webcraft/, last visited 25 June 2015
3
https://thimble.webmakwer.org, last visited 25 June 2015
4
www.khanacademy.com, last visited 25 June 2015
5
www.coursera.org, last visited 25 June 2015
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student feedback and integrates with the GitHub.com revision control system to allow
changes to be saved permanently. A comparison of the features of the dierent ver-
sions of the editor is provided in table 7.4. Furthermore, the editor shares similarities
with existing online code editors (table 7.2). The technical architecture of the system
is illustrated in gure 7.2. Several freely licensed, open source software components
were used to create the WAE, including:
• ACE Editor for editing code, maintained by Cloud 9.
• Share.js for real-time collaborative text editing using the operational transforms
algorithm to sync changes, by Joseph Gentle and others.
• Octocat.js Github API javascript library, by Phil Schatz.
• Rawgit for fetching and proxying github les, by Ryan Grove.
• W2UI for the user interface management, by Vitali Malinouski.
• JsTree for managing le structures, by Ivan Bozhanov
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Figure 7.1: Screenshot of the Web App Editor
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Table 7.2: Comparison of online collaborative code editors as of March 2016.
“Cloud IDEs” “Prototyping playgrounds”
























Technology stack: Node Node Node Ruby Node PHP(?) Node
Bundled code editor
(CM=Code Mirror):
Ace Ace CM CM CM CM Ace
Source code
licensing:
Open Dual Closed Closed Open Closed Open
Price/business
model:
n/a Freemium Free Trial Freemium Freemium Free Free
Footnotes:
1. Real-time collaboration requires a premium Codepen account.
2. Text chat and audio conferencing provided through Mozilla’s Together.js library.
3. Operations include le management, version control and changing the editor layout to edit mul-
tiple les.
4. Unlike the WAE, version control is only oered via a terminal and require familiarity with the
Git command line.
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Figure 7.2: Technical architecture of the Web App Editor
Table 7.3: Comparison of the cohorts participating in the study.







Evening course: 12 weekly
three hour classes.
Intensive course: 1 week
with full time classes.
Students in class 8 8
Students surveyed 7 3
WAE version used v.0.1 v.0.2
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7.2 Part 1 - Use of the WAE in education
The purpose of this part of study was to examine to what extent and how the WAE
facilitated collaboration and digital skills acquisition among users who are new to app
development. To examine this, the WAE was evaluated during two certied courses
in app development for beginners. I taught the courses, which had a nominal contact
time of 36 hours and were oered at higher college level (SCQF 6), approximately one
year apart.
7.2.1 Methods
At the end of each course, students were invited to participate in an short online ques-
tionnaire about the use of the WAE in the course (see appendix B.1). The questions
explored students’ prior experience of installing, using and creating apps. It also asked
them to comment on and rate the editor using the System Usability Scale (Brooke,
1996). However, it was not answered by a sucient number to merit analysis.
Because the number of respondents are small, the results from both classes will
be discussed together. Although both cohorts attended the same course, there were
some dierences (see table 7.3). Most notably the WAE was under heavy development
during the courses. The rst cohort used the initial prototype version that had a much
smaller feature set (see table 7.4). Cohort two used a more fully-featured version, also
incorporating feedback and bug xes, identied in part by students in the rst cohort.
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Storage and le management
Temporary le storage (localStorage). - - X
Permanent storage with version control
(GitHub.com integration).
X X -
File handling (uploads, renaming, etc). X X -
Development and testing
Syntax highlighting and checking. X X X
Project hosting and instant preview. X X X
Split-screen editing X X -
Collaboration
Real-time pair programming (ShareJS). X X -
Text, audio and video chat (WebRTC). - X -
Collaborator activity feed (Github). - X -
Preferences and customisation
Editor theme and font options. - X -
Flexible, tab-based user interface. X - -
The objectives of the course was to give students an opportunity to plan, create and
evaluate a mobile app. There were no course prerequisites and to bring everyone up
to speed the rst four sessions were dedicated to HTML, Javascript and jQuery Mobile
- a library for creating mobile web applications.
Prior to collecting any data, participants were informed about the purpose of the
research and how their answers would be used. Their responses are reported anony-
mously. Permission was also obtained to present sample student work.
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7.2.2 Results
Nineteen students enrolled in the courses, but three withdrew early for dierent rea-
sons. This left sixteen students, of which ten - six women and four men - agreed to
participate in the study. Two students were 24 or younger, two were between 25 and
34, two were between 35 and 44, and the remaining were 55 or older.
Background of participants
Students were condent mobile phone users and a majority reported using apps on a
regular basis (g. 7.3). For instance, one student claimed that their phone is “always
on and always getting used” (female, 35-44). Another felt that “apps have become part
of everyday life, however, I only use a handful of the many that I download” (male,
25-34).
Figure 7.3: Prior experience of mobile technology among the students.
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Figure 7.4: Condence in technical web design skills at the end of the courses.
That said, it is important to emphasise that not everyone who participated in the
course used apps or had signicant smartphone experience. For example, one partic-
ipant reported: “I personally do not download extra programmes onto my telephone”
(female, 55-64). Although one third of students indicated that they sometimes rate apps
in the app stores, only one person had prior experience of creating them:
“I regularly update, remove and install apps. As I am interested in computer de-
velopment as a whole I have made a few apps, though I cannot say I have great
experience of the subject.” (male, 24 and under)
When asked to evaluate their own skills at the end of the course, many participants
indicated that they have a good grasp of web technologies (g. 7.4). However, several
students also acknowledged that they still have much to learn:
“Whilst the fundamentals of HTML and CSS are there, I strive to learn as much as
possible to improve skills. With more browsers adopting modern standards, the
use of HTML5, CSS3 and Javascript to create quality user experiences is becom-
ing the norm. I would appreciate any opportunity to enhance my knowledge of
Javascript.” (male, 25-34)
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Furthermore some students had not done much web development before: “It was
the rst time I used a lot of Javascript and HTML” (male, 65 and over). When asked if
the approach of the course could encourage more people to develop apps, one partici-
pant argued that the lack of course prerequisites was important in achieving this:
“The approach of the course was very inclusive and assumed no prior knowl-
edge, I think this would encourage people who would otherwise feel alienated by
technology to ’give it a go’ ” (male, under 24)
This is supported up by a statement made by another student who had little initial
condence about using apps: “I knew very little about apps when I started the course.
I would feel more condent about using them in future” (female 55-64). Of the more
advanced students, two had professional web design experience and were able to create
more sophisticated apps. They also often shared their skills with the rest of the class.
Although the diverse range technical experience of the class made it hard to meet
each learners’ individual needs, one student saw this diversity as something valuable,
perhaps due to the sharing of skills between peers:
“I think the class was a mixture of people who had a lot of experience with apps
and others who had very little experience. It is certainly a good mixture of back-
grounds which is to be commended.” (female, 55-64)
Eectiveness of the development environment
When asked to rate the development environment and code examples, most students
agreed that it was easy to create apps using this approach, especially for changing
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content (g. 7.5). Modifying the structure of the app, such as creating new pages,
was felt to be harder and only ve out of seven agreed or strongly agreed it was easy.
Notably, a majority of participants did not agree that modifying the core functionality
of the app was easy. Given that most students lacked strong programming skills at
the start of the course, this was not unexpected. For example, one of the students felt
that understanding the code was challenging, and would have liked more time to learn
programming:
“The technical language is dicult and not easy to decipher. Once I saw the
pattern of the code it was easier to input my own. [...] I think the course should
be longer to give time to practice.” (female, 55-64)
However, another student felt that with adequate support, coding became easy: “I
nd coding easy once you are shown how to do it” (female, 35-44). Coupled with the
sample code and teaching support, the development environment was perceived as a
useful way of editing code:
Figure 7.5: Participants’ experience of using the Web App Editor (WAE).
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“The code examples provided were very useful, as was the input of the course
tutor who helped with steering the code in the direction of the functionality you
were looking to achieve. The editor helped with real time changes. ” (male, 25-34)
Although one student also used another editor, which he was already familiar with,
he agreed that the Web App Editor was easy to use, and the live preview particularly
so:
“I used my own text editor (Sublime Text 2) for most of the work I did during the
course. However, when I did use the online code editor it was simple and easy to
use, especially the live demo. ” (male, 24 and under)
In terms of improvements, one student suggested that integration with a revision
control system, such as GitHub, would be advantageous for storing and reviewing code
changes.:
“GitHub would help us to make the app more eectively, roll back changes, even
enable collaboration, but most importantly, introduce the user to a valuable tool
and resource for the future.” (female, 55-64)
This feature was subsequently added to the editor. I will now describe some of the
apps that the students created using the WAE during the courses.
Resulting apps
All students succeeded in creating apps, suggesting that the course and development
environment was eective for people new to app development. Figure 7.6 shows screen
captures from a selection of the diverse range of apps that were completed.
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Figure 7.6: Screenshot of some of the apps created by the students.
The most popular code template was for geolocative mapping. It was used by stu-
dents to create apps for exploring public woodlands, industrial heritage and commu-
nity learning resources (g. 7.6, bottom centre). Another template was used to create a
dictionary for translating yoga terms and postures from English to French and Sanskrit
(g. 7.6, left hand side). The same template was used to create a sports car gallery and
an app recommending play activities for parents with young children (not pictured).
One advanced student created a working physics simulation, intended for use in
teaching primary school students about collisions, forces, mass, velocity, restitution,
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friction, and gravity (g. 7.6, centre top). Finally, one student used another template to
develop an app for retrieving and displaying college students’ badges issued through
the Open Badges API
6
(g. 7.6, right). A badge is a graphical certicate of achieve-
ments, commonly used for gamication (Kapp, 2012, 89).
7.2.3 Views on future app development
Figure 7.7: Participants’ views on mobile app development.
Interestingly, all the respondents agreed that they were likely to work on apps
in the future (g. 7.7). For example, one of the students predicted that HTML5 app
development will grow in popularity once more people learn about this approach:
“Apps are the new web design. I think once it gets around that you can design
your own app more people will be interested. [—] I enjoyed working on my app
and will keep improving it. And maybe think of a new project” (female, 35-44).
Another student indicated that he had enjoyed the course, highlighting the value
6
www.openbadges.org
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of having the time to learn by trial and error, and that he wanted to continue to explore
jQuery Mobile in the future:
“Plenty of time to investigate the software and experiment with code during the
sessions, coupled with good one to one discussions with the tutor made for a very
interactive learning experience. The course programme also gave a good insight
into the development life cycle. I will certainly be investigating jQuery Mobile
further.” (male, 25-34)
A majority of students agreed that they learnt a lot from looking at the code ex-
amples. This is an important result because the source code of HTML5 web apps can
be easily readable (unlike native apps). Inspecting source code is a well-established
learning strategy employed by many web designers. In contrast, opinion was divided
about whether mobile apps would improve as a result of greater user contributions.
Some students were vocal in their support:
“I passionately agree that users ought to be involved (I am a user) and I also believe
that small scale community and voluntary sector groups should engage with new
technology and learn how it might help them.” (female, 55-64)
Others felt less sure about whether a single user’s requirements and contributions
would generalise to broader app audiences:
“Allowing contributions from users could be both positive and negative. The in-
clusion of some functionality by some users may not be useful for others.” (female,
35-43)
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7.3 Part 2 - Use in stroke app development
This second part of the chapter explores the use of the second version of the Web
App Editor (WAE) in the development of an app in stroke medicine. The project was
carried out by Helen Mamalaki, a Masters in Informatics student in collaboration her
supervisor and a consultant neurologist at a local hospital. She has consented to be
named in the thesis. I was invited by Helen’s supervisor to advise the project from the
outset and suggested that she might want to test the WAE since she was developing a
web app.
7.3.1 Methods and context
The aim of this part is not to analyse the stroke app, but rather to understand He-
len’s experience of using the WAE, and to explore her views about its role in medical
app development and collaboration. To achieve this, I interviewed Helen at the nal
stages of completing the stroke app development process. I used a semi-structured in-
terview (see appendix B.2) and analysed the ndings thematically. Helen summarised
her project in the following way:
"The purpose of the project was to create a web interface that elicit details of
stroke patients, such as medical history and symptoms regarding their last stroke
attack. [...] The information would be used to aid diagnosis and what treatment
direction the doctor is going to use."
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7.3.2 Helen’s background
To establish the context, it is important to briey outline Helen’s background. She has
an undergraduate degree in Computer Science and the six month stroke app project
formed the basis for her dissertation for her Masters in Cognitive Science degree. One
of the main reasons that she undertook the project was because she felt it could con-
tribute to improving patient care in a practical way:
“I wanted to combine computer science with a discipline that focuses on [...] hu-
man well-being. Cognitive science studies how computational models help un-
derstand human cognition. This project was going to be used in a medical envi-
ronment to improve [the care of stroke patients]. I liked the idea because it was
more practical as opposed to research-oriented. Developing something that could
be used; or if it doesn’t get used, it provides a prototype that could be improved
and [...] eventually used by real users.”
When initiating the project, she already had some experience of web design. In the
rst year of her undergraduate degree, she had used HTML5, CSS and a small amount
of Javascript (mainly jQuery) to create a simple website:
“We had to make a very simple website. It wasn’t for data input, so it had no
input forms or checkboxes. It was just a content display website on some of the
module material. [...] It was part of my rst year, so it wasn’t very technically
demanding. It was just HTML and CSS. I didn’t actually use Javascript, although
I used jQuery [Javascript library] code that I copied and pasted to make a funky
menu.”
During her undergraduate degree she had also created a language learning app
using Java and the Android SDK (Software Development Kit). She reected on her
past experience of developing using web and native Android technologies:
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“The Android SDK comes with a GUI [graphical user interface] that you can use
to insert buttons and text boxes. I don’t remember there being any layout issues.
But to be fair, we were designing it for a tiny mobile screen, so not many things
tted on the screen. Android doesn’t give you as much exibility, in terms of what
you can do [...] There’s huge exibility with HTML [...] the more exibility you
have, the more things can go wrong and the more things you have to specify.”
In contrast to creating the Android app, she found laying out the rst year website
using Cascading Style Sheets (CSS) frustrating:
“Using CSS to create the layout was really, really annoying. I think I eventually
managed to get it to do what I wanted it to do. [...] I don’t know if it is a limitation
of how I knew to use CSS, but I knew [...] that getting something to go exactly
where you want it to go on the screen – even though it may be simple – might be
annoying.”
As she learned more about web technologies and related tools, she felt the web
development experience was becoming less frustrating however:
“It is becoming less so as I get to know HTML5 more, especially the Chrome
Developer Tools. They’re really helpful. I never used them before. [...] I knew it
would be [...] a lot of minuscule changes and a lot of time spent on layout. [—]
Having done [web design] once before, it was better and easier this time around.”
The stroke app project was also the rst time she had used Javascript and libraries
such as jQuery and Knockout
7
for making web-based applications, an experience she
enjoyed:
“I did a little Javascript in rst year. That was the language used to teach pro-
gramming [...] I think javascript used in web programming is slightly dierent. I
mean jQuery has a slightly dierent syntax. This is the rst time I’ve used it for
web programming purposes. I liked it. I thought it was easy to use, and there’s a
lot of purpose built functions, for animations, for displaying content.”
7
Library for two-way data-binding based on the Model-View-Viewmodel pattern
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7.3.3 Experience of using the Web App Editor (WAE)
On the whole, Helen enjoyed using the WAE and commented extensively on its strengths.
“I remember that when you showed it to me, I was just trying to understand what
advantages it would have over the tools I was thinking of using. [—] I found the
editor very valuable to my project. There are some features which I don’t know
where else I would have found them.”
Helen used the editor to complete several tasks necessary to create the stroke symp-
tom reporter app. She also suggested several improvements which will be discussed at
the end. Figure 7.8 shows a screenshot of the stroke app being worked on in the WAE.
Two screenshots of Helen’s nal app are displayed in gures 7.9 through to 7.10.
Figure 7.8: How the Web App Editor was used to develop the stroke app by activating
the split-view mode, showing code and a live preview of the app. Screenshot used with
permission of author.
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Figure 7.9: Opening screen of an app for recording the medical history of patients with
stroke or transitory ischemic attack (TIA). Used with permission of author.
Figure 7.10: The app allows patients to visually indicate where on the body they expe-
rience symptoms. Screenshot used with permission of author.
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Validating CSS and HTML syntax
As was mentioned previously, the WAE is based on the ACE editor. It supports static
code analysis and provides errors or warnings if programming language or scripting
rules are violated. These are notied to the users in the margin of the code inside the
editor. Helen felt that this feature signicantly helped her to develop her app because
it was easier to spot errors.
“I liked the highlighting [in the editor]. So a lot of the time I would copy and paste
from Notepad into your editor to check the syntax because yours highlights the
HTML syntax errors, because Notepad doesn’t. [...] Which was so helpful, as
it would take me ages to nd which closing tag I had missed out or deleted by
accident. Usually I deleted a <div> tag by accident or missed an angle bracket,
and it would screw up everything. As it is multipage app [a single, large le with
thousands of lines] it was really hard to debug, and I don’t know what I would
have done without the syntax checking in your editor.”
Auto-indenting and code folding
Another feature of Ace is automatic parsing of code that enables the visibility code
fragments to be selectively hidden from view (code folding). This makes it easier to
concentrate attention to specic parts of the code, and to identify if the code is in-
correctly parsed due to syntax errors. I implemented a feature (“beautify”) that would
automatically indent code to make it more legible:
“I like the ’beautify’ [feature] as well - that was really nice. Beautify basically in-
dents the code so that each opening and closing tag is aligned, so it makes it much
easier to [spot syntax errors]. Apart from the obvious, that it presents the code
much more nicely (hence beautify) it makes it much easier to debug. It creates
like a pyramid structure of opening and closing tags. So it’s more readable.”
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Saving changes using version control
Version control is a systematic way of managing changes to code using a dedicated
software tool, such as Subversion, Mercurial or Git. Git is now widely used in software
projects, not the least due to its popularisation by the website GitHub.com which oer
additional collaboration features.
The version of the WAE that Helen used integrated with GitHub.com to allow code
changes to be saved (called “commit” in Git) and retrieved easily, something that can
be daunting to beginners as it involves typing commands, e.g:
git commit -am ’Test commit’; git push origin master.
Helen praised the simplicity of saving to Github with the WAE:
“One of the things that immediately became clear was that it was really easy to
commit things. Especially as I had problems with committing using the GitHub
Desktop application [...] I had gured out how to use Git in the terminal [by]
entering lots of commands. So, it was so easy to commit – literally pushing a
button!”
With version control, it is also easy to track changes to code over time (gure 7.11).
GitHub also facilitates code discussions and an example is provided in gure 7.12 where
Helen and I shared ideas to work out the best way to capture user’s reaction times on
a touchscreen device.
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Figure 7.11: Example of Github’s history of changes from Helen’s project.
Figure 7.12: Discussing changes to the code in the stroke app on GitHub. Changes to
the code are colour-coded (new, inserted code is green and old, removed code is red).
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Instant preview on mobile devices
Reducing the time from making a code change to seeing that change on the mobile de-
vice is critical for productive mobile app developers. The WAE has a server component
that hosts applications as they are being worked on. A QR code with the web address
of the application allowed Helen to quickly preview her work on a mobile device, or
share a preview of the application with collaborators:
“I also like how it hosted my website. That was awesome (laughing). I like the
quick [QR] code thing. That was really cool. [...] It was impressive how it almost
transfers [the app] onto your phone, kind of like Chromecast, but not really. You
can automatically load the web page on any device from your programming en-
vironment. So you can have your testing device separately from your computer
where you’re programming using the editor.”
7.3.4 Improvements
The WAE is a work in progress and there are many areas of improvement. Helen’s
feedback helped me realise just how important customisation is for users. Enabling
settings such as editor font size, tab stops, syntax highlighting, colour theme and layout
to be individually customised is critical to provide a good code editing experience.
However, the settings dialogue was slightly dicult to nd in the user interface:
“One thing that drew me back to notepad was something simple [...] I wish you
could zoom in, increase the font size of the code. Whenever I open the code in
Notepad, it would be so much more crisper and clearer because the font-size is
much bigger. [Later, on discovering font-size setting] I really want to increase the
font size right now. Oh, it looks more like Notepad now. [Changes colour themes]
I like this one. I really like this feature. It does exactly what I want it to do”.
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Similarly, Helen pointed out that other areas of the user interface could be improved
and oered helpful suggests for how to re-organise it.
“... they’re very nice icons. But there’s a lot of learning involved. You have to
gure out what they all are. I think there are quick tips, when you hover over the
button it tells you want it does. That’s good. But a lot of the time it looks like a
bunch of buttons and I have no ideas what they each do. I think it would be good
to have the most commonly used features as buttons at the top. And then have
submenus, like they do in the old Windows, where they had them under menus.”
7.3.5 Collaboration in medical apps
When I asked her about the role of collaboration in medical app projects, she explained
that this is desirable and that using web technologies could enable patients to give
feedback during software development and implementation processes:
“I think it would be a good thing to encourage collaboration. It would be great
if users could give input. Because they could test the system before it is released
[...] Since [the stroke app] is online, the NHS could just refer its patients to a
demo or prototype website and ask: ’What’s your feedback on this, we’re plan-
ning to introduce this in the NHS and would love your feedback’. That’s another
advantages of having a health-related website available as open source. You have
a huge population of testers available to you on the Internet.”
She also felt that developing medical software as open source was a good idea, but
dicult to realise:
“I think it is a good idea [to make medical software available as open source]. But
I think there are a lot of barriers not related to the actual code [...] I think a lot
of the time the developer moves on. So that’s a problem, not related to the actual
product. It needs to be someone who stays on to maintain, debug and oversee.”
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When I asked her about whether she was going to make her code available under an
open source license, she was positive about the prospect of others potentially re-using
or improving her code:
“I haven’t really thought about it. I don’t expect anyone want to use my code
as a template. But if they do, that’s ne. I’ll keep it public, so I guess I made
that decision a while ago [...] It would be great if someone after me could come
and improve the code, even if they point out things that I could have made better
or debug certain things. That would be really useful and helpful for me to im-
prove. So if I had to do this again from the beginning, I would know what to do
dierently.”
In fact, she later recalls that someone had asked her about reusing part of her code
(shown in g. 7.13):
“When I was presenting my project [...] I did get one supervisor saying that they
were unable to access the code for the reaction time and pairs game for the UK
Biobank, and they really wanted it [...] She was kind of "Would I be able to use
your implementation?" because the UK Biobank didn’t make its implementation
open to the public. So I thought that was really interesting, I’d be happy to do
that. [—] It’s always attering if someone wants to use your code work [—] as
long as they refer to where they got the code from.”
However, Helen was hesitant about allowing commercial reuse or getting into a
situation where people requested changes or code maintenance without appropriate
remuneration:
“It’s dierent if someone wants to collaborate and contribute, versus someone
who just want a nished product and who just want to use it. Because then that
puts a lot of responsibility on me. I’d have to be there to maintain, debug it and
alter it for their needs [...] Whereas if somebody wanted to do that for themselves,
then obviously I wouldn’t have a problem with that. [—] It depends on how it was
used [...] If it’s used in an NHS environment, I’m more happy. But if [they] are
proting from it, maybe if a private clinic wanted to use it, then I would want
them to pay.”
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Figure 7.13: The stroke app measures cognitive function through built-in tasks. On
this screen patients play a game of pairs, a test of short-term memory part of the UK
BioBank test suite. Screenshot used with permission of author.
7.4 Discussion
Few app developers engage with users and current app development processes are
often closed to users who are typically limited to review or rate apps (VisionMobile,
2013; Pagano and Walid, 2009). Similarly, when interviewing eleven medical device
manufacturers Money et al. (2011) found that many were hesitant to collaborate with
users during the design process. They identify several reasons for this, including:
• The conation of the "customer" and the "user" (who, of course, typically have
dierent needs, priorities and sway) and the decision to only engage with the
former;
• The belief that less senior healthcare practitioners and patients are unable to pro-
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vide valuable design input, and that engaging with them is a waste of resources;
• The shying away from research involving patients or changes to clinical care
due to the inexible and demanding nature of ethical regulations.
• A lack of appropriate collaborative design methods.
While it is important to acknowledge the reality that engaging with users can be
dicult, and that they hold less sway than powerful gatekeepers or those directly fund-
ing a product, users can be an important source of domain knowledge and innovation.
Who the users are, and their precise contributions, varies depending on the domain.
For example, patients with rare diseases have developed new therapies for themselves
(Oliveira et al., 2015) and healthcare practitioners have discovering new uses of exist-
ing drugs (DeMonaco et al., 2006).
In this study, I explore how one could encourage users of mobile apps to become
more active contributors by making the collaborative app design process easier. Al-
though eorts to simplify the app development process has come some way, the bar-
riers to get started with native app development are still relatively high. This chapter
has presented and evaluated a system designed to lower the barriers for beginners to
create and contribute to web apps.
Ten students with little previous experience used the Web App Editor during two 12
week app development courses. During the two courses, the students created a diverse
range of apps. Their feedback suggested that the editor was easy to use and that cre-
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ating apps from code templates worked well. The online development environment
enabled in-browser development and debugging of apps. It also did not require any
special software, access to specic hardware or emulators. The development process
was accelerated through the use of code examples and a supportive learning environ-
ment.
Following student requests, integration with the GitHub revision control system
was added to the development environment. This allows code changes to be perma-
nently committed, reviewed, branched, rolled back and merged in a controlled fashion.
This approach is used by many open source projects and is useful for coordinating con-
tributions from multiple authors.
7.4.1 Future work and limitations
The editor remains a work in progress and there are several features that could improve
it further. For example, integrating with the Phonegap Build service would allow code
to be retrieved directly from GitHub and make it easy to create native packages suitable
for publishing on iOS, Android, Blackberry and other mobile operating systems. This
would remove a manual step and make it easier to compile HTML5 app projects into
native packages that can be distributed through the various app stores.
However, this features was not made available before the course nished, and was
therefore not evaluated. Moreover, it was challenging to evaluate the quality of the
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development environment in isolation from other aspects related to the delivery of the
course, such as teaching approach and student backgrounds.
Furthermore, as the study was carried out at the end of the course, this may bias
the results towards students who are more condent learners. I hope to be able to
continue to develop the system further and test it with a larger user group under more
rigorous conditions. Nonetheless, the development process described in this chapter
could lend itself well to solicit app contributions from users. However, more research
is required to investigation how this process can be made as simple and intuitive as
possible for people who are new to app development.
7.5 Conclusion
There are many dierent stakeholders in medical app and medical device projects who
have dierent needs, priorities and inuence on the nal outcome of the design pro-
cess. Of course, those who use a mobile app or medical device are often dierent from
those who commissioned, developed the specication, payed for it or built it.
Prior work have shown that users have limited means of becoming active contrib-
utors to the app and medical device design processes. While the value of the views,
needs and priorities of the ’user’ remains contentious among product developers, prior
work in user-centered design and user-led innovation suggests that users may oer
valuable input and can have a critical role to play in ensuring the outputs of the design
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process meets the needs of the end users.
In this chapter, I presented and evaluate a new collaborative tool designed to sim-
plify the collaborative app design process. The Web App Editor was well received by
students in two introductory app development courses, and by a postgraduate student
who used it to create an app intended to help patients communicate stroke symptoms.
Hence, the WAE enabled novice app developers to learn about how web apps work and
how they can be created and modied. It also enabled collaboration between students,
who were encouraged to share their skills in the classroom.
Among the most important features was the live preview facility which enabled
students to see and share work in progress with peers immediately. The use of ver-
sion control enabled collaboration at the level of code and oered a tracked history
of changes. However, feedback from the students suggested that the usability of the
editor could be improved. This includes making the user interface more intuitive, such
as highlighting the preferences.
In conclusion, with appropriate tools and support, those who are new to app de-
velopment can pick up the skills to collaborate on mobile apps. This argument extends
to healthcare practitioners who should be encouraged to acquire the skills to critically
analyse and contribute to the mobile medical app that they increasingly rely on. More
open app development environments and easy to use development tools can lower the
barriers for users to participate in app development. However, it is important to recog-
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nise the time, eort and commitment needed to develop programming skills required
to make signicant contributions and put strategies in place to support this.
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Chapter 8:
Study 4: Usability Evaluation of the
SBC App
This chapter returns to the Special Blood Components app and discusses the us-
ability study of the second revision (v.0.2) by 54 nal year medical students. After
outlining the background and evaluation methods, the students’ ratings and feedback
are discussed. The chapter concludes with a list of improvements and lessons learned,
including reections on the usefulness of remote evaluations.
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8.1 Introduction
Following my presentation of the Special Blood Components (SBC) app at the British
Blood Transfusion Society conference, I was invited by a course organiser at a UK
university to evaluate the SBC app during a training day for nal year medical students.
This was an excellent opportunity to collect feedback from an important user group.
I reasoned that the students were likely to have experience of using mobile technology
and would be aware of medical apps, but likely lack experience of prescribing or ad-
ministering blood transfusions. Rather than to focus on students’ knowledge of blood
transfusion, the purpose of this opportunistic evaluation was to solicit feedback and
measure the usability of the app.
Hence, previous experience of blood transfusion or special blood components was
not a criteria when recruiting participants. Furthermore, I was interested in exploring
the feasibility of evaluating the app remotely using an online feedback system incor-
porating web analytics. Thus, the purpose of this study was to evaluate the usability
and content of the second revision of the Special Blood Components (SBC) app, and to
identify further improvements to it.
8.2 Methods
This was an online evaluation study where the students accessed and evaluated the
SBC app during two computer-based learning sessions on university premises.
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The rst session ran in the morning and the second in the afternoon. Students were
split approximately equally between the morning and afternoon sessions. During both
sessions, the training organisers circulated the URL of the app, instructing the students
to explore it and then leave feedback using an online questionnaire.
Figure 8.1: Sample page of the SBC v.0.2 app, showing in-app evaluation reminders
(top and bottom) presented to respondents.
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To improve the completion rate, a button linking to the questionnaire was displayed
at the bottom of every page in the app. Additionally, after interacting with the app for
ve minutes, the app popped up a message reminding users to complete the question-
naire (see g. 8.1). Users could dismiss this message completely, ask to be reminded
later or click a button to open the questionnaire. None of the authors or contributors
to the app were present during the training day. Nor were they acquainted with any
of the participants, reducing risk of biasing the responses.
8.2.1 Online questionnaire
The evaluation questionnaire had four parts. The rst part asked students to rate their
overall impression of using the app and identify any problems. The second part of the
questionnaire encouraged students to rate and comment on the sections of the app:
• The “information” section explained mistakes involving special blood compo-
nents.
• The “indications” section listed the circumstances when special blood compo-
nents are required according to national guidelines in the UK.
• The “checklist” section provided users with decision support through a question-
based algorithm.
• The “quiz” section allowed users to test their knowledge of the indications by
answering questions.
The third part of the questionnaire consisted of the System Usability Scale (SUS)
(Brooke, 1996). This is a validated ten-item inventory that measures how easy a system
is to use on a scale of 0-100. The nal part of the questionnaire aimed to capture
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students’ experience of blood transfusion and demographic information such as age
and smartphone experience. A copy of the questionnaire is provided in appendix C.3.
8.2.2 Remote monitoring
During the evaluation the use of the app was monitored. Data about which pages of
the app were visited, for how long and using what computing device (operating sys-
tem, screen resolution, browser) was collected and analysed using Google Analytics
1
.
The data was analysed in conjunction with the questionnaire to better understand the
strengths and weaknesses of the user experience.
The analytics service time-stamped important user interactions within the app,
such as page navigation. By comparing the time between the rst and last interaction,
I estimated visit duration for all users. Google Analytics also provided an approximate
geographical location (country and city level) based on the IP address of the user that
was used to verify that only user sessions originating from the medical school were
included in the analysis.
When a web browser requests the app for the rst time Google Analytics assigns
users a session identier (a unique text string). This identier is stored in as a browser
cookie and was used to identify whether a visitor is a new user or a returning one, and
to associate page events with that user. The cookie is insucient to identify a person
by name, unless it is correlated with other information, such as personal information
1
https://analytics.google.com
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voluntarily divulged by the respondent. Participants were provided with information
that explained what data was recorded and why (see appendix C.2).
8.3 Results and discussion
Approximately 270 nal year medical students attended the training day. Google Ana-
lytics recorded 186 unique visits to the app originating from the city where the training
was taking place. This suggests close to 70% (186/270) of the attending nal year stu-
dents opened the app. Of these, 65 students provided evaluation feedback. Only 54
responses were suciently completed for analysis, yielding an eective response rate
of about 29%, based on unique visits (54/186). For the system usability scale (SUS)
inventory, only 40 responses could be included in the analysis due to incomplete an-
swers.
8.3.1 Respondent demographics
All respondents were aged 20-29, except for one person who was in the 30-39 age
group. With the exception of one foundation year 1 (FY1) trainee, the respondents
were all nal year medical students. The FY1 was included in the analysis.
8.3. RESULTS AND DISCUSSION 225
Figure 8.2: Smartphone use among nal year medical students. Base: 42 respondents
who answered the question “Do you use a smartphone?”
When asked if they use a smartphone, 85% (39/42) indicated that they use a smart-
phone both at home and at work (g 8.2). This is in line with other surveys of smart-
phone adoption among medical students (Payne et al., 2012). However, only six par-
ticipants accessed the app on their smartphones according to Google Analytics. The
others accessed the app on desktop computers running Microsoft Windows with the
Google Chrome (version 31) or Microsoft Internet Explorer (v.10) web browsers.
8.3.2 Blood transfusion experience
The large majority did not regularly carry out responsibilities related to blood trans-
fusions. Only 12% (5/42) indicated that they were involved in blood transfusions on a
monthly or more frequent basis. Fewer still, 7% (3/42), reported working with patients
requiring irradiated or CMV-negative blood components.
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When asked about irradiated and CMV-negative blood components, 40% (17/43)
felt they were not condent about the indications for special blood components. Only
a quarter of respondents (11/43) felt that the guidance for special components was
easy to use, and 70% (30/43) agreed that having an app for special components would
be useful.
8.3.3 App interaction times
Across all 186 unique visits, the app was accessed for an average of duration of eight
minutes. Among the 54 respondents to the questionnaire, the average duration was just
over 10 minutes and the median duration was close to eight minutes (range: 1m 20s to
38m; s.d: 9m). Figure 8.3 summarises their interaction times for the 54 respondents.
Figure 8.3: Frequency distribution of the 54 medical students’ interaction times using
exponential bins (rounded to nearest minute). Multiple sessions belonging to the same
user have been collapsed.
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8.3.4 App ratings
The app generated a mixed response. The comments ranged from positive (“The app
was quite useful.”) to negative (“Overall [I am] very disappointed in this app and [I]
do not see it being used.”). When asked to indicate their overall reaction to the app
(g. 8.4), over 80% (44/54) agreed or strongly agreed that they could see a use for the
app and 62% (32/54) would recommend it to others. Furthermore, just over half of the
respondents (27/52) felt that their experience of using the app had been enjoyable and
nearly a quarter (12/52) reported the reverse. Close to half the students (25/54) believed
that they were likely to use the app in the future, but 35% (19/54) thought it unlikely.
Figure 8.4: Overall ratings for the SBC app (v.0.2).
This polarised response is likely due in part to factors extrinsic to the design of the
app. Several respondents cited unfamiliarity with the topic and diculty of taking in
all the information in the app. For example:
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“This was so detailed compared to any teaching we have had before as medical
students, so to try and remember the exact type of irradiation/CMV for each in-
dication seemed far too complex. Well-designed and clear though.”
As respondents were nal year medical students with little knowledge or experi-
ence of special blood components, some respondents felt that the app was beyond the
scope of their current role:
“The app is useful, however, the information provided seems more useful for spe-
cialist registrar level as opposed to medical student level.”
“I feel that this app probably aims above the level of a medical student.”
Some local hospital guidelines reduce the information to a simple list of indications
that t on one page. However, the app aims to reect the national guidelines, which
are relatively complex and lengthy. There is a trade o between a simple app that
demands minimal attention and one that aims to reect the national guidelines more
fully. It is encouraging that the app was rated very favourably by three respondents
who reported caring for patients with special requirements on a daily or weekly basis.
8.3.5 The information section
Judging by the Google Analytics data, most respondents appeared to go through the
app systematically, starting with section one which covers background information.
The ratings (g. 8.5) show that the information section was well-received. 90% (45/50)
of respondents felt it was worth reading and 75% (38/51) agreed that it was succinct
and easy to read.
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Figure 8.5: Ratings for the “information” section of the app. Answers to the question
“How would you describe the ’information’ section?”.
That said, several respondents provided comments related to the amount of con-
tent. Some, who had clearly given the contents of the app some careful thought, asked
for more details, such as:
“Why do you have to irradiate blood from rst or second degree relatives?”
“[The app] needs to explain the risks rather than just say how to avoid them.”
“There wasn’t a good introduction explaining the need for CMV-negative and
irradiated blood products. If I understood the mechanism behind this I would be
more likely to be able to give an educated guess for what is required, rather than
[relying on] ’pattern recognition’.”
The latter comments highlights the rationale for introducing the information sec-
tion: to go beyond a simple list of indications to something that could provide users
with a deeper understanding of the subject. However, to provide adequate answers
to the questions raised above would require an extended information section. At the
same time, many respondents requested even more summarised information:
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“The app had a lot of information which wasn’t very easily accessible.” “There are
a lot of big chunks to read which are o putting.” “There was too much informa-
tion to pull out the main points quickly, which is what an app like this should be
for.” “I found there was quite a lot on information of the one page, which made it
dicult to get through and focus on each section.”
In domains with high levels of complexity, such as healthcare processes, bad design
can make users feel things are more complicated then they need to be. But even the
best design cannot remove the underlying complexity (c.f Norman, 2011). Hence, it
is important to remember that the app cannot be a replacement for users taking the
necessary time to learn about the subject in sucient depth. Some suggestions for how
the content might be structured dierently to make it easier to take in were oered by
participants:
“Maybe have summaries of which conditions require certain types of transfu-
sions.”
“The information could also have been grouped into CMV-negative and irradi-
ated blood and listed which conditions require which rather than the other way
around.”
Other options might be to have a frequently asked questions and links to further
online learning resources. For example, the Blood Bank Guy website has a good video
explanation of the role of shared HLA haplotypes between close family members in
developing Graft versus Host Decease (Chan, no year).
Additionally, indicating the time requirement that the app places upon the user
could perhaps manage their expectations. For example, if it is made clear upfront that
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it will take 10 minutes to get through the background information section, it may be
more acceptable to users and make it easier for them to manage their time.
8.3.6 The indications section
70% of respondents felt that it was easy and quick to look up the indications for irradi-
ated and CMV-negative components (Fig. 8.6). Even participants who were otherwise
quite negative about the app felt that the indications section was valuable:
“[The indications section is the] only useful section and one that I would use again
on the ward if I was unsure.”
“The indications section should be published on it’s own to be accessed by hospital
sta and medical students as it was very useful. Bin the rest.”
Only 6% (3/50) of respondents felt that the indications were unclear. This is positive
because presenting indications in an unambiguous way that is true to the original
national guidelines was an important design goal.
Figure 8.6: Ratings for the “indications” section of the app. Answers to the question
“How would you describe the ’indications’ section?”.
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Moreover, it is necessary that medical apps cite their sources so that users can
verify the claims made in the apps by consulting the original source. Adhering to this
principle can ensure that apps build on current medical knowledge.
None of the respondents felt that the app failed to reect national guidelines or was
poorly referenced. However, one participant felt that the way the app cited its sources
could be toned down to make the main text easier to focus on:
“I don’t know if references are the most important thing about an app like this.
The text makes everything seem too busy.”
Another criticism was the way that the indications were laid out, and the resulting
back and forward navigation required to explore details of multiple indications:
“The information is relevant and useful and very clear. However, I think the for-
mat of going back and forth is time-consuming.”
8.3.7 The checklist section
The checklist section is essentially an algorithm which aims to identify what, if any,
indications for special blood components are likely to be relevant in a particular sce-
nario. This is achieved by asking two simple questions and providing a restricted set
of answers: what blood component is to be transfused and who will receive it?
Although two thirds (33/50) agreed it was logically structured, and almost as many
(32/50) felt it was quick and easy to use (Fig. 8.7), several students felt they struggled
to understand the purpose of the checklist:
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“I did not understand what I was meant to do here and what the function of this
section was.”
“Section three is dubious and unclear. I thought that was what a checklist is:
something you can check if you are unsure.”
“I wasn’t sure how the checklist section was meant to work. It said to answer
a question, but I wasn’t sure what the question was supposed to be. It also kept
sending me back to the indications page, which was annoying when I just wanted
to get back to the checklist.”
Figure 8.7: Ratings for the “checklist” section of the app. Answers to the question “How
would you describe the ’checklist’ section?”.
As with the information section above, it appeared that some respondents felt over-
loaded with information and that this got in the way of using the checklist eectively:
“Again I found there was a lot on information on the one page, a lot of the head-
ings were similarly named and I found it a bit confusing to work through. The
information contained was good, but it was exhaustive and I felt I got a bit lost
while I worked my way down the checklist.”
“It is logically laid out, but the list is a bit too clunky. Some of the information
takes a bit of time to nd.”
The challenges of designing a checklist are quite similar to those related to the
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information section. It has to be quick and easy to use, yet be comprehensive to gen-
erate a result which is reliable, or at the very least unlikely to cause harm. In relation
to this point, one of the students made a perceptive comment of the pitfalls of relying
on “fail-safe” cognitive aids in complex cases:
“[There is] no such thing as fail safe, complex issues will always throw a spanner
in the works.”
8.3.8 The quiz section
Most respondents were positively inclined towards the quiz, with 77% (36/47) agreeing
that it was an useful way of learning and nearly as many (35/47) felt that the questions
were well-phrased (g. 8.8).
Figure 8.8: Ratings for the “quiz” section of the app. Answers to the question “How
would you describe the ’quiz’ section?”.
8.3. RESULTS AND DISCUSSION 235
However, many students provided feedback suggesting how the section could be
improved and expanded. Most notably by providing a total score to allow users to
check their performance:
“Quiz loops after completion. Consider showing results of questions, allow for
identication of areas of ignorance.”
“It would be helpful if you could get a score on the quiz part of the app.”
“I would have liked a summary of my answers and overall score for the quiz at
the end.”
Others requested more detailed feedback, explaining why each answer is correct
or incorrect:
“Quiz could be more useful with reasons why answers are right or wrong. Also a
summary page to show all questions answered would be useful.”
“It could elaborate slightly more on reasons for certain answers.”
“More information in the answers section as to why each answer was correct or
incorrect would be helpful.”
Several students also commented that the phrasing of some of the questions could
be improved:
“Some questions were repeats of the same theme with dierent parameters, which
didn’t help interest.”
“Two questions in the quiz were duplicated.”
“I didn’t think the phrase ’how should they be transfused’ was very clear.”
8.3.9 Interaction design
Comments provided by participants about the app’s user interface design and layout
were mixed:
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“Useful app structure, fast and easy to use UI [user interface]”
“The app had a very complicated layout and was dicult to navigate eectively.”
Many respondents felt that the navigation was cumbersome, with six respondents
feeling that there was too much back and forward navigation. It is important to re-
member that students mainly accessed the app, which is optimised for smartphone
use, through desktop computers. These typically have large screens, which are bet-
ter suited to larger sections of text that a user can skim, compared to the smaller a
smartphone or tablet screens, where multiple pages might be more suitable.
Hence, device form factor may account partly for these comments. That said, it is
possible to optimise common navigational paths and eliminate some steps. A couple
of comments suggested alternative layouts that might improve usability:
“I would recommend perhaps dragging options into one of the 5 categories (since
there are always the same options), or simply going through each one, so clicking
next from the rst one takes you onto the second one.”
“Might be better to use expanding menus rather than a new page since it can be
confusing to go back and forth. Or perhaps making a table to further clear things
up?”
There were also a couple of interaction niggles identied by the students, including:
“...when you go back, it automatically goes back to the top of the page, so you
have to scroll down to where you were again which is a bit annoying.”




The system usability scale (SUS), based on 40 completed submissions, yielded a score
of 63 on a scale of zero to a hundred. This is not a simple percentage score, but should
be interpreted as a score that has to be “graded on a curve”, as commonly done in
university marking. Thus, average SUS scores are somewhere around 68-70, the failure
threshold is around 50 and excellent scores are in the 80s and 90s (Sauro, 2011; Bangor
et al., 2008, p. 592).
The app scored below average, but well above the failure or unacceptable threshold.
In short, the SUS rating, together with the other ratings and feedback, suggests that
there is room for usability improvement.
8.4 Conclusion
This study has provided valuable usability evaluation data from potential users. The
students identied a number of shortcomings in the design of the SBC app that required
additional work to address. A summary of the areas of improvements is provided in
table 8.1.
Despite these weaknesses, many of which were addressed in the subsequent ver-
sion, the app received an acceptable score on the system usability scale. Additionally,
the use of a remote evaluation survey exceeded expectations as the collected data was
quite rich and insightful.
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The exibility of evaluating medical apps online opens up opportunities to more
easily integrate formative evaluation into the app development process. However, an
important limitation in this study was that most of the students lacked experience of
blood transfusions
Furthermore, it was an open-ended evaluation which took place without a strong
task context. It is possible that respondents with more experience, and who would have
been given explicit patient scenarios to consider, would have evaluated the app more
critically. Thus, in the next and nal study, more experienced healthcare practitioners
were invited to evaluate the SBC app using patient scenarios.
Table 8.1: Summary of areas of improvement identied by the students.
Content
Make the content more concise and include addi-
tional learning materials, including more informa-
tion on the rationale for special blood components.
Quiz
The quiz was a valued feature that many students re-
quested to be expanded with more detailed scoring
and feedback.
Task eciency
Students felt that there were too many navigational
events required to access the information. It is pos-
sible to reduce some of these. For example, the in-
dications table could be converted into an accordion
menu that expands and contracts information with-
out triggering a page refresh.
Usability
The strong highlighting of references got in the way
of reading the information. Referencing colour style
should be made more subtle. Excessive scrolling and
vertical jumping on some pages requires xing. The
checklist section was dicult to understand and use
for many respondents.
Chapter 9:
Study 5: A Randomised Controlled
Pilot of the SBC App
This chapter presents a web-based randomised controlled pilot study of the re-
vised Special Blood Components (SBC) app with healthcare practitioners. The chapter
is structured in line with the main principles of the CONSORT guidelines for reporting
randomised controlled clinical trials (Schulz et al., 2010) as adapted to eHealth interven-
tions (Eysenbach et al., 2011). It begins by describing the features of the revised Special
Blood Components (SBC) App, methodological considerations, research questions and
methods. This is followed by the presentation of the main results, the discussion and
the conclusion.
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9.1 Introduction
As mentioned in previous chapters, the impacts of healthcare technology cannot be
taken as “given” and require systematic empirical research. Yet, few eHealth interven-
tions and medical apps for healthcare practitioners have been rigorously evaluated.
This study examines the second major revision of the SBC app (v.0.2 November
2014) which featured a re-designed graphical user interface, expanded learning mate-
rials, global search and faster access to the clinical indications for special blood com-
ponents (see screenshot in gure 9.1).
Figure 9.1: Main screen of the second revision of the SBC app, rendered on a wide
screen display in landscape orientation.
Furthermore, the revised app followed better coding and design principles, includ-
ing responsive design and graceful degradation. That is to say, dierent screen reso-
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lutions were better supported through the use of CSS media queries, ensuring an im-
proved user experience on desktop, tablet and smartphone devices. Greater emphasis
on the educational aspect of the app, which was highlighted in the usability evaluation
with the nal year medical students (reported in the previous chapter), resulted in an
expanded learning section.
Additionally, the “checklist” page, enabling relevant clinical indications to be iden-
tied by answering two questions, was excluded because participants in the previous
study found it unintuitive. Similarly, the built-in “quiz” was temporarily removed be-
cause its questions were almost identical to those that would be put to participants as
part of the study’s knowledge test, and could thus cause confusion or an unfair ad-
vantage. The aim of the SBC app remained the same as before: to promote the correct
use of irradiated and Cytomegalovirus (CMV) negative blood components by provid-
ing practitioners with quick and easy access to the clinical indications and learning
materials. With this aim in mind, possible research designs were considered.
9.1.1 Methodological considerations
A common criticisms leveled at evaluations of eHealth initiatives is their failure to
assess clinically meaningful outcomes. Hence, the “gold standard” for demonstrating
the eectiveness of the SBC app was carefully considered. One such measure, for ex-
ample, is the number of patients with special requirements who incorrectly received
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non-irradiated or CMV-random blood before and after introducing the app to practi-
tioners in a ward.
Unfortunately, training practitioners and auditing patients with special transfusion
requirements was beyond the scope and resource constraints of the project. Given the
stringent ethical regulations that govern who can retrieve and analyse patient data,
this research design would require recruiting a member of NHS sta to analyse the
data, which was not possible.
Furthermore, it would still be challenging to attribute changes in clinician be-
haviour and rates of mistakes to the design of the app, and rule out the eect of existing
training and other sources of uncontrolled variation. For example, mistakes involving
blood transfusion often have multiple causes and involve human factors explanations,
such as distractions in the workplace.
For these reasons, I decided to abandon direct clinical outcomes and attempt to in-
stead evaluate the impact of the SBC app on practitioner knowledge. As an educational
aid that complements existing transfusion training, the SBC app should be an easy to
use intervention that enhances understanding of the importance and rationale for us-
ing irradiated and CMV-negative blood components with healthcare practitioners.
Although e-learning is an established part of many medical education programs,
the eectiveness of Internet-based learning interventions in continuing medical ed-
ucation has rarely been explored. For instance, Curran and Fleet (2005) reviewed 86
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studies published before December 2003 that pertained to Internet-mediated continu-
ing medical education for doctors. Only 31 studies provided some level of evaluation
and the other 55 studies were descriptive in nature. Of the 31 studies, most assessed
learner satisfaction and about half assessed learning outcomes (knowledge). Only two
studies assessed whether the intervention lead to changes in clinical practice. None
of the studies assessed the eectiveness of the training interventions on actual patient
and healthcare outcomes measures.
There are many methods for assessing medical knowledge, each with their strengths
and weaknesses (Cox and Irby, 2007). The concept of “competence” is frequently used
as a measure of a person’s suitability to carry out medical procedures, and includes not
just basic knowledge, but also other dimensions such as observed practical skills, pa-
tient care, professionalism, reection and self-awareness (Cox and Irby, 2007). These
latter aspects are more dicult to gauge.
Adapting Donald Kirkpatrick’s inuencial “four levels” model for training evalu-
ation (Kirkpatrick and Kirkpatrick, 1994), Curran and Fleet (2005, 563) suggest that
web-based medical education interventions can be assessed using the following levels:
learner satisfaction, learner outcomes (knowledge), performance improvement (be-
haviour) and patient/health outcomes (results). Bates (2004) oers a critique of Kirk-
patrick’s four levels model, arguing that it lacks supporting evidence for the causal
relationships between the four levels of the model. Furthermore, they argue that the
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model ignores other possible evaluation criteria and contextual factors that inuence
the impact of training programs. Despite these criticism, the model provides a useful
way of thinking about some of the possible dimensions of an educational intervention.
9.2 Methods
Having previously rened the SBC app according to mostly qualitative feedback, the
purpose of this study was to quantitatively assess the two rst levels of Kirkpatrick’s
evaluation model: acceptability and impact on practitioner knowledge.
The study assessed these aspects using a pre-post parallel groups research design
involving doctors, nurses and biomedical scientists who had completed the Safe Trans-
fusion Practice module of the Learn Blood Transfusion in the previous twelve months.
The evaluation followed a pragmatic web-based parallel groups randomised controlled
study design, summarised in gure 9.2.
Participants were allocated to the SBC app or guidelines using stratied randomisa-
tion to balance the eect of professional experience. Knowledge was measured through
two eight item multiple-choice tests, completed before and after the SBC app or guide-
lines was made available to participants. After completing the baseline test, partici-
pants could make use of the allocated intervention, which was displayed adjacent to
the remaining questions. Ratings of the app and guidelines were captured using ve
point likert scales measuring the ease of nding information, enjoyment, likelihood
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to use again and to recommend to others. A copy of the questions are provided in
appendix D.5.
Figure 9.2: Study design.
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9.2.1 Selection of control treatment
Local hospital guidelines that contain a list of the clinical indications were selected
as control treatment because they represent the current practice in the hospitals. The
guidelines were converted from a Microsoft Word document to a web page that was
easy to search, supported by current web browsers and could be embedded in the
study’s web-based interface.
9.2.2 Outcome measures and hypothesis
This study assessed acceptability and ecacy on practitioner knowledge. The follow-
ing hypotheses were tested:
H1: There is a signicant dierence in the ecacy of the SBC app and
existing hospital guidelines on participants’ knowledge of the correct use
of irradiated and CMV-negative blood components. (primary outcome)
H2: There is a signicant dierence in the acceptability of the SBC app
and existing hospital guidelines. (secondary outcome)
Ecacy was dened as the change (learning gain) in practitioners’ knowledge of
irradiated and CMV-negative blood components as measured through multiple-choice
tests administered before and after using the app or guidelines (pre-post-gain). The
tests were composed from two sets of eight questions designed to probe knowledge
underpinning correct clinical practice (see appendix D.5). To minimise spurious learn-
ing gain, the test questions were ordered randomly. For the same reason, no answer
feedback was provided to participants.
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Acceptability was assessed through written feedback and likert scale ratings ex-
amining four dimensions: ease of nding information, enjoyment of use, desire to use
again and likelihood to recommend to others. Acceptability ratings were analysed with
the Mann-Whitney U test and aggregated to create a single acceptability index with a
scale of 0-100. Within-group learning gain was analysed with the T-Test and between-
group dierences were analysed using generalised linear models (GLM) controlling for
baseline knowledge scores. All statistical analyses were conducted in the R software
v. 3.0.2 (R Team, 2013).
It should be noted that knowledge retention is a key indicator for assessing the
eectiveness of educational interventions, and this aspect was originally one of the
outcome measures included in the study. However, investigating knowledge retention
proved infeasible since less than half of those who took part in the study (29/61) ex-
pressed interest in participating in a follow-up study. Even with a low attrition rate, a
follow-up study would likely be unsuccessful in recruiting sucient numbers of par-
ticipants to draw meaningful conclusions.
9.2.3 Population and sampling
All healthcare practitioners involved in blood transfusion in Scotland are required to
complete Module 1 (“Safe Transfusion Practice”) of the Learn Blood Transfusion (LBT)
online e-learning programme at least bianually.
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Responded 19 (8.7%) 37 (15.2%) 5 (83.3%) 61 (13%)
* Estimate based on sta within the sampled health board who completed one of the following Learn Blood
Transfusion modules between 1 March 2012 and 31 August 2014:
• Module 1 Safe transfusion practice (aimed at all sta groups).
• Module 1 Safe transfusion practice for Paediatrics.
• Transfusion Laboratory - Safe Practice Module.
** Approximation calculated from the 336 direct personal email invitations and 133 (estimated) invitations
sent via local hospital deaneries.
Working with the Better Blood Transfusion Team at the Scottish National Blood
Transfusion Service (SNBTS), I was able to identify participants through this pro-
gramme. Measures, including encryption of data, were put in place to protect the per-
sonal data of participants and minimise any unsolicited email communication. Copies
of the email messages sent to participants, and the participant information sheet, are
provided in appendix D. An estimate of the sampling frame is oered in table 9.1.
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9.2.4 Power calculation
A total target sample size of 68 was derived based on the primary outcome measure
(dierence in learning gain between the arms). This value was calculated using the
GPower (v.3.1.9) software with the following parameters: a priori power analysis for
ANCOVA, alpha = 0.05 and power = 0.8. As this was a pilot study without a prior
comparable study, an moderate eect size was used (f=0.35). All the parameters used
to calculate the sample size are summarised in table 9.2. A visual representation of the
power calculation is provided in gure 9.3.
Figure 9.3: Power calculation performed with the GPower software.
Post-hoc analysis using GPower with the actual sample (61) and eect size (Co-
hen’s d=0.02) showed that the study’s achieved power (0.05) was insucient to either
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Statistical test ANCOVA: Fixed eects, main eects and interaction
Test family f-test
Type of power analysis A priori
Eect size f 0.35*
Alfa err prob 0.05
Power (1-beta err prob) 0.8
Numerator df 1
Number of groups 2
Number of covariates 1
Table 9.2: Parameters used to calculate required sample size with the GPower software.
* Denotes a moderate eect size and is an estimated due to lack of existing comparable
studies.
conrm or refute H1 with condence. Reasons for this are oered in the discussion.
9.2.5 Inclusion criteria
Participants were required to meet the following criteria to participate:
1. Working at one of three hospitals selected to be included in the study.
2. Completed module one of the Learn Blood Transfusion (LBT) e-learning program
between 1 January 2014 and 1 September 2014.
3. Registered in the LBT database as either doctor, registered nurse or midwife, or
as a hospital blood bank sta (e.g. biomedical scientist).
4. Registered in the LBT database with a professional email address (such as nhs.scot.uk
or nhs.net), rather than a personal email account (such as hotmail, gmail, etc).
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9.3 Results
Despite extending the study deadline, the recruitment target sample size (68) was not
reached and only 61 practitioners participated (estimated 13% response rate). Of these,
29 were randomly allocated to the SBC app and 32 to the guidelines control group. The
two groups were well-balanced (see table 9.3 and 9.4).
Mean scores at pre-test were 32% (M=2.59, SD=1.90) in the app group and 34%
(M=2.72, SD=1.97) in the control. Scores increased signicantly at post-test to 58%
(M=4.66; SD=2.07; t(28)=4.69; p<0.01; 95.CI=1.17-2.97) and 61% (M=4.84; SD=2.14; t(31)=6.28;
p<0.01; 95.CI=1.44-2.81) respectively. Between-group dierences in learning gain was
negligible (d=-0.0261; 95.CI=-0.5287-0.4764). However, the acceptability of the app was
rated signicantly higher (median [IQR]: 75 [75-88] vs 69 [50-75]; Mann–Whitney
U=693.5; p<0.001; median dierence in location: 13.3; 95.CI=6.67-26.7). The test scores
statistics are summarised in table 9.5 and the qualitative feedback on the SBC app and
guidelines is reported as part of the discussion.
50 participants (82%) completed the study on a desktop or laptop computer, 8 (13%)
completed it on a smartphone and only 3 (5%) used a tablet. In terms of the web
browsers used to complete the study, Internet Explorer (IE) 8 was used by 34 (56%),
Safari by 13 (21%), Chrome by 8 (13%) and Firefox by 3 (5%). Two respondents (both
in the app group) used Internet Explorer 6 and 7. Neither reported any issues even
though it is 10 to 15 years since these browsers were rst released.
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Table 9.3: Respondent demographics by group allocation.
App (n=29) Guidelines (n=32)
Age group





Not answered 1 1
Position
Consultant 3 6
Specialty Registrar 2 1
Specialty Trainee Registrar 3 2
Foundation Doctor (any year) 12 8
Nurse 6 10
Biomedical Scientist 2 3
Other 1 2
Specialty
Anaesthetics or Theatre 2 8
Accidents or Trauma 3 1
Bloodbank, Haematology or Oncology 5 5
General Medicine 5 5
Obstetrics, Neonatology or Paediatrics 1 2
Surgery (any type) 4 4
Other 8 7
Not answered 1 0
If you use a smartphone or tablet device, where do you use it?
At home and at work. 21 15
At home only. 6 14
I do not use a smartphone or tablet. 1 2
Not answered 1 1
Have you used apps in your education or practice before?
Yes, in both. 15 14
Yes, in education only. 3 3
Yes, in practice only. 0 2
No, in neither. 9 13
Not answered 2 0
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Table 9.4: Respondents’ medical experience, familiarity with special requirements and
self-rated condence in the indications for special blood components by group alloca-
tion.
App (n=29) Guidelines (n=32)
How many years of medical experience do you have?
30 or more 3 2
20 to 29 3 6
10 to 19 6 11
1 to 9 6 5
Less than 1 11 8
Service in workplace with patients who have special requirements. *
Over 36 months, in current workplace 8 14
13-24 months, in current workplace 2 1
4-6 months, in current workplace 2 1
1-3 months, in current workplace 2 2
13-24 months, in past workplace 2 1
4-6 months, in past workplace 2 0
No exposure to this patient group 11 13
How often do you work with patients who have special requirements?
Every day 3 2
Every other day 1 1
Every week 1 1
Every other week 0 1
Every quarter 2 0
Every six months 0 1
Less frequently than every six months 13 14
Never 5 5
Don’t know 4 7
How condent do you feel about the indications for special blood components? **
Very condent 1 1
Condent 7 5
Neither condent nor uncondent 8 3
Uncondent 10 18
Very uncondent 3 4
Don’t know 0 1
* Composite of two conditional questions: “Does your current place of work have patients who require
CMV-negative or irradiated blood components, and if so how long have you been with your current
workplace?”; and “Have you previously been part of a workplace with patients who require CMV-negative
or irradiated blood components, and if so how long did you work there?”
** Condence was measured prior to knowledge tests.
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Table 9.5: Means scores at the pre- and post knowlegde tests, with standard deviation
and eect sizes (Cohen’s d).
App (n=29) Guidelines (n=32)
Test score means (sd)
Baseline 2.59 (1.90) 2.72 (1.97)
Follow-up 4.66 (2.07) 4.84 (2.14)
Change 2.07 (2.37) 2.12 (1.91)
Within group eect size 95% (CI)
Cohen’s d 1 2
95% CI 1 to 2 1 to 2
Between groups eect size (95% CI)
Cohen’s d -0.0261 (-0.5287 to 0.4764)
9.4 Discussion
As can be seen in tables 9.3 and 9.4, participants in the app group were somewhat
younger (66% were below age 40 compared to 52% in the control group), had fewer
years of medical experience (median 4 vs. 11.5) and held less senior positions.
However, the groups were well-balanced in terms of smartphone and mobile app
use, baseline knowledge, spread of medical specialties, condence about the clinical
indications and frequency of working with patients who have special requirements.
A majority of participants (48/61) did not work with this patient group on a bian-
nual or more frequent basis. About one third (21/61) reported having never worked
with such patients or were unsure if they ever had. Consequently, most participants
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(35/61) felt uncondent about the indications for irradiated and CMV-negative blood.
These results reect the heterogeneity of sta involved in blood transfusion as
captured by the Learn Blood Transfusion database. The sampled population thus ex-
tended beyond the specialties which are likely to have the most experience of patients
with special requirements, such as haematology, oncology, neonatology, obstetrics and
blood banking.
Furthermore, nearly two-thirds (37/61) reported having used apps in either their
education or practice previously, which is similar to prior surveys of mobile app use
among healthcare practitioners (Mobasher et al., 2015; O’Reilly et al., 2014; Carter et al.,
2014; Payne et al., 2012; Franko and Tirrell, 2012).
9.4.1 Ecacy of the SBC app
Both groups nearly doubled scores on the post-test compared to pre-test. Mean scores
at pre-test were quite low with only 32% (M=2.59, SD=1.90) correct answers in the app
group and 34% (M=2.72, SD=1.97) in the control group. The scores increased signif-
icantly at post-test to 58% correct (M=4.66; SD=2.07; t(28) = 4.69; p<0.01; 95.CI=1.17-
2.97) in the app group and 61% (M=4.84; SD=2.14; t(31)=6.28; p<0.01; 95.CI=1.44-2.81)
in the control.
Analysis of the questionnaire suggested that the questions were balanced (correct
answer percentage: M=46.2; SD=18.4; range=25-85.2) and discriminated performance
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well (point-biserial correlation: M=0.34; SD=0.09; range=0.17-0.54) (Varma no year,
6). However, as can be seen from the large standard deviations in the scores, there
was considerable variation in the performance of members within each group. This
contributed to a much smaller than hypothesised between-group eect size (d=-0.02;
95.CI=-0.5287-0.4764). Coupled with the small sample size, this resulted in insucient
power to refute or conrm whether the app or guidelines is more eective (H1). As
discussed above, variations in participants’ prior experience of patients with special
requirements contributed to the variation.
9.4.2 Post hoc analysis
Post hoc analysis sought to identify and compensate for sources of variation. A mod-
erate correlation (r
2
=0.4) between follow-up score and the time spent exploring the
app or guidelines, and then answering the follow-up questions, was noted up to about
ten minutes. Using more than ten minutes to explore the guidelines and app, and com-
pleting the follow-up questions, was not associated with an improvement in score.
Overall scores were also signicantly aected by a small number of participants
who clicked through the evaluation without studying the app or guidelines. For exam-
ple, two participants who spent less than two minutes reviewing the app and answer-
ing the eight follow-up questions, went from a score of four on the baseline to zero
and one on the follow-up test.
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When excluding participants who had very short completion times, presumably
due to random guessing, the app group performed better than the guidelines group
(Cohen’s d=0.15). However, even at this eect size, the sample size was too small to
rule out a type I error.
When designing the evaluation, I considered forcing all participants to spend a min-
imum amount of time studying the app or guidelines before they could proceed to the
remaining questions. However, I decided against this because it could cause frustration
and unnecessary stress, particularly since many participants would be completing the
study at their workplace.
In retrospect, putting some boundaries on the interaction time with the app and
guidelines could perhaps have improved the quality of the collected data and reduced
some of the variability arising from the time participants chose to spend in reviewing
the app and guidelines.
Another important source of variability was participants’ medical specialty. Biomed-
ical scientists and haematology sta performed signicantly better than participants
from other specialties where blood transfusion and patients with special transfusion
requirements are less likely to be encountered. The groups were reasonably well-
balanced in this regard because the nal sample reected the stratied randomisation
strategy.
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9.4.3 Acceptability of the SBC app
The SBC app was rated signicantly more positive on all of the four acceptability di-
mensions (ease of nding information, enjoyment of use, intent to reuse and likelihood
to recommend) compared to the guidelines (g. 9.4). The aggregate acceptability index
(range 0-100) was signicantly higher for the app (median [IQR]: 75 [75-88]) vs 69 [50-
75]; Mann–Whitney U=693.5; n1=29, n2=32; p<0.001; median dierence in location:
13.3; 95.CI=6.67-26.7).
Figure 9.4: Ratings of the revised SBC app and existing local hospital guidelines. Base:
All 61 participants.
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The comments oered by participants shed light on this result. Ten participants
provided wholly positive comments relating to the SBC app. Utility and relevance to
current or future work responsibilities were among the most frequently praised aspects
of the app:
“It is a good reference for people who are taking part in transfusion. [...] I would
buy it to have on my phone as a reference.” (Nurse, 30-39, Haematology)
“Don’t use bloods with special requirements much [...] but this app would be
extremely benecial for future roles, especially oncology.” (FY1, 20-29, General
Surgery)
In particular, its function as a cognitive aid oering access to information that is
required sporadically and dicult to memorise was emphasised:
“Having an app reference for this is very useful, as I don’t need to prescribe these
products often. So I have no means to build up experience, and would always
worry that I’m forgetting about a key indication.” (Foundation Year 1 [FY1] Doc-
tor, 30-39, Plastic Surgery).
Several participants commented that the app was easy to use and contained clear
and interesting information worthy of further study. For instance:
“Easy to use, short statements that make rationale for indication clear. May take
more than one read to cement all knowledge but this is achievable in short time
frame so not a daunting task.” (Specialty Trainee Registrar, 30-39, Anaesthesiol-
ogy)
“Easy to follow and information interesting. I now want to go back when I have
more time and look at the information. Denitely need to know more about this.”
(Nurse, 40-49, General Medicine)
However, one participant struggled to understand and nd answers to some of the
questions, and felt that a “simple list of conditions” would have been easier to use.
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Another participant experienced a technical problem that caused the app to freeze. As
this was the only report and no details were provided, it is dicult to determine the
cause of the issue.
The remaining comments about the SBC app expressed a mix of positive and nega-
tive sentiments, often together with constructive feedback. Three participants felt the
user experience could be further improved:
“Very informative, could be easier to navigate though, with more headings” (Nurse,
30-39, Haematology).
Furthermore, two participants felt that there was a large amount of information
that could perhaps be presented better:
“A lot of information in the app. Perhaps could be simplied [...] a simple path-
way could be used, with the option to then read/access more detail.” (FY1, 20-29,
General Medicine)
Others felt that the app’s use of trac light icons would benet from an explicit
explanation (green: no special blood required; amber: special blood may be required;
red: special blood required). In contrast, only one participant left detailed positive
feedback in relation to the guidelines:
“The guidelines were clear and concise with not too much jargon which would re-
quire too high a level of medical knowledge for our role. Anyone in Blood Sciences
should be able to follow these guidelines without diculty.” (Blood bank/Hospital
lab sta, 30-39, Haematology)
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Another three participants felt that the extensive use of bullet points in the guide-
lines made it easy to nd information quickly. However, an equal number commented
that the guidelines contained too much information and that it was dicult to use:
“The guideline is incredibly wordy! Trying to read through it to identify the cor-
rect information is a painful process.” (Consultant, 40-49, Anaesthesiology)
Several participants suggested ways in which the guidelines could be improved and
suggested using techniques such as colour-coding, a tabular format, re-organising by
medical condition and subdividing information into more manageable chunks. Fur-
thermore, an explanation of the rationale for irradiated and CMV-negative blood com-
ponents was requested;
“It would be helpful at the start of the section to clearly state what is achieved
by irradiation and a little more explanation of the reasons for this. Otherwise it
will be dicult to retain this info. In the CMV section, again a reason why CMV
negative blood should be used in these specic instances, as this has changed a
bit over the years.” (Consultant, 50-59, Anaesthesiology)
9.4.4 Limitations and lessons learned
This study has several limitations related to overall research design, choice of control
treatment, methods of assessing clinician knowledge and sample size. In pre-post test-
ing it is dicult to rule out that measured eects are not a side eect of the research
design (so called learning or practice eects) rather than the intervention being tested.
It was to reduce this confounding eect that all questions were unique and ran-
domised, and answer feedback was withheld from participants. Ultimately, a solomon
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four group design could have enabled the eect of simply answering the question-
naire on test scores to be factored out. However, it would have required a much larger
sample size and was not feasible for this reason.
On the topic of sample size, the response rate was slightly lower than anticipated
and this is likely due to the timing of the study coinciding with the Christmas period
and survey fatigue. It is possible that alternative recruitment methods, such as a postal
invitations, would have enticed additional participants. In retrospect, it is clear that the
study was underpowered as the dierence in eect size between the two groups was
much smaller than theorised. Reasons for this has been explored above, but are likely
due to heterogeneity in respondents. Future studies may achieve greater statistical
power by targeting a more homogenous subgroup, such as biomedical scientists.
Other limitations of the study pertain to the suitability of the control treatment
(hospital guidelines). While they represent current practice, the guidelines diered in
length compared to the app by a factor of ten. This meant that the required time to
review the app could dier signicantly from the guidelines. As discussed above, this
was not something that was easily compensated for in this research design, although
controlling for time retrospectively helped identify and quantify this issue.
One can question the validity of a short multiple-choice quiz as an adequate mea-
sure of knowledge. As discussed at the start of the chapter, there are dierent kinds
of knowledges and dierent ways of measuring them. A more comprehensive study
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would aim to capture a broader spectrum of knowledges using a combination of quan-
titative and qualitative methods. However, this was beyond the scope of the current
study. Additionally, I had originally hoped to assess, by means of a follow-up survey
scheduled, whether participants retained newly gained knowledge over time. Unfortu-
nately, due to the low response rate and the small number of respondents who agreed
to participate in a follow-up survey it was not feasible.
9.5 Conclusion
This study is among the rst to evaluate a mobile learning app targeting practitioners
in transfusion medicine. The results conrmed low levels of existing knowledge and
condence of the correct use of irradiated and CMV-negative blood components among
healthcare sta. As participants had completed e-learning on safe transfusion practice
within the last 12 months, the result raises questions about the eectiveness of current
training programmes.
Performance on the follow-up test signicantly improved from baseline in both
groups, suggesting that the guidelines and SBC app could be eective ways of en-
hancing practitioner knowledge. The study was not powered to detect a statistical
dierence in superiority of either intervention. Reasons for this are likely to include
heterogeneity among research participants and variation in the time invested by par-
ticipants in completing the questions.
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That said, the SBC app was rated considerably more positively than the local hos-
pital guidelines, suggesting it has potential to be more widely adopted. As there is
a shortage of existing learning interventions addressing this topic, the SBC app could
complement existing blood transfusion education initiatives. Further research is, how-








This chapter discusses the ndings from the literature and the empirical work. I
begin by summarising the aims and objectives, and key ndings from prior work. The
main results and limitations of the thesis are then discussed, including the outputs of
the collaborative project. I then discuss the implications of the ndings and relate them
to prior work. Finally, I conclude by highlighting the contributions to knowledge and
oering recommendations for practice.
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10.1 Research aim and related work
The purpose of the thesis was to explore how the quality and credibility of medical apps
for healthcare practitioners could be improved by adopting a collaborative approach
to app design and evaluation. To achieve this, I initiated a project where I worked
with practitioners in transfusion medicine to create and evaluate a mobile learning
app to improve the care of patients with special transfusion requirements. To inform
the project, I reviewed prior work related to the adoption, design and evaluation of
medical apps, and literature examining transfusion medicine practice in the UK.
10.1.1 Prior work in eHealth and related elds
The review identied ve key ndings that were relevant to the project. Firstly, mobile
apps are increasingly used by healthcare practitioners in both their medical education
and clinical practice. However, barring a few notable exceptions, there is a shortage of
published evidence for the eectiveness of many medical apps.
Secondly, several studies have identied signicant shortcomings in a large number
of available apps covering a wide range of medical specialties, and in apps intended for
both patients and healthcare practitioners. The causes of these limitations have rarely
been carefully examined in the literature. However, weaknesses in design, a lack of
input from medical professionals and inadequate evaluation have been suggested as
possible causes.
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Thirdly, prior work in eHealth and related elds draw attention to the importance
of evaluation research to understand the impact of healthcare information technologies
on a variety of outcomes. Fourthly, embedding healthcare information technologies
into existing work practices and organisational processes have been highlighted by
several scholars as critical for the successful uptake of such interventions. Depending
on the type of system, signicant implementation eort may be required to achieve
this.
Finally, previous attempts at assuring the quality of medical apps have met with
limited success. For example, notable third party intermediaries, such as the NHS
Health Apps Library and Happtique, have failed to review apps in a transparent, ef-
fective and timely fashion. Similarly, the vast majority of medical apps fall outside the
remit of regulators. Thus, addressing this problem requires another approach. One
method is to develop mechanisms that encourage healthcare practitioners to partici-
pate actively in the design and evaluation of medical apps. However, there are as yet
few examples where this strategy has been successfully demonstrated.
10.1.2 Prior work in transfusion medicine
The review of the composition, manufacture and use of blood components provided a
further foundation for the research project. It identied four key points. Firstly, blood
transfusion practice takes place in a complex socio-technical system involving many
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actors with specialised knowledges. Thus, changing existing practices is not trivial
and requires interventions at several levels.
Secondly, the management of blood transfusion risks is an ongoing challenge as the
scientic basis evolves. It requires careful consideration of all parts of the transfusion
chain, from blood donor recruitment through to patient monitoring.
Thirdly, work by Serious Hazards of Transfusion (SHOT) have identied that the
use of “special blood components” is a challenging area where mistakes occur. SHOT
have recommended that practitioners’ knowledge of the correct use of irradiated and
cytomegalovirus-negative blood components should be improved to prevent mistakes.
Finally, there is a shortage of learning resources addressing this topic in detail. This
nding became the starting point of the collaborative action research project and the
resulting Special Blood Components (SBC) mobile learning app.
10.2 Findings from the empirical work
The ve empirical studies shed light on a wide range of issues related to how the
quality and credibility of medical apps might be improved by adopting collaborative
design and evaluation methods. In this section, I will briey discuss the ndings and
limitations of each study.
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10.2.1 Study 1: review of an existing app
The objective of this study was to review an existing blood transfusion app target-
ing healthcare practitioners in order to learn from what has gone before. The study,
among the rst independent reviews of an app in transfusion medicine, revealed no-
table weaknesses in the clinical content, dose calculator and usability of the NHSBT
Platelets app. The ndings highlight how medical apps released with bugs and usabil-
ity problems are not only likely to be rejected by practitioners, but could potentially
also contribute to medical errors.
In particular, the platelet dose calculator does not check for input errors. Instead of
failing, it will recommend a standard dose of platelets. This software bug, which has
remained unxed since the app was published, could lead clinicians to over-transfuse
patients. It in turn can lead to risks such transfusion-associated circulatory overload
(TACO).
10.2.2 Study 2: concept validation of the proposed app
The purpose of this study was to gauge the extent to which an app could be an accept-
able intervention for improving the use of irradiated and CMV-negative blood compo-
nents. It also aimed to examine the assumptions underpinning the proposed Special
Blood Components app and solicit early feedback on the initial working prototype
from practitioners.
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Interviewing participants from dierent hospitals, specialties, and with dierent
professional responsibilities and priorities, deepened my understanding of the problem
that the SBC app sought to address. This included the challenge of providing continuity
of care given variations in information systems and processes between hospitals.
A limitation of this study was that it only captured the views of a small number of
practitioners. However, it was sucient to observe dierences and similarities in how
practitioners from dierent medical specialities dened and analysed the problem, and
the emphasis they placed on potential interventions. This early feedback was essential
for developing a better understanding of the problem, for identifying inaccuracies in
the prototype data model, for improving the usability, and rening the purpose and
audience of the app.
Moreover, the practitioners were enthusiastic and generous with their time. It was
not dicult to recruit them because access was brokered through the Scottish National
Blood Transfusion Service (SNBTS). Establishing an eective feedback loop would en-
courage the participants to remain engaged in the project, since they would be able to
see the eect of their feedback. However, I found that it is was dicult to incorporate
and communicate changes back to participants in a timely way. An important reason
for this was the lack of good collaborative development tools.
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10.2.3 Study 3: collaborative app design with the WAE
To facilitate the collaborative working on the SBC app, I created the Web App Editor
(WAE). It is a browser-based authoring tool that allow multiple users to collaborative
during the development of web apps. The current version supports code highlight-
ing and syntax checking, multi-le editing, web hosting and easy preview of work in
progress on desktop and mobile devices, version control and le management.
In this study, I discussed the design and testing of the the Web App Editor with
students in two certied introductory courses on mobile app development, and in a
Masters project aiming to create an app to elicit symptoms of stroke patients.
In these contexts, the WAE enabled users with little prior experience to learn about,
create and test mobile apps. These results show that it is possible to collaborate with
beginners at the level of code. This is a departure from how medical apps projects
are often approached, but an extension of the participatory method used to design
and evaluate the SBC app. The approach is informed by user innovation theory and
extends studies where medical students and junior doctors experiment with creating
medical apps (Masters, 2014; Subhi et al., 2014).
10.2.4 Study 4: usability evaluation of the SBC app
The purpose of this study was to evaluate the usability and content of the second revi-
sion of the Special Blood Components (SBC) app, and to identify further improvements
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to it. 54 medical students identied weaknesses in the content, usability and learning
quiz which required additional work to address.
Despite these limitations, the app was rated acceptably on the system usability
scale. However, an important limitation in this study was that most of the students
lacked experience of participating in blood transfusions. It is possible that respondents
with greater experience would have been able to more critically evaluate the app.
Additionally, the use of a remote evaluation survey exceeded expectations as the
collected data was quite rich and insightful. The exibility of evaluating medical apps
online opens up opportunities to more easily integrate formative evaluation into the
app development process
10.2.5 Study 5: randomised controlled pilot of the SBC app
This study aimed to evaluate the ecacy and acceptability of the SBC app with health-
care practitioners involved in blood transfusion. To conduct the study, I created the
Web App Trial (WAT) system. It is an application for conducting online randomised
controlled trials of web apps.
The study conrmed low levels of existing knowledge of the correct use of irra-
diated and CMV-negative blood components among healthcare sta as reported by
SHOT. As participants had completed e-learning on safe transfusion practice within
the last 12 months, the result raises questions about the eectiveness of current train-
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ing.
Follow-up knowledge test scores signicantly improved from baseline, suggest-
ing that the SBC app could be an eective way of enhancing clinicians’ knowledge.
However, the study was not powered to detect a statistical dierence in the magni-
tude of performance change between the app and local hospital guidelines (control
intervention). Furthermore, the SBC app was rated considerably more positively than
the control, suggesting it has potential to be more widely adopted. More research is
required to assess the impact on clinical outcomes and knowledge retention over time.
Additionally, the study provides a validated knowledge test and a benchmark dataset
that is valuable to future research and audits of healthcare practitioners’ understanding
of special blood components. The results could also inform the development of blood
transfusion e-learning materials that are increasingly accessed on mobile devices in
both medical educational and practice contexts. Finally, the study demonstrated the
feasibility of conducting controlled evaluations of medical apps using an entirely web-
based system. This is an area that should be explored further as there is a need to
develop methods that enable rigorous and cost-eective evaluations of medical apps.
10.3 Discussion
Published apps related to transfusion medicine and other medical specialties have sev-
eral limitations. Some limitations could be considered so serious that the apps are
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unsafe to use (yet fall outside the remit of regulators). It is not only apps by “rogue
developers”, hoping to scam gullible patients, that are problematic. Apps promoted by
recognised medical bodies and intended for healthcare practitioner can also be aected
by serious limitations.
I argue that attempts at tackling this problem would benet from adopting an in-
tegrated approach that considers the whole life-cycle of medical apps and the socio-
technical context in which they are produced. Concentrating eorts to a single stage of
the archetypal software life-cycle, such as design, testing, evaluation, implementation
or maintenance is likely to be an unsatisfactory strategy. The implementation, evalu-
ation and design of healthcare systems are deeply interwoven activities that demand
high levels of participation by healthcare practitioners (Granlien, 2010).
Furthermore, successful technology projects demand that users are innovative dur-
ing system implementation to resolve issues at the point of use (Fleck, 1994). That is to
say, design is not an upfront activity. Rather it continues throughout the project life.
With this more nuanced view of the innovation process, the quality and credibility of
medical apps could be regarded as emergent properties of the complete life-cycle of
the project.
To give a concrete example, although the brunt of the empirical work concerns the
design and evaluation stages (a reection of the PhD timeline), it became clear over
the course of the project that the quality and credibility of medical apps depend just
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as much on appropriate software testing, implementation planning and active main-
tenance after launch. These in turn are conditioned on a combination of technical and
social aspects, such as the choice of technical architecture, organisational capacity,
commissioning practices, budgeting and mindset.
So, what form should a holistic approach to improving medical apps take? Research
on medical apps is underdeveloped (Lupton, 2014, p.618), but can nonetheless inform
strategies. For instance, inadequate involvement of healthcare professionals in medical
app projects has been identied as a cause of deciencies by several authors (Masters,
2014; Visvanathan et al., 2012; Hamilton and Brady, 2012; Haey et al., 2013b; O’neill
and Brady, 2012; Zhou et al., 2012). This is an astute observation as eective interdis-
ciplinary collaboration throughout healthcare information technology (or “eHealth”)
projects is critical to create quality interventions that are supported by strong evidence
(Pagliari, 2007).
Furthermore, studies of other kinds of eHealth interventions, such as electronic
healthcare records, are informative. For example, a systematic review of eHealth stud-
ies published between 1997 and 2010 concluded that the presumed benets of many
eHealth interventions have not been demonstrated empirically (Black et al., 2011).
This nding stems in part from a widespread and erroneous belief that the pre-
sumed impacts of eHealth interventions are self-evident and do not warrant investiga-
tion (Car et al., 2008, 386). When evaluations were available, Car et al. (2008, 387-389)
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found that the robustness and validity of the ndings were severly limited by issues
such as inappropriate research design, unclear outcome measures and failure to assess
long-term impacts.
10.3.1 Challenges of evaluating medical apps
There is an urgent need to develop better methods to quality-assure medical apps, most
of which fall outside the remit of regulators. The task of regulating mobile medical apps
on the market through centralised bodies, such as the US FDA or the MHRA in the UK,
is challenging due to the large number of health apps. Top-down central regulation is
inadequate and quality assurance eorts have to come from intermediaries and the
“grass roots”.
Evaluating the eectiveness of healthcare technology can be very challenging and
is rarely undertaken. With the exception of a small number of apps, most apps ap-
pear to be developed without a clear research agenda to investigate and evidence their
eectiveness, and lack associated peer-reviewed publications. Formal evaluations of
apps are important to give them credibility.
However, rigorous evaluations are resource-intensive and may detract from the
resources available to make practical improvements to an app. For this reasons, it is
important to develop scalable evaluation strategies that can make the evaluate-improve
cycle fast and eective. The Web App Trial system, used in study ve, attempts to strike
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this balance between research rigour and exibility. However, improving this situation
requires more than tools.
10.3.2 Role of interdisciplinary collaboration
Improving the quality and credibility of medical apps require that app developers,
medical experts, potential users and other stakeholders collaborate eectively. This
was evident from previous work on the design and evaluation of eHealth interven-
tions (Pagliari, 2007), as well as studies drawing attention to the lack of participation
of healthcare practitioner in the design of medical apps (Masters, 2014; Visvanathan
et al., 2012; Hamilton and Brady, 2012; Haey et al., 2013b; O’neill and Brady, 2012;
Zhou et al., 2012).
These ndings from the literature were readily conrmed in the empirical stud-
ies. For example, in the review the NHSBT Platelets app, reported in the rst study,
important shortcomings in the clinical content, user interface design and the platelet
dose calculator were identied. These ndings suggest that the app had been designed
without sucient involvement of healthcare practitioners who were target audience
for the app.
Furthermore, the design and evaluation of the Special Blood Components (SBC)
app, reported in studies two, four and ve would not be possible without the generous
cooperation of many medical practitioners and students. Indeed, over the course of
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project, more than one hundred individuals contributed to the SBC app. Two striking
examples of the importance of this interdisciplinary collaboration are illustrated in
study two and four, where participants challenged key assumptions of the SBC app.
10.3.3 Need for collaborative tools and training
As highlighted in study two and three, collaborations involving medical apps are made
dicult by the lack of good tools that enable eective collaborative practices. In order
to be responsive to the needs of users, the design process has to be iterative and exible.
This is one of the guiding principles of “agile” software development methodologies.
Minimising the friction, time and eort required to solicit feedback from user, make
the required changes and feed the results back to user can make a considerable impact
on the rate of quality improvement.
Developing such a process of continuous improvement was challenging. The Web
App Editor (WAE) is a system supporting collaborative development of apps. The WAE
editing environment simplies the development process and lowers the barriers to col-
laborate on apps. It achieves this by removing dependency on special software or hard-
ware, providing direct access to source code and a live preview of the app. Integration
with the Git distributed versioning system allows a history of changes made by any
number of contributors.
The editor is relevant to current research exploring teaching initiatives where med-
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ical students and healthcare professionals learn about and develop medical apps (Youm
and Wiechmann, 2015; Masters, 2014). A good way to learn is by studying the work
of others. Unfortunately, this is dicult as at the moment many medical apps are de-
veloped proprietary software, leaving users to rate and comment in app stores, rather
than to inspect the code and contribute to them directly. Moreover, for users of medi-
cal apps, appreciating how they work and have been created can inform judgement on
whether to use an app or not. By exposing the inner workings of apps, it is also easier
for evaluators to examine the correctness and reliability of an app.
Thus, making apps open source have potential to encourage wider participation
in their development, evaluation and maintenance, as well as leading to new apps re-
using previous code. There are collaborative platforms, such as Github.com, where
it is possible to cooperate eectively on software code. However, there is a lack of
awareness and uptake experience of these tools outside of less technical communities.
There is therefore a need to support the acquisition of knowledge and skills among
interested healthcare practitioners.
10.4 Conclusion
The results of the review in chapter two suggest that apps spanning a wide range of
specialties may suer from important shortcomings and their use could be detrimental
to patient safety. Mitigating these risks is not trivial and requires multiple interven-
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tions. Attempts at top-down regulation of medical apps have met with limited suc-
cess as the majority of medical apps fall outside the remit of regulators. Indeed, some
of the most publicised examples of apps that have been withdrawn from the market
originate from consumer protection agencies targeting consumer-oriented apps which
make misleading marketing claims, rather than from the bodies that regulate medical
device safety.
Repeated calls from scholars and medical professionals for a “certied selection”
or “white-list” of trusted medical apps also look increasingly unlikely to gain traction.
Notable initiatives, such as the defunct NHS “Health Apps Library” and Happtique,
which both intended to be oer comprehensive app certication programmes, have
failed to review apps in a transparent, eective and timely fashion.
A more promising approach is to invest in training to enable healthcare practi-
tioner to manage the opportunities and perils of (untested) medical apps. The notion
of an “eHealth literacy” (or “medical app literacy”) is pertinent as practitioners retain
responsibility to patients and must exercise caution whether they rely on a paper-based
medical guideline or an “appied” version. Although some medical schools have en-
couraged their students to learn about and create apps, other educational programmes
may be failing to provide students with the necessary IT skills and knowledge.
A novel way to attempt to tackle this issue is to develop mechanisms that encourage
healthcare practitioners to participate actively in the design and evaluation of medical
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apps. Failure to involve healthcare practitioners in the development process, together
with a general lack of medical app evaluation research, are among the most frequently
cited causes of deciencies in apps. Thus, there is a need for collaborative app design
and evaluation research across professional boundaries.
The open source and open science movements could oer lessons for such an en-
deavor. These seek to promote increased transparency and openness in software de-
velopment and medical research by opening up access to computer code and research
data, including data from clinical trials. These approaches could potentially make it
easier to inspect how apps work, and to assess their correctness. However, there are as
yet few examples where this strategy has been successfully used. Apart from a small
number of counter-examples, political and cultural barriers, such as entrenched power
structures, have previously impeded these approaches in medicine.
Additionally, it is critical to develop a more integrated approach to app develop-
ment that incorporates iterative design with evaluation research. Perspectives from
user-centered design, co-design, user innovation and evaluation research are valuable
in furthering this agenda. As are insights from the social studies of technology and
innovation that suggest that design, implementation and innovation should be under-
stood as interleaving processes. Thus, simple linear models of the software life-cycle
are misleading and brush over the potential for innovations by users. Additionally,
there is a need to develop appropriate app evaluation methods that strike a balance
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between validity, reliability, cost and rigour, and which generates data that can be
used to improve the quality and credibility of apps.
To summarise, the growing adoption of apps by practitioners raise questions about
the extent to which medical apps are safe to use and how one would determine this.
It also raises questions about how development and evaluation processes should be
carried out to ensure medical apps are “t for purpose”. There is little research evidence
to answer these questions with condence.
The thesis contributes to knowledge by oering a critical and reexive (Finlay,
2002) analysis of the research, design, engineering and socio-technical (c.f. Hughes,
1987) challenges of developing and evaluating medical apps for and with healthcare
practitioners. I have argued throughout the thesis that concerns related to the lacking
quality and credibility of many medical apps cannot be eectively addressed by “mar-
ket forces” (such as consumer behaviour on app stores), “vetting” by trusted third par-
ties or top-down regulation by governmental bodies with relatively limited resources.
Rather, these issues are symptoms of limitations in the current app commission-
ing, development and evaluation practices. Drawing on prior work, and using the
SBC app as example of how healthcare practitioners, medical students and others con-
tributed quality improvements and helped evidence its usability and ecacy, I suggest
that these issues could be overcome by development strategies that promote on-going
interdisciplinary teamwork.
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Dedicated collaborative app design and evaluation tools, such as the WAE and WAT,
can facilitate such strategies, but are still in their infancy. It is also critical to develop
and reward the digital skills of healthcare practitioners so that they can become critical
consumers of apps and can actively shape the information technologies that they are
increasingly reliant on.
This thesis has furthered understanding of the adoption, design and evaluation of
medical apps by healthcare practitioners. On the basis of these ve studies, I argue
that the design and evaluation of high quality medical apps supported by evidence re-
quires specialised knowledges and skills. Close collaboration between medical domain
experts, software developers/designers, healthcare technology evaluators and other
stakeholders is therefore critical to improve the quality and credibility of medical apps.
In conclusion, creating high quality medical apps that are supported by evidence is
a considerable undertaking and depends on a mix of knowledges and skills. It requires
that healthcare practitioners, software developers and others work together eectively.
Hence, the WAE and WAT are key research outcomes. They enabled participants to
contribute improvements and assess the usability and ecacy of the SBC app. The
results suggest that the SBC app is easy to use and can improve practitioner knowledge.
Further work remains to pilot and evaluate the SBC app in a hospital setting.
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10.4.1 Implications for transfusion medicine
In terms of improving the correct use of irradiated and CMV-negative blood compo-
nents, the thesis conrms earlier work that identify gaps in the knowledge among
healthcare practitioners. Thus, it rearms the importance to follow SHOT recom-
mendations to improve training in this area.
The Special Blood Components (SBC) app is the result of collaboration with over
one hundred doctors, nurses, medical students and others. It can promote the correct
use of irradiated and CMV-negative blood components by providing practitioners with
easy access to learning materials and clinical indications. The usability, ecacy and
acceptability of the app have been demonstrated in the evaluation studies reported in
the thesis.
For example, evaluations with medical students and practitioners suggest that the
SBC app is an attractive, ecacious and easy to use intervention that could help ad-
dress this gap in current transfusion learning provision. That said, it is important to
emphasise that mistakes occur within complex healthcare systems and require mul-
tiple approaches. Further research is therefore required to promote the SBC app in
medical education, and to assess its potential impacts on clinical practice and patient
outcomes.
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10.4.2 Implications for medical app design
There are many factors that lead to weaknesses in medical apps. Preventing them
require a change in mindset and development practices. Many medical app projects
appear to adopt a shortsighted approach, which can be summed up as: “We need an
app for that. Let’s hire someone to build it for us and promote it.”. One problem with
this approach is that it commits little or no resources to evaluate the impact of the
intervention. Similarly, the technical work is “outsourced” and the app’s code becomes
a “black box” controlled by an external party. This makes it dicult and expensive to
inspect the quality of the code, and to maintain it after launch.
In contrast, producing and supporting high quality medical apps require a strategic
approach that recognises the critical role of iterative design, evaluation and mainte-
nance. This requires longer-term funding, higher levels of clinician involvement and
close interdisciplinary collaborations with software developers, designers and health-
care evaluators. It may also involve training and capacity-building to ensure members
of sta have the required skills to evaluate, implement and maintain information tech-
nology interventions.
For this reason, I propose that future work should consider the CREDIBLE princi-
ples presented in table 10.1. The principles are geared towards anyone about to embark
on a medical app development project and who would benet from consulting a brief
list of key considerations.
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To gain support and
buy-in from users, subject
experts and gatekeepers.
Identify and approach a small number of key people to work with.
Negotiate organisational and political demands pragmatically.
Adopt methods and tools to support collaborative activities.




To rene goals, context
and methods, and learn
from what’s gone before.
Search broadly for related work and contact people who have tackled
similar issues in the past (perhaps it is possible to extend their work).
Identify and evaluate existing tools and design methods.





To demonstrate that the
app is based on best
available evidence.
Incorporate citations to current peer-reviewed literature.
When scientic consensus is lacking, represent the range of current
opinion or signal and justify specic stance adopted.




To help users understand
the origin, purpose and
scope of the app.
Prominently highlight the purpose, scope, target audience, intended
use and any signicant limitations of the app.




To improve usability and
reduce risk of errors due
to poor design.
Schedule user testing sessions early in the development process so
that improvements can be incorporated in a timely fashion.
Adopt user-centered design and agile software development methods.
B
Budget for the full
app life-cycle.
To ensure resources are
available over the whole
life of the app.
The cost of an app is greater than any single ’upfront’ design cost.
Budget for an iterative design process, evaluation, training, promotion
and future maintenance (typically over several years).
L
Learn as you go
and share lessons.
To continuously improve,
improve team skills and
advance knowledge.
Highlight the “learning journey/curve” and the need to be exible.
Reect on the process and modify as needed to achieve the goals.
Identify and disseminate lessons learned.




To test the design and
generate strong evidence
to encourage adoption.
Incorporate formative evaluation into the iterative design process.
Conduct the most rigorous evaluation of the app using the strongest
available outcome measures given the constraints of the project.
Publish the results of the evaluation.
While these principles were designed to apply widely, they cannot be exhaustive.
There is great diversity of medical app projects which cannot be catered to in a single
table. For example, projects seeking to produce apps that potentially fall under the
medical device regulation should take legal advice. Similarly, while these principles
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A.1 Information and consent form
An app for checking indicators for irradiated and CMV negative blood
Karl Monsen. PhD candidate at the University of Edinburgh, UK.
[[personal contact details removed]]
Dr. Brian McClelland. SNBTS (retired). Medical adviser to project, Edinburgh, UK.
[[personal contact details removed]]
1. Introduction
Errors continue to occur in the ordering of special blood components. In 2011, 69 cases were reported in the UK where irradiated
and Cytomegalovirus (CMV) negative components were indicated but not requested. We have developed an app to aid prescription
of irradiated and CMV negative blood. Additionally there are apps aiming to reduce unnecessary transfusion, such as the Mayo
Clinic TransFuse iPad app and the NHSBT Platelets webapp, which we are interested in evaluating.
There is some controversy over the use of apps in medicine and a dearth of published evidence to demonstrate their eectiveness.
We need your help to facilitate access to clinical sta involved in transfusion decision making to evaluate the apps.
2. What we need from you
Names and email addresses of sta involved in transfusion decisions. We propose to evaluate the usability of the apps by means of
an online survey and a follow up focus group.
Advice on how to evaluate the quality of transfusion decisions. We are interested in understanding whether and how apps can help
improve the speed and accuracy of decision making in transfusion. This includes understanding causes of errors and how to
evaluate decisions where evidence is lacking.
Advice on whether clinical apps ag up legal-ethical issues. “In the United Kingdom apps that are ’medical devices’ must be
registered with the MHRA [...] what constitutes a medical device is a grey area—for example, the agency said that an app that
charted changes in skin moles would not be a device, whereas one that oered diagnosis would be” (McCartney, 2013, 1), http:
//www.bmj.com/content/346/bmj.f1811
Comments and feedback on the apps Any data you provide will be treated condentially. Your answers will be made anonymous
in any publications. You may withdraw your data at any time and for any reason. Please ask if you have any questions about any
of the above.
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A.2 Topic guide
INTRODUCTION
• Who we are, our aliations.
• Why we are working together.
• What the research project is about.
• Why we have arranged the meetings.
• Hand out informed consent form for participants to read through and sign.
• Check for any questions at this point.
• Ask if happy that we record the meetings.
If yes, turn on audio recorder.
MAIN MATTER
1. Special requirements app.
Explain that this is the app we have developed, intended for clinical decision making and ed-
ucation by answering the question ’Does my patient require irradiated or CMV negative com-
ponents?’ We showed all participants this app.
2. NHSBT platelets app
Explain that this app was not developed by us and was designed to help prescribe platelets
conservatively. We showed all participants this app as a point of comparison to our app.
3. Mayo Clinic TransFuse app
When time allowed, and we felt it was relevant to the participants specialisms (e.g. anaes-
thetists), we showed this free game-based learning app to promote conservative use of blood.
4. Australian Blood Service website on indications for irradiated blood
We discovered this website during the last day of meetings. Because it was quite similar to
our app, we decided to show it to one participants, as a point of comparison to the app we are
developing.
TOPIC GUIDE FOR EACH APP/WEBSITE
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• General impression and perceived usefulness?
• Scope and correctness of content?
• Audience, how to reach them and evaluate impact of app?
• Usability?
NB: Where it was possible, we conducted simple usability testing by asking participants to
think aloud whilst nding their way around the app or website without our help. We used two
iPads, an iPhone and NHS computers running Windows XP and Internet Explorer.
CONCLUDING
• Ask any outstanding questions, including returning to questions on consent sheet.
• Remind participants to sign and return consent sheet.
• Ask if participants are happy that we contact them again.
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A.3 Follow-up message
Dear <name>
I hope you are well. It was a pleasure to meet you at the end of April to talk about the app with
indications for irradiated and CMV negative blood that Brian McClelland and I are developing.
We have been quietly working away for the last six months:
• Aligning the app’s recommendations to BCSH and SaBTO guidelines.
• Adding a section with background information, common mistakes and good practice.
• Creating a simple ’algorithm’, which points users to the relevant indications.
• Improving the usability
We would now like to invite you to have a look at the new version, which is available online
at: http://www.optimalblooduse.eu/app/
There is a facility for leaving feedback in the app/webpage (scroll to the very end and press the
green ’leave feedback’ button). This will take you to an online form where you can evaluate
the app and leave feedback.
Alternatively, simply reply to this email with your comments. If you include a phone number,
a date and a time, I can call you to go through your feedback.
I am presenting the app on the 18th of October at the BBTS annual conference. Hence it would
be very useful if you could nd some time to look at the app in the next week or so (thus
hopefully eliminating any glaring omissions or errors!).
There is a section in the app for acknowledgements. If you would like to be named there, please
provide me with your:
Title, name, position and aliation (as you want it to appear)
We would also acknowledge you in the BBTS presentation.
Thank you once again for your help. Brian and I look forward to hearing your thoughts.
Kind regards,
Karl Monsen
PhD student at The University of Edinburgh
Appendix B:
Web App Editor evaluation
B.1 Survey consent and questions
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B.2 Interview consent and topic guide
Evaluation of an online editor for collaborating onmobile web apps: Informa-
tion Sheet For Participants (v. 1, updated 23 July 2014)
I would like to invite you to participate in a research interview. Before you decide
whether to take part, I want you to know why I need your help and what’s involved
in taking part.
1. What is the aim of the research?
The purpose of the interview is to help understand how you used the web app
editor, what benets and problems you encountered, and how one could improve its
design.
2. What will you be asked to do?
Answer questions from the below indicative list of topics:
1. Are you happy for me to record the interview?
2. Your background and why you became interested in software development?
3. The background and aim of the project? Why did you decide to work on it?
4. How did you determine which technologies to use? What were the pros and
cons of HTML5?
5. How you were introduced to and why you agreed to test the web editor?
6. How did you use the editor for? What tasks did it do well? What tasks did it do
poorly on?
7. What other IDEs have you used? (JSddle, JSbin, Eclipse, Netbeans, Visual Stu-
dio) and how does the system compare?
8. Did you at any point invite any other users to use the editor? If so, in what ways
did the editor allow you to collaborate with others?
9. How did you feel about using using version control using Git?
10. Did the editor make it easier to do version control compared to command line
or a GUI-based git client?
11. On the whole, are you satised with the outcome of your project so far, why or
why not? Is there anything you would you have done dierently?
12. What will happen next in your project? Will someone continue to improve and
maintain the app?
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13. Will you keep it hosted on GitHub and encourage others to contribute to your
app?
14. If so, have you thought about using a particular software license?
15. Are you agreeable to reporting your answers using your real name or do you
require anonymity?
16. Do you grant me permission to allow me to use screenshots of your app in my
thesis?
3. How will we maintain your privacy and condentiality?
Any data that you provide will be treated condentially. Your answers can be re-
ported anonymously if so desired in publications. The data will be held securely for
the duration of the research (3 years) and then destroyed.
4. Who is Conducting the Research?
The research is led by Mr Karl Monsen (contact details omitted)
5. Do you agree to participate?
Participation in the research is voluntary. Any data you provide will be treated con-
dentially. Your answers will be made anonymous in any publications. You may with-
draw your data at any time and for any reason. Please ask if you have any questions
about any of the above. Sign below to indicate your informed consent to participate:
............................ ..........................
This page is intentionally left blank.
Appendix C:
Survey of medical students
C.1 Participant information sheet
Before participants could leave feedback, they were provided with the following infor-
mation.
Thank you for exploring the Special Blood Request application, which aims to make it quick
and easy to learn about, look up and test your knowledge of the indications for irradiated and
cytomegalovirus (CMV) negative blood components.
1. Research objectives
Special Blood Request is an early prototype and not a nished product. We now want to gain
more structured feedback from potential users to help evaluate and shape the design.
2. Terms of participation
Any data you provide will be treated condentially. Your answers will be made anonymous in
any publications. You may withdraw from the research at any time and for any reason. Please
contact us if you have any questions about any of the above.
3. Research team and contact details
Karl Monsen. PhD candidate at The University of Edinburgh, UK.
[[Contact details removed]]
Dr. Brian McClelland. SNBTS (retired). Medical adviser to project, Edinburgh, UK.
[[Contact details removed]]
4. The questions
There are 16 questions split over eight pages. They should take about 5 minutes to complete.
Press "next page" to begin. By proceeding you give your informed consent to participate in the
research.
C.2 Terms of use
The following information was oered to users of the app when they rst accessed it:
Terms of use
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Use of the app is subject to these terms. Please read them.
Disclaimer
Special Blood Request (“the app”) was created during a PhD research project and is made avail-
able for evaluation use only. There may be inaccuracies in the content. The developers and
contributors cannot be held liable for any harm resulting from the use of the app. The app is
not intended to be a substitute for local hospital guidelines, professional medical advice, diag-
nosis, or treatment. Always seek the advice of a qualied health provider with any questions
regarding medical matters.
The app is based on (but in no way endorsed by) the British Committee for Standards in Haema-
tology (BCSH) 2010 guidelines on the irradiation of blood components and the 2012 position
statement on the use of CMV negative blood components by the Advisory Committee on the
Safety of Blood, Tissues and Organs (SaBTO).
Recommendations for irradiated and CMV negative blood components is only displayed in the
app when it is indicated or contraindicated in these national UK guidelines. Guidance may not
be appropriate in all patient situations. Local hospital policies may dier.
Data protection - what data we collect and how we use it
The app is developed for a research project seeking to evaluate and improve the design of
clinical apps. The use of the app is therefore monitored. We may publish our ndings in schol-
arly publications, observing the usual academic principles of anonymity, informed consent and
voluntary participation. The following data is recorded:
• Which pages you visit and for how long.
• Information about your computing device (operating system, screen resolution, browser,
IP address).
• Your approximate geographical location (country, city).
• Your responses to the quiz.
• Keywords that you input in the app’s search functionality.
If you choose to provide additional feedback (using the ’leave feedback’ button), we may cor-
relate your browsing behaviour with your feedback answers to help us better understand the
strengths and weaknesses of the app design. To do this we store a browser cookie on your
device.
We do not collect any personally identifying information, unless you disclose this through the
online feedback form.
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No warranty
THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL
THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR
OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE,
ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR
OTHER DEALINGS IN THE SOFTWARE.
C.3 Evaluation questionnaire
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Appendix D:
Web App Trial evaluation
D.1 First invitation to practitioners
Sent: 2014-11-10 08:54:01 to all 336 selected practitioners (5 messages bounced)
Subject: SPECIAL Blood Components Study invitation
From: Special Study specialstudy@optimalblooduse.eu
Message:
Dear [FIRSTNAME] [LASTNAME]
We would like your support to evaluate a new educational app in transfusion medicine aiming
to improve sta knowledge of special requirements and patient safety. Failures to provide
patients with irradiated and cytomegalovirus (CMV) negative blood components are frequently
reported to Serious Hazards of Transfusion (SHOT), putting patients at unnecessary risks.
You have been invited to participate in the study because you have recently completed Module
1 Safe Transfusion Practice. Taking part will require approximately 15 minutes. For more infor-
mation and to participate please follow the link below: http://optimalblooduse.eu/specialstudy/
?i=[EVALUATIONCODE]
The completion date for the evaluation is November 24, 2014.
Your participation is really valuable and will contribute to providing new evidence about app
based learning. All participants in the study will have the choice of entering into a draw for a
chance to win a £50 national book voucher.
The study is endorsed by the Chair of [[healthboard removed]] Transfusion Committee and
has approval from [[healthboard removed]] Clinical Governance & Risk Management Support
Team. The project is conducted by researchers at The University of Edinburgh in collaboration
with the Better Blood Transfusion Team at the Scottish National Blood Transfusion Service.
Thank you for taking the time to read this email and considering participating in the study.
Yours Sincerely,
[[Chair of the Transfusion Committee removed]]
Mrs. Susan Cottrell, Nurse Specialist in Education, Better Blood Transfusion, SNBTS.
Mr. Karl Monsen, PhD candidate at the University of Edinburgh.
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D.2 Reminder to practitioners
Sent: 2014-11-24 15:14:38 to all 336 participants (6 messages bounced)
Subject: Evaluation of a new app in transfusion medicine
From: SPECIAL Study specialstudy@optimalblooduse.eu
Message:
Dear [FIRSTNAME] [LASTNAME]
Two weeks ago we asked you to help us evaluate a new educational app in transfusion medicine,
but we have not heard back from you. With your help we will know if the app improves
sta knowledge and is likely to reduce mistakes in the care of patients who require irradiated
and/or CMV-negative blood transfusion. We understand that this is a very busy time of the
year, so we have extended the deadline for completing the online evaluation until December 8,
2014. Participating is easy and should take less than 15 minutes, simply follow the link below:
http://optimalblooduse.eu/specialstudy/?i=[EVALUATIONCODE]
We hope that you will support our eort to reduce the risks associated with blood transfusions
and decide to take part in the study. All participants will have the choice of entering into a
draw for a chance to win either a £50 national book token voucher or an Apple Ipod Shue
audio player, which can be engraved with a message of your choice.
Thank you for considering to take part in the study.
Yours Sincerely,
[[Chair of the Transfusion Committee removed]]
Mrs. Susan Cottrell, Nurse Specialist in Education, Better Blood Transfusion, SNBTS.
Mr. Karl Monsen, PhD candidate at the University of Edinburgh.
The study is endorsed by the Chair of [[healthboard removed]] Transfusion Committee and
has approval from [[healthboard removed]] Clinical Governance & Risk Management Support
Team. The project is conducted by researchers at The University of Edinburgh in collaboration
with the Better Blood Transfusion Team at the Scottish National Blood Transfusion Service.
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D.3 Second reminder to practitioners
Sent: 2014-12-08 03:42:33 to 160 non-respondents in arm 2 (app group) (3 bounced).
Subject: Help us appraise an app for special requirements in transfusion
From: SPECIAL Study specialstudy@optimalblooduse.eu
Message:
Dear [FIRSTNAME] [LASTNAME]
We recently requested your help to evaluate a new educational app about the use of special
blood components. This is an area of blood transfusion where mistakes are frequently reported,
putting patients at unnecessary risks.
For anyone who have not yet had a chance to take part in the study, we have extended the dead-
line by another week. Should you wish to participate, please complete the online evaluation
before Monday December 15 2014 by following the link below:
http://optimalblooduse.eu/specialstudy/?i=[EVALUATIONCODE]
Participating is easy and should take less than 15 minutes. All participants have the choice
of entering into a draw for a chance to win either a £50 national book token voucher or an
Apple Ipod Shue audio player. We hope that you will support our eort to reduce the risks
associated with blood transfusions and decide to take part in the study. We will not extend the
deadline again or send any further invitations.
Thank you for considering to take part in the study.
Yours Sincerely,
[[Chair of the Transfusion Committee removed]]
Mrs. Susan Cottrell, Nurse Specialist in Education, Better Blood Transfusion, SNBTS.
Mr. Karl Monsen, PhD candidate at the University of Edinburgh.
The study is endorsed by the Chair of [[healthboard removed]] Transfusion Committee and
has approval from [[healthboard removed]] Clinical Governance & Risk Management Support
Team. The project is conducted by researchers at The University of Edinburgh in collaboration
with the Better Blood Transfusion Team at the Scottish National Blood Transfusion Service.
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D.4 Participant information sheet
After opening the link in the email, participants were presented with the following
information about the study, and asked to indicate their informed consent:
[[University of Edinburgh Logo]]
Stopping and Preventing Errors in CMV-negative and Irradiated blood transfusion through
App-based Learning (SPECIAL).
We would like to invite you to participate in the SPECIAL study. Before you decide whether
to take part, click on the headings below to nd out why we need your help and what we will
ask you to do.
1. What is the aim of the research?
Blood transfusion is a complex process and about one hundred mistakes related to the pro-
vision of irradiated and Cytomegalovirus (CMV) negative blood ("special blood components")
are reported every year to Serious Hazards of Transfusion (SHOT) in the UK.
Researchers at the University of Edinburgh are collaborating with experts in transfusion to
create an app with learning materials about special blood components for sta involved in
key stages of the transfusion process. This pilot study will evaluate whether the app increases
knowledge of the correct use of special blood components.
2. What will I be asked to do?
We are asking you to answer two sets of 8 multiple choice questions about special blood com-
ponents. After the rst set of questions, you will be presented with [[medical guidelines (dis-
played if participant randomised to arm 1)]] [[the Special Blood Components app (shown if
participant randomised to arm 2)]] to help you answer the remaining questions.
Taking part in the study should take you about 15 minutes. You can choose to participate at
a time and from a location that is convenient to you. You will need access to a computer or
mobile device with an Internet connection.
3. Why should I participate?
By taking part, you will help shape the design of a new learning resource. If results are positive,
wider dissemination of the app could reduce mistakes and enhance patient safety. Taking part
in the study is also an excellent opportunity to test your knowledge in a safe environment,
although we regret we are unable to provide you with a test score.
Additionally, there is a chance to win a £50 national book token voucher or an engraved Ap-
ple iPod Shue audio player. Participation is completely voluntary and there are no risks to
D.4. PARTICIPANT INFORMATION SHEET 347
participating.
4. How will you use my data?
Any data that you provide will be treated condentially and your answers will be reported
anonymously in publications. The information will be held securely for the duration of the
research project (3 years) and then destroyed.
5. Who are you asking to participate?
We are inviting all grades of doctors, registered nurses, midwives and transfusion laboratory
sta who recently completed the Module 1 Safe Transfusion Practice (or equivalent) using the
Learn Better Blood Transfusion programme from three NHS [[name of healthboard removed]]
hospitals.
[[List of hospitals removed]]
Sta who do not meet these criteria are excluded from participating. If you have received a
personal email invitation from the research team you are likely to be eligible.
6. Who is conducting the research?
The research is conducted by Mr. Karl Monsen, a PhD candidate at The University of Edin-
burgh, in collaboration with Mrs. Susan Cottrell, Nurse Specialist in Education, at The Better
Blood Transfusion Team, The Scottish National Blood Transfusion Service.
The study is endorsed by [[chair of the healthboard Transfusion Committee removed]], and
Dr. Brian McClelland is medical adviser to the project.
If you have any questions, please contact Karl at the following email address:
[[Email address removed]]
Alternatively, you can write to:
[[Mail address removed]]
Thank you for your time.
The study has approval from [[healthboard removed]] Clinical Governance and Risk Manage-
ment Support Team.
Ready to begin?
Press the green button to indicate that you have read the above information and freely consent
to take part in the study. [[Green button labelled “I agree to participate”]]
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D.5 Items in the knowledge test
The knowledge test was composed of 16 questions, divided into two groups. The rst
group of questions (items 1 to 8) probed participants knowledge of special blood com-
ponents. This included, how special blood components are prepared, how they should
be administered, how they prevent transfusion complications and reasons for why
mistakes can happen.
The second group of question (items 9 to 16) probed participants knowledge of the
indications for special blood components, by asking them to select the correct blood
component in eight patient scenarios. The questions are given below, together with
their answer options, the correct answer (in bold), the item diculty (percentage of
participants who answered it correctly) and item discrimination, calculated from the
point-biserial correlation with data from all 61 study respondents (Varma, no year).




• All of the above
• None of the above
• Don’t know
Item diculty: easy (85.2%).
Item discrimination: good (biserial correlation: 0.298).
2. What are risk factors for Transfusion Associated Graft versus Host Disease?
• Shared HLA haplotype between donor and recipient
• Viable donor lymphocytes in component
• Severe T-lymphocyte immunodeciency in recipient
• All of the above
• None of the above
• Don’t know
D.5. ITEMS IN THE KNOWLEDGE TEST 349
Item diculty: hard (31%).
Item discrimination: acceptable (biserial correlation: 0.174).
3. How is the risk of TransfusionAssociatedGraft versusHostDisease best prevented?
• Leucodepletion
• Methylene blue treatment
• X-ray or gamma irradiation
• All of the above
• None of the above
• Don’t know
Item diculty: hard (36%).
Item discrimination: good (biserial correlation: 0.353).
4. How can the risk of cytomegalovirus (CMV) infection be minimised?
• Restrictive use of transfusion
• Use of CMV-negative blood
• Leucocyte depletion
• All of the above
• None of the above
• Don’t know
Item diculty: medium (59%).
Item discrimination: acceptable (biserial correlation: 0.232).
5. What statements about leucodepletion (LD) in the UK are correct?
• LD signicantly reduce white cells
• All red cells and platelets are LD
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• Granulocytes cannot be LD
• All of the above
• None of the above
• Don’t know
Item diculty: hard (30%).
Item discrimination: good (biserial correlation: 0.468).
6. What statements about irradiation of blood components in the UK are true?
• All red cells are routinely irradiated
• Irradiation inactivates lymphocytes
• Irradiation increases component shelf life
• All of the above
• None of the above
• Don’t know
Item diculty: medium (45%).
Item discrimination: good (biserial correlation: 0.339).




• Case by case decision
• Irradiation is not required
• Don’t know
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Item diculty: medium (54%).
Item discrimination: good (biserial correlation: 0.433).
8. Why do patients fail to receive irradiated blood appropriately?
• Poor handover in shared care
• Mistaken patient identity
• Errors in information systems
• All of the above
• None of the above
• Don’t know
Item diculty: easy (82%).
Item discrimination: good (biserial correlation: 0.309).
9. Red cells donated by a mother to her two year old child.
• Irradiated & CMV negative
• Irradiated
• CMV negative
• No special component required
• Not enough information to answer
• Don’t know
Item diculty: hard (26%).
Item discrimination: good (biserial correlation: 0.236).
10. Red cells for an adult male treated with Alemtuzmab (Campath).
• Irradiated & CMV negative
• Irradiated
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• CMV negative
• No special component required
• Not enough information to answer
• Don’t know
Item diculty: medium (50%).
Item discrimination: good (biserial correlation: 0.308).
11. Elective red cell transfusion for an immunocompetent pregnant woman in second
trimester.
• Irradiated & CMV negative
• Irradiated
• CMV negative
• No special component required
• Not enough information to answer
• Don’t know
Item diculty: medium (46%).
Item discrimination: good (biserial correlation: 0.313).
12. Fresh frozen plasma for a patient with Hodgkin’s lymphoma.
• Irradiated & CMV negative
• Irradiated
• CMV negative
• No special component required
• Not enough information to answer
• Don’t know
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Item diculty: hard (25%).
Item discrimination: good (biserial correlation: 0.338).
13. HLA-matched platelets for an elderly female patient with refractoriness.
• Irradiated & CMV negative
• Irradiated
• CMV negative
• No special component required
• Not enough information to answer
• Don’t know
Item diculty: medium (39%).
Item discrimination: good (biserial correlation: 0.422).
14. Platelets transfused in utero to treat neonatal alloimmune thrombocytopenia.
• Irradiated & CMV negative
• Irradiated
• CMV negative
• No special component required
• Not enough information to answer
• Don’t know
Item diculty: medium (53%).
Item discrimination: good (biserial correlation: 0.348).
15. Red cells for an eight year old girl who had a bone marrow transplant within the
last 3 months.
• Irradiated & CMV negative
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• Irradiated
• CMV negative
• No special component required
• Not enough information to answer
• Don’t know
Item diculty: hard (25%).
Item discrimination: good (biserial correlation: 0.264).
16. Platelets for a 60 year old male receiving purine analogue drugs.
• Irradiated & CMV negative
• Irradiated
• CMV negative
• No special component required
• Not enough information to answer
• Don’t know
Item diculty: medium (53%).
Item discrimination: good (biserial correlation: 0.538).
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D.6 Flow through the Web App Trial
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Appendix G:
Abbreviations and denitions
• BBT (UK) - Better Blood Transfusion.
Initiative to improve UK transfusion safety, active between 1998 and 2012. Replaced by
Patient Blood Management (JPAC, no year).
• BBT (Scotland) - Better Blood Transfusion.
A multi-disciplinary team, formed in 2003 by the SNBTS to promote “safe, eective,
ecient and appropriate transfusion for patients” (SNBTS, no year).
• BCSH - British Committee for Standards in Haematology.
UK body resposible for national guidelines in haematology and transfusion medicine,
including guidelines for irradiated blood components. A sub-committee of the BSH.
• BSH - British Society for Haematology.
UK professional body for haematologists established in 1960. It is associated with the
British Journal of Haematology and publishes guidelines developed by the BCSH.
• CMV - Cytomegalovirus.
Herpes virus carried by about half the UK population. It causes asymptomatic infection
in healthy individuals, but poses a risk to vulnerable patient groups. The virus remains
latent in white blood cells and can be transmitted via blood transfusions (SaBTO, 2012b).
• CSS - Cascading Style Sheets.
A web technology for controlling the layout and formatting of page elements in an
HTML document, such as type face, colours and positioning.
• EBM - Evidence-Based Medicine
“... de-emphasizes intuition, unsystematic clinical experience, and pathophysiologic ra-
tionale as sucient grounds for clinical decision making and stresses the examination
of evidence from clinical research.” (Guyatt et al., 1992).
• eHealth - Electronic healthcare
“eHealth is an emerging eld of medical informatics, referring to the organisation and
delivery of health services and information using the Internet and related technologies.”
(Eysenbach, 2001).
• Engraftment (of transfused blood cells)
Engraftment in the context of blood transfusion (and transplants more widely) occurs
when blood cells (or transplanted organs) are introduced into a patient without being
destroyed by their immune system, and instead becomes a functioning part of their body.
It is a pre-condition for TA-GvHD.
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• FDA - Food and Drugs Administration.
US body responsible for regulating medicines, medical devices, food, cosmetics and other
products, including medical apps that meet the denition of a medical device (FDA,
2015).
• HLA - Human leucocyte antigen.
Proteins on the surface of cells, enabling the immune system to distinguish the body’s
own cells from foreign cells. The transfusion of HLA haplotype homozygous donor
lymphocytes (i.e. donated blood cells that share cell surface proteins with the reipient)
can lead to TA-GvHD (Treleaven et al., 2010).
• HTML - Hypertext Markup Language.
A standard, currently in its fth revision (HTML5), for creating web pages (“hypertext”
documents) by enclosing portions of text using semantic tags (“marking up”). For exam-
ple, a large heading can be created by wrapping text with the <h1> tag:
<h1>This is a large heading</h1>
• LBT - Learn Blood Transfusion.
E-learning program for blood transfusion developed by the BBT team at the SNBTS
(SNBTS , no year).
• mHealth - Mobile healthcare.
“Medical and public health practice supported by mobile devices, such as mobile phones,
patient monitoring devices, personal digital assistants (PDAs), and other wireless de-
vices.” (WHO, 2011, 6).
• Medical App - Medical application.
Software application intended for patients or healthcare practitioners that is designed for
use on a portable computing device, such as a smartphone. Medical apps are regulated
under existing medical device legislation. According to the FDA (2015, 8), only those
medical apps that are deemed to meet the criteria for a medical device (e.g. intended “for
diagnosis of disease or other conditions, or the cure, mitigation, treatment, or prevention
of disease”) and “whose functionality could pose a risk to a patient’s safety if the mobile
app were to not function as intended” are actively regulated.
• MHRA - Medicine and Healthcare products Regulatory Agency.
UK body that regulates medicines and medical devices in the UK, including some med-
ical apps (MHRA, 2014). Monitors the safety of blood transfusions through the SABRE
scheme.
• NICE - National Institute for Health and Care Excellence.
UK body that produces quality standards and evidence-based guidelines for health, pub-
lic health and social care practitioners (NICE, no year).
• NHSBT - National Health Service Blood and Transplant.
Body responsible for the safety and supply of blood, organs, stem cells and tissues,
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formed in 2005 through a merger of the National Blood Service and UK Transplant
(NHSBT, no year).
• RCOG - Royal College of Obstetricians and Gynaecologists.
Founded in 1929 to advance the science and practice obstetrics and gynaecology. Pub-
lishes the Green-Top Guidelines (RCOG, no year).
• SABRE - Serious Adverse Blood Reactions and Events
MHRA’s system for monitoring incidents in UK blood transfusions.
• SaBTO-Advisory Committee on the Safety of Blood, Tissues and OrgansCommit-
tee that “advises UK ministers and health departments on the most appropriate ways
to ensure the safety of blood, cells, tissues and organs for transfusion/transplantation”
(SaBTO, no year), including the use of Cytomegalovirus negative blood components
(SaBTO, 2012b).
• SBC - Special Blood Components.
SBC is the name of the app that that was developed as part of the thesis. It refers to
specially prepared blood components (CMV-negative and irradiated) that are indicated
for patients at risk of TT-CMV and TA-GvHD.
• SIGN - Scottish Intercollegiate Guidelines Network.
“... develops evidence based clinical practice guidelines for the National Health Service
(NHS) in Scotland” (SIGN, no year).
• SNBTS - Scottish National Blood Transfusion Service.
“SNBTS is the specialist provider of transfusion medicine in Scotland, supplying high
quality blood, tissues, cells and services” (SNBTS, no year).
• SHOT - Serious Hazards of Transfusion.
UK professionally-led haemovigilance scheme encouraging reporting, analysis and dis-
semination of lessons from incidents and near misses involving blood transfusions, es-
tablished 1996 (SHOT, no year).
• TA-GvHD - Transfusion-associated Graft versus Host Disease.
A rare, almost universally fatal disease caused by the transfusion of cellular blood com-
ponents (red cells, platelets and granulocytes) containing viable lymphocytes, that is
prevented by irradiating cellular blood components prior to transfusion (Treleaven et al.,
2010).
• TT-CMV - Transfusion-transmitted CMV infection.
Cytomegalovirus infection (or re-infection) caused by transmission of the virus via blood
transfusion. CMV infection is asymptomatic in a majority of adults worldwide, but can
be fatal or cause lifelong disability in at-risk patients (SaBTO, 2012b, 16).
• WAE - Web App Editor.
A collaborative web-based editor that enables multiple authors to work together to build
mobile apps. It is one of the outcomes of the thesis.
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• WAT - Web App Trial.
A system for conducting pragmatic randomised controlled trials of medical apps. It was
developed to evaluate the SBC app with healthcare practitioners.
